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Background: Obesity is twice as common in people with schizophrenia as in the general population.
The National Institute for Health and Care Excellence guidance recommends that people with psychosis
or schizophrenia, especially those taking antipsychotics, be offered a healthy eating and physical activity
programme by their mental health care provider. There is insufficient evidence to inform how these
lifestyle services should be commissioned.
Objectives: To develop a lifestyle intervention for people with first episode psychosis or schizophrenia and
to evaluate its clinical effectiveness, cost-effectiveness, delivery and acceptability.
Design: A two-arm, analyst-blind, parallel-group, randomised controlled trial, with a 1 : 1 allocation ratio,
using web-based randomisation; a mixed-methods process evaluation, including qualitative case study
methods and logic modelling; and a cost–utility analysis.
Setting: Ten community mental health trusts in England.
Participants: People with first episode psychosis, schizophrenia or schizoaffective disorder.
Interventions: Intervention group: (1) four 2.5-hour group-based structured lifestyle self-management
education sessions, 1 week apart; (2) multimodal fortnightly support contacts; (3) three 2.5-hour group
booster sessions at 3-monthly intervals, post core sessions. Control group: usual care assessed through
a longitudinal survey. All participants received standard written lifestyle information.
Main outcome measures: The primary outcome was change in weight (kg) at 12 months post
randomisation. The key secondary outcomes measured at 3 and 12 months included self-reported nutrition
(measured with the Dietary Instrument for Nutrition Education questionnaire), objectively measured physical
activity measured by accelerometry [GENEActiv (Activinsights, Kimbolton, UK)], biomedical measures, adverse
events, patient-reported outcome measures and a health economic assessment.
Results: The trial recruited 414 participants (intervention arm: 208 participants; usual care: 206 participants)
between 10 March 2015 and 31 March 2016. A total of 341 participants (81.6%) completed the trial. A total
of 412 participants were analysed. After 12 months, weight change did not differ between the groups
(mean difference 0.0 kg, 95% confidence interval –1.59 to 1.67 kg; p = 0.964); physical activity, dietary
intake and biochemical measures were unchanged. Glycated haemoglobin, fasting glucose and lipid profile
were unchanged by the intervention. Quality of life, psychiatric symptoms and illness perception did not
change during the trial. There were three deaths, but none was related to the intervention. Most adverse
events were expected and related to the psychiatric illness. The process evaluation showed that the intervention
was acceptable, with participants valuing the opportunity to interact with others facing similar challenges.
Session feedback indicated that 87.2% of participants agreed that the sessions had met their needs. Some
indicated the desire for more ongoing support. Professionals felt that the intervention was under-resourced and
questioned the long-term sustainability within current NHS settings. Professionals would have preferred greater
access to participants’ behaviour data to tailor the intervention better. The incremental cost-effectiveness ratio
from the health-care perspective is £246,921 per quality-adjusted life-year (QALY) gained and the incremental
cost-effectiveness ratio from the societal perspective is £367,543 per QALY gained.
Conclusions: Despite the challenges of undertaking clinical research in this population, the trial successfully
recruited and retained participants, indicating a high level of interest in weight management interventions;
however, the STEPWISE intervention was neither clinically effective nor cost-effective. Further research will be
required to define how overweight and obesity in people with schizophrenia should be managed. The trial
results suggest that lifestyle programmes for people with schizophrenia may need greater resourcing than for
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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other populations, and interventions that have been shown to be effective in other populations, such as
people with diabetes mellitus, are not necessarily effective in people with schizophrenia.
Trial registration: Current Controlled Trials ISRCTN19447796.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 65.
See the NIHR Journals Library website for further project information.
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Glossary
Blinded/blinding Concealment of group allocation from individuals involved in a randomised
controlled trial.
F20 The International Classification of Diseases, Tenth Revision, code for schizophrenia.
F25 The International Classification of Diseases, Tenth Revision, code for schizoaffective disorder.
First episode psychosis First episode psychosis is defined as 3 years since presentation to mental
health services.
Framework analysis A qualitative method, suited for applied policy research.
Logic model A tool used to evaluate the implementation of a programme of care.
NVivo (QSR International, Warrington, UK) A computer software package for qualitative data analysis.
Stata® (StataCorp LP, College Station, TX, USA) A computer software package for statistical analysis.
Triangulation A method used by qualitative researchers to establish trustworthiness by comparing the
findings of different methods or perspectives.
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Plain English summary
People with schizophrenia are often overweight. Losing weight and being more active can reducethe risk of diabetes mellitus and heart disease and dying early. The NHS recommends offering a weight
loss programme; however, mental health care providers do not know how best to do this.
We assessed whether or not an education programme to help people with psychosis to lose weight would
be better than the usual care provided by the NHS.
A total of 414 people took part. We selected half of them at random to attend an education programme
run by trained facilitators. The other half received their usual health care.
We found no important difference in weight between the two groups, at either 3 months or 12 months.
We also found that the programme did not provide good value for money. In interviews, service users
said that they liked the education programme and that it helped them to eat healthily and lose weight.
However, we found no change in their diet and activity levels in either group. The trained staff thought
that the programme could benefit service users, but were unsure if the NHS could afford it. They also
wanted to know whether or not service users were losing weight during the programme.
People were interested in the trial and stayed in the trial until the end. Unfortunately, although some
people benefited, the programme did not work for most people. Therefore, we need to look for better
ways to help people with psychosis to lose weight.
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Scientific summary
Background
Schizophrenia is a psychotic illness that affects around 1% of the population. The prevalence of obesity in
people with schizophrenia is approximately twofold higher than that in the general population and is associated
with higher levels of morbidity, especially cardiovascular disease, diabetes mellitus and early mortality.
Objectives
l To develop a group-based, structured self-management lifestyle education programme for people with
schizophrenia, schizoaffective disorder and first episode psychosis.
l To conduct a multicentre randomised controlled trial (RCT) to investigate whether or not the intervention
leads to a clinically important difference in weight change, as well as physical activity and diet, compared
with usual care.
l To conduct a mixed-methods process evaluation to explore intervention delivery and participant and
facilitator experiences, and to explain discrepancies between expected and observed outcomes.
l To conduct an economic evaluation of the intervention.
l To assess the fidelity of intervention delivery when undertaken at 10 different sites.
Design
Intervention development
The intervention development was guided by the Medical Research Council framework for complex
interventions: (1) identifying the evidence base through a literature review; (2) identifying/developing a
theory and modelling the process and outcomes, through consultation with service users and health
professionals; and (3) four plan–do–study–act cycles incorporating qualitative interviews.
Randomised controlled trial
The trial was a two-arm, parallel-group RCT with a 1 : 1 allocation ratio, using web-based randomisation
and with the principal investigator and analysts being blinded to allocation until after the final analysis.
Mixed-methods process evaluation
The process evaluation used three main approaches:
1. logic modelling, integrating contextual factors with the National Institute for Health Behaviour Change
Consortium fidelity framework and Linnan and Steckler’s process evaluation framework
2. a qualitative single-case design, with the unit of analysis variably at the participant level (n = 24
participants) and at the level of the experimental intervention programme (n = 20 facilitator interviews)
3. a triangulation protocol to compare quantitative process data with qualitative findings.
Economic evaluation
The economic evaluation was undertaken from a health and social care and societal perspective and
included the costs of medicines and NHS professionals in primary and community care and inpatient
settings, as well as social care costs (including costs of education, and employment and informal care).
The cost-effectiveness of the physical activity and healthy eating programme was assessed by combining
costs with the primary outcome and quality-adjusted life-years (QALYs) generated from the EuroQol-5
Dimensions, five-level version (EQ-5D-5L) questionnaire.
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Fidelity of the intervention delivery
Fidelity was assessed by facilitator talk time and direct observation of the facilitator behaviour and conduct
at sessions.
Setting
Community settings in 10 UK mental health NHS trusts.
Participant selection and recruitment
Potential participants were eligible for inclusion if they were adults aged ≥ 18 years with a diagnosis of
schizophrenia, schizoaffective disorder or first episode psychosis, were being treated with an antipsychotic
drug, were willing and able to give consent and to attend group education sessions delivered in English,
and had a body mass index of ≥ 25 kg/m2 (≥ 23 kg/m2 for adults with South Asian and Chinese backgrounds)
or were concerned about weight. People with physical illnesses that could seriously reduce life expectancy
or affect metabolic measures or weight gain were excluded. Those with a primary diagnosis of a learning
disability, who were currently pregnant or < 6 months post partum, who had significant alcohol or substance
misuse or a (tentative) diagnosis of psychotic depression or mania or were currently (or within the past
3 months) engaged in a systematic weight management programme were also excluded.
Intervention development study
Twenty-four service users were recruited between May and December 2014 in four waves at one centre
(Sheffield) to refine a prototype intervention before the RCT.
Randomised controlled trial
Between 10 March 2015 and 31 March 2016, 1223 adults with schizophrenia, schizoaffective disorder or
first episode psychosis were screened for eligibility. A total of 423 consented to participate in the trial and
414 participants (target: n = 396) were randomised (intervention arm, n = 208 participants; usual care,
n = 206 participants).
Interventions
All participants received standardised written lifestyle information about diet, physical activity, smoking and
alcohol use. The use of external weight loss programmes was permitted at the individual level.
The intervention group received a complex intervention based on Bandura’s self-efficacy theory, Leventhal’s
self-regulation theory and Marlatt and Gordon’s relapse prevention model. The programme comprised
(1) four 2.5-hour group-based structured lifestyle self-management education sessions, 1 week apart,
facilitated by trained professionals delivering manualised content; (2) fortnightly support contacts from
facilitators (face to face or via telephone, mail or e-mail, by participant preference); and (3) three 2.5-hour
group booster sessions delivered at 3-monthly intervals post core sessions, reinforcing further behaviour
change/self-management strategies.
The control group received treatment as usual, captured through a survey at the site level and a health and
social care resource questionnaire.
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Main outcome measures
The main outcome measures were weight change (primary outcome at 12 months), body mass index, waist
circumference, objectively measured physical activity [wrist-worn GENEActiv (Activinsights, Kimbolton, UK)
accelerometer], adapted Dietary Instrument for Nutrition Education questionnaire, blood pressure, fasting
glucose, lipid profile, glycated haemoglobin, health state utility (EQ-5D-5L), Short Form questionnaire-36
items, Brief Illness Perception Questionnaire [(B-IPQ) weight], Brief Psychiatric Rating Scale, health and social
care resource use (Client Service Receipt Inventory), Patient Health Questionnaire 9-item depression scale,
weight loss programmes, session feedback (intervention only) and adverse events. Analyses were undertaken
on an intention-to-treat basis, with the treatment effect adjusted for the baseline value, recruiting site, years
since the person started antipsychotic treatment and the clustering effect of the course attended.
Results
The trial closed on 31 March 2017, with 341 (81.6%) participants completing the trial. Forty-seven
(25 intervention, 22 control) participants withdrew consent, three died (intervention) and 21 (11 intervention
and 10 control) participants were lost to follow-up. The intention-to-treat analysis excluded two participants
(control); one was erroneously randomised, having previously not consented, and one withdrew all consent to
use their data. Therefore, 412 (207 intervention and 205 control) participants were included in the analyses.
Two hundred and ten participants (51.0%) were male, 349 participants (84.7%) were white European and
the average age was 40 years.
Randomised controlled trial outcomes
At baseline, the groups were well balanced; however, the intervention group participants were, on average,
3 kg heavier at baseline, which is partially explained by the higher proportion of men in the intervention arm
(55.6% vs. 46.3%). Three hundred and forty-nine participants (84.7%) had a diagnosis of schizophrenia or
schizoaffective disorder and 63 (15.3%) were categorised as having first episode psychosis. One hundred
and eleven intervention group participants (53.6%) attended three or more core sessions and one or more
booster sessions; 36 participants (17.4%) did not attend any intervention sessions.
After 12 months, the primary outcome of weight change (kg) was almost identical between the trial arms, with
a non-significant mean reduction in weight of 0.47 kg in the intervention group and 0.51 kg in the control
group (difference = 0.0 kg, 95% confidence interval –1.59 to 1.67 kg; p= 0.964). Weight change by centre
varied, with 15 intervention participants at one centre losing an average of 4 kg [standard deviation (SD) 4.30 kg]
and 18 control group participants gaining on average 3 kg (SD 4.30 kg). In contrast, 21 intervention participants
at another centre lost an average of 0.5 kg (SD 6.89 kg), whereas 24 participants in the control group lost 3 kg
(SD 9.15 kg). There were no significant differences in change in weight, body mass index or waist circumference
at the 3- and 12-month assessments. Laboratory and vital signs were unchanged at 12 months.
The intervention had no overall effect on dietary intake, as measured by the Dietary Instrument for
Nutrition Education (DINE); physical activity at baseline was similarly low in both groups. At the 3-month
assessment, weekend moderate or vigorous physical activity was significantly higher in the intervention
arm, but this difference had disappeared by 12 months.
Self-reported quality of life (QoL), measured using the Short Form questionnaire-36 items, suggested higher
QoL post randomisation in the intervention group for physical functioning and bodily pain, but a higher level
of emotional well-being in the control group. On the main measure of the EQ-5D-5L, there was no significant
difference between the groups. However, on the ‘thermometer’ health scale, the control group showed
more improvement at 12 months, with a difference of 4.4 points (p = 0.028). For self-reported depressive
symptoms, measured using the Patient Health Questionnaire-9, there was minimal change in both groups
over time. In terms of perceptions of weight problems, the B-IPQ total score showed a small improvement in
both groups over time, although the changes in the eight dimensions of the B-IPQ were mixed. There were
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no significant differences between the groups for the total score or any dimension. For both groups, the
observer-rated Brief Psychiatric Rating Scale showed little change over time, with no significant difference
between groups.
Twelve participants (eight in the control arm and four in the intervention arm) attended one or more weight
loss programmes outside the trial at 3 months, of whom five were still attending at 12 months. At 12 months,
25 participants (7.4%; 8 in the control arm and 17 in the intervention arm) reported attending a weight loss
programme outside the trial.
Anonymous intervention session feedback was invited at all seven group sessions, and 708 forms were
returned. Overall, the majority (≈90%) of responses were positive, with 87.2% of participants agreeing
that the sessions had met their needs. Three-quarters of the free-text comments were also positive. As
feedback could not be linked to individual outcomes, these were analysed by centre (five were excluded,
owing to no site code). There were no significant correlations between mean weight change and mean
feedback scores for centres at 3 or 12 months (Spearman’s rank-order correlation = –0.20, p = 0.476,
and Spearman’s rank-order correlation = 0.042, p = 0.454, respectively).
Adverse events
A total of 46 adverse events occurred in 37 intervention participants and 34 adverse events occurred in
26 control participants. Fifty per cent of adverse events in both groups were psychiatric hospitalisation.
Four deaths were reported, all in the intervention group; the causes were pulmonary embolism following
a ruptured Achilles tendon; left ventricular hypertrophy, hypertension and obesity; diabetic ketoacidosis
leading to cardiac arrest; and myocardial infarction. Three of the deaths occurred during the trial and one
occurred 37 days after trial completion.
Cost-effectiveness
The incremental cost-effectiveness ratio (ICER) from the health-care perspective was £246,921 per QALY
gained and the ICER from the societal perspective (including employment and education for patients and
informal care) was £367,543 per QALY gained.
Process evaluation
Both the participants and the facilitators described how the intervention was popular and well received.
The participants particularly enjoyed meeting others facing the same challenge of managing weight.
It was relatively easy to fill places on the STructured lifestyle Education for People WIth SchizophrEnia,
schizoaffective disorder and first episode psychosis programme (STEPWISE) course, indicating a high level
of interest in weight management programmes among people with severe mental illness.
The process evaluation found potential barriers to self-management at the level of the individual’s
psychological functioning (e.g. cognitive or attention deficit) and participative capabilities (e.g. low income,
anxiety about social interaction), as well as the attitudes of family members and health professionals
(paternalism and gatekeeping). Detailed case studies suggested that achieving and maintaining weight loss
was particularly difficult for those with first episode psychosis (< 3 years since antipsychotic treatment
initiation) and for those with more severe symptoms.
Interviews with developers suggested that the intervention was well grounded in behaviour change theory and
had a high level of acceptability to participants. Facilitators reported that they understood and constructed
value for the intervention, but were sometimes sceptical about the commitment of senior NHS management to
the programme and rarely felt adequately resourced at an organisational level. They would have preferred to
have been kept abreast of changes in body weight to assess the effects of the programme on its participants.
Facilitators anticipated changing STEPWISE if adopted at the sites, or integrating ideas from it into their own
practice if it did not. Although there were opportunities for sharing stories and action-planning, facilitators
felt that they needed greater feedback on biomedical and lifestyle data during the sessions to support
individuals better.
SCIENTIFIC SUMMARY
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Analysis against the logic model highlighted the potential role for quality assurance infrastructure in
raising and maintaining the quality of delivery. Facilitator training courses and materials were valued and
facilitators were generally skilled and motivated. Senior management commitment was generally good,
but this did not always translate into appropriate resourcing, and gatekeepers did not always refer eligible
patients. The availability of taxi fares for group attendance played a key part in patient engagement. The
work of programme and case management was almost always described as inadequately resourced and
the number of facilitators who left the trial was high (an average of 20% over 40 weeks). The reason
for this was not formally assessed but was often related to work promotions rather than discontent with
the intervention.
The fidelity assessment indicated that the delivery was largely as planned, with the mental health care
professionals avoiding didactic teaching while adopting facilitative behaviours that allowed the participants
to contribute to the groups.
Conclusions
Despite concerns about the ability to recruit and retain people with schizophrenia, the STEPWISE trial was
completed successfully within the original time frame; however, the STEPWISE intervention was neither
clinically effective nor cost-effective. Current National Institute for Health and Care Excellence guidance
recommends that lifestyle programmes should be offered to people with severe mental illness, but does
not state how these should be commissioned. The results of this trial suggest that lifestyle programmes
that have been shown to be effective in other populations, such as in people with diabetes mellitus, are
not necessarily effective in people with schizophrenia.
Recommendations for research
Further research should investigate if:
l a more intensive lifestyle management programme with longer periods of maintenance support,
complemented by objective measures of weight, diet and exercise, delivered by more experienced
facilitators or by people from different professional backgrounds is clinically effective and cost-effective
l a more flexible approach, including both group and one-to-one sessions, is more effective
l a broader approach, incorporating adjustment of antipsychotic treatments and the use of adjunctive
pharmacological interventions, may be required
l it is possible to overcome the barriers to attendance at lifestyle management programmes
l other formats, including family members or carers, would be more effective
l lifestyle management programmes should be tailored on the basis of the duration of psychotic illness;
for example, preventative approaches for people with first episode psychosis may need to be different
from those for people with more established disease
l a lifestyle intervention should be combined with specific medication review and/or pharmacological
approaches to weight management.
Trial registration
This trial is registered as ISRCTN19447796.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Obesity and weight gain in people with schizophrenia
Schizophrenia, a psychotic illness, affects ≈1% of the population. Mortality rates in people with schizophrenia
are increased twofold to fourfold, with life expectancy reduced by 10–20 years.1–3 Around 75% of people
with schizophrenia die from physical illness, most commonly cardiovascular disease. Weight gain is a key
contributor to excess morbidity and mortality, with obesity being two or three times more prevalent in people
with schizophrenia than in the general population.4 The rates of obesity have increased substantially and have
risen faster than in the general population over the past three decades.5
The cause of the increase in obesity is multifactorial and includes environmental factors (such as poverty,
urbanisation, poor diet6,7 and physical inactivity), disease effects (such as altered neuroendocrine functioning,
altered reward perception) and treatment effects; antipsychotics cause weight gain in 15–72% of patients.8
Weight gain is observed early in treatment; between 37% and 86% of people with a first episode of
psychosis gain > 7% of their body weight over 12 months.9 Much of this weight gain occurs within 12 weeks
of treatment initiation10 but continues in the longer term, albeit at a slower rate.11
Interventions to control or reduce antipsychotic-related weight gain
The British Association of Psychopharmacology has reviewed interventions designed to promote weight
loss or attenuate weight gain in people taking antipsychotics. Given the underlying mechanisms associated
with weight gain, these have taken three, usually exclusive, approaches: (1) lifestyle interventions to
improve diet and physical activity, (2) adjustment of antipsychotic medication to minimise the use of drugs
associated with the greatest weight change and (3) the use of adjunctive medications that may attenuate
the antipsychotic effect. The STructured lifestyle Education for People WIth SchizophrEnia, schizoaffective
disorder and first episode psychosis programme (STEPWISE) intervention was intended to promote weight
loss through lifestyle modification. However, when the intervention was designed, the developers also
considered the effect of the illness and treatment and how these could interact with lifestyle modification.
Prior to the STEPWISE project, a systematic review of randomised controlled trials (RCTs) reported that
non-pharmacological interventions lead to a mean 3.12-kg weight reduction over a period of 8–24 weeks in
people with schizophrenia, with commensurate change in other cardiovascular risk factors.12 Programmes
offered benefits regardless of treatment duration, modality (individual vs. group setting), behaviour change
versus educational content or whether they aimed to prevent weight gain or promote weight loss. Most
interventions contained cognitive behavioural elements as well as diet or exercise-based content. The sample
size of RCTs was generally small (median 53, range 15–110) and most participants were not followed up
beyond 12 weeks. Of the few studies with long-term follow-up, not all sustained long-term weight control.13
The systematic review team called for larger trials with long-term follow-up and a focus on weight maintenance
following initial intervention.
The 2014 National Institute for Health and Care Excellence (NICE) guidance on psychosis and schizophrenia
in adults14 expanded this review to 24 studies with similar conclusions. Several of these studies included
significant numbers of individuals with other types of mental illness, for whom the strategies needed to
promote weight loss may be different. Consistent with the earlier systematic review, few studies examined
weight change beyond 6 months, and only six studies included > 100 participants. No study was undertaken
in the UK, most were rated as being at moderate risk of bias and there was substantial heterogeneity of
effect size. NICE concluded that lifestyle interventions were effective in reducing and maintaining body
weight in the short term, but, without longer-term data, the effects beyond 6 months were unknown.
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The most recent systematic review published in August 2017 included 17 studies and 1968 participants.15
Sixty-six per cent of participants had schizophrenia spectrum disorders. Consistent with previous publications,
the 10 studies reporting short-term interventions of < 6 months’ duration showed greater weight loss than
usual care [standardised mean difference (SMD) –0.20, 95% confidence interval (CI) –0.34 to –0.05], but
with significant heterogeneity in response. The six studies that reported interventions lasting longer than
1 year showed a more consistent weight reduction (SMD −0.24, 95% CI −0.36 to −0.12). However, within
this group, only two of the six studies achieved a statistically significant weight loss, both of which included
people with other severe mental illnesses.
Although some weight loss programmes have promoted behaviour change through intensive one-to-one
counselling strategies, resource scarcity in many health services makes the sustainability of such programmes
challenging.16 An alternative is structured education, which encompasses patient-centred, group educational
programmes with a clear philosophy, a written curriculum and a basis in behaviour change theory and empirical
data and is delivered by trained, quality-assessed educators.17 The NICE diabetes mellitus prevention guidance
advocates structured education as a potentially cost-effective method for the promotion of self-management
and behaviour change in people with chronic disease.18
The Leicester Diabetes Centre structured education approach
The STEPWISE intervention was developed by the Leicester Diabetes Centre (LDC), using the same process
used in developing the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed
(DESMOND) programme.19 The DESMOND programme and other adaptations have effectively promoted
lifestyle change and induced weight loss in multicentre RCTs. The curricula promote physical activity, a
healthy diet and weight loss by encouraging self-regulation through self-monitoring (feedback), relapse
prevention (identifying and addressing barriers to change) and goal-setting strategies. It incorporates
standardised educator training and a quality assurance programme.
Rationale and objectives
Rationale
Pragmatic interventions that offer long-term weight control or reduction in people with schizophrenia or
first episode psychosis are needed. The STEPWISE trial aimed to evaluate if a structured lifestyle education
programme, delivered in a community mental health setting, supported weight loss at 1 year in adults with
schizophrenia, schizoaffective disorder or first episode psychosis.
Objectives
l To develop a group-based, structured self-management lifestyle education programme for people with
schizophrenia, schizoaffective disorder and first episode psychosis.
l To conduct a multicentre RCT to investigate if the intervention leads to a clinically important difference
in weight change, as well as physical activity and diet, compared with usual care.
l To conduct a mixed-methods process evaluation to explore intervention delivery, participant and
facilitator experiences and explain discrepancies between expected and observed outcomes.
l To conduct an economic evaluation of the intervention.
l To assess the fidelity of intervention delivery when undertaken at 10 different sites.
INTRODUCTION
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Chapter 2 Intervention development
The aim of the intervention development phase was to develop a sustainable evidence-basedprogramme to support people with schizophrenia, schizoaffective disorder or first episode psychosis
with their weight management in a way that is acceptable and feasible to deliver within NHS settings
and available resources. The intervention was developed by a team from the LDC, together with expert
colleagues, patients and public involvement.
Literature review
The meta-analysis of non-pharmacological interventions designed to address antipsychotic-associated
weight gain by Caemmerer and colleagues12 was updated by re-running the search strategy across the
PsycINFO, MEDLINE, PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and
Cochrane Library databases using the original search terms, and only one further paper was identified.20
The literature review reported the benefits of non-pharmacological interventions, but the effectiveness did
not differ between modalities or intervention duration, or between interventions that employed group-based
versus individual approaches. The only difference was the benefit of outpatient over inpatient interventions.
Some studies suggested that nutritional interventions were more effective than cognitive–behavioural therapy,
but there was considerable overlap between interventions, making these distinctions difficult to determine.
Most interventions ran as 12–24 weekly sessions, delivered either in groups or individually. Some interventions
provided specific cardiovascular exercise training. Common dietary themes included:
l reading food labels
l switching drinks from full sugar to low calorie
l eating healthy snacks
l eating more slowly and deliberately
l recognising satiety.
Several used ‘psychoeducation’, but further details were not specified, and a theoretical basis was reported
in only one study that employed social cognition theory.21
Development of a theoretical framework
As the theoretical basis of the interventions was specified in only one paper, despite this being widely
considered to be good practice,22 we used the wider behaviour change and weight management literature
to inform our approach. We considered three key areas that are core to weight management interventions
in people with schizophrenia:
1. behaviour change theory, specifically with a focus on food and physical activity
2. the psychological processes underlying weight management
3. the challenges of living with psychosis and the impact on eating and weight.
These core factors determined the draft theoretical framework that guided the overall intervention
development (Figure 1). We thus ensured a focus on key hypothesised problem behaviours, were clear
about the receipt of the intervention by participants24 and thus applied appropriate behaviour change
techniques.25,26 The intervention was inspired by a number of theories, but systematically employed three
(Table 1), and intervention components were coded using the behaviour change taxonomy.25
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Background
determinants
Factors inluencing
motivation
Peer/normative
beliefs re food PA
Affect tolerance
Impact of psychosis
and medication
Support
Impact on QoL
Mood 
Well-being
Ability to engage in
weight management 
behaviours  
Cultural experiences/
factors
Intentions
Action plans
Individuals goals
Self-eficacy for
weight management 
Perceived and actual
behavioural control
Family inluences
Distal and proximal
reinforcements 
Food 
Weight 
Physical activity
Values, goals for
life and health
Beliefs about weight
Outcome expectancies
Knowledge around
food and PA
Relationship with food
Support
Demographics
Factors related
to psychosis 
Socioeconomics
Early-life experiences
FIGURE 1 Theoretical framework of the STEPWISE intervention. Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to the original text.
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TABLE 1 Development of the Intervention based on the three core theories
Identified target
behaviour/problem Theory
Participant receipt and
potential behavioural
outcome
Intervention on the STEPWISE
course
Mapping to behavioural
taxonomy
Belief about weight problems
(e.g. because of their
medication, they can have no
impact on their weight)
Self-regulation theory – specifically,
illness representations around weight
management
l Signs of a weight problem
l Causes
l Consequences
l Treatment
l How long it will last
To have identified their own
potential erroneous beliefs
and questioned these in order
to directly influence their
decisions around weight
management
‘Your story’ session: elicit
participants’ beliefs about what
caused their weight problem,
what ‘treatment’ would help to
manage it, the consequences for
them and their health
Topic sessions: information
sessions throughout the course,
specifically the impact of
medication on their weight and
the strategies that they can
employ to manage their weight
Not completely specified, but
included in:
l information about health
consequences
l framing/reframing
Low levels of confidence around
being able to engage in
successful weight management,
possibly related to multiple
unsuccessful attempts at
sustained weight loss
Self-efficacy
l Mastery (previous successful
attempts at the behaviour)
l Modelling (observing others
engaging in the behaviour)
l Verbal persuasion (talking through
the process of change, expecting
success)
l Emotional arousal (managing the
emotional barriers to change,
particularly anxiety around change
and fear of failure)
Increased belief in their ability
to engage successfully in
weight management.
Identified strategies to increase
their self-efficacy and engage
in behaviour change
‘Sharing stories’ session:
eliciting what has gone well in
terms of behaviour change,
problem-solving around
challenges and observing and
learning from others’ successes
and problem-solving. Discussing
feelings as activators of, and
barriers to, change
Next steps: action-planning,
identifying barriers,
problem-solving and setting
small graded tasks
l Focus on past successes
l Self-monitoring outcomes of
behaviour and consequences
l Instruction on how to perform
the behaviour
l Graded tasks
l Behavioural experiments
l Credible source
l Habit reversal
l Review behavioural goals
l Social comparison
l Focus
l Goal-setting
l Action-planning
l Problem-solving
l Information about antecedents
l Information about emotional
consequences
l Reduce negative emotions
l Self-incentive
l Self-reward
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TABLE 1 Development of the Intervention based on the three core theories (continued )
Identified target
behaviour/problem Theory
Participant receipt and
potential behavioural
outcome
Intervention on the STEPWISE
course
Mapping to behavioural
taxonomy
Maintenance of behaviour
change, particularly as there
are strong cues to previous
behaviours and thus high
likelihood of relapse
Relapse prevention model:
l High-risk situations with strong cues
need to be managed by avoidance
or coping strategies
l Coping strategies need to be
prepared in advance
l Management of relapse will result in
increased self-efficacy
Reviewed the situations that
would most likely result in
relapse. Developed plans of
how to manage these when
they occur
View relapse as a natural part
of the change process and as
an opportunity to learn rather
than berate themselves and
reinforce a potential negative
self-perception
Keeping it going: visual tools
and interactive exercises to
explore potential sources of
relapse and develop plans to
overcome this when it occurs
l Self-monitoring of behaviour
l Information about antecedents
l Behaviour assessment
l Goal-setting
l Problem-solving
l Action-planning
l Review behavioural goals
l Restructuring physical and
social environment
l Avoidance/reducing exposure to
cues for behaviour
l Reduce negative emotions
l Prompts
l Remove access to the reward
l Framing/reframing
l Verbal persuasion about capacity
Note
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original text.
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Intervention development
Initially, we planned to adapt the STEPWISE programme from the DESMOND ‘Let’s Prevent Type 2 Diabetes
programme’ intervention, which seeks to promote lifestyle changes in people who are at an increased risk
of developing type 2 diabetes mellitus, and results in modest benefits in biomedical and lifestyle outcomes.
Although significant weight change was not achieved, progression to diabetes mellitus in those who were
at risk of developing it decreased.27 However, it rapidly became apparent from the literature review, early
meetings with stakeholders and the expert opinions of health-care professionals actively providing local
weight management interventions in mental health settings that, although the underlying principles of the
Let’s Prevent Type 2 Diabetes programme were relevant, the programme itself was not suitable for people
with schizophrenia.
The STEPWISE intervention was therefore developed from first principles, using an established pathway
and robust framework28 (Figure 2). The prototype STEPWISE intervention aimed to promote autonomous
problem-solving around dietary and physical activity choices, with a specific focus on relapse prevention
and weight improvement.
The intervention development incorporated four stages, the first three of which are described in
this section:
1. foundation of the programme
2. prototype
3. pilot of prototype and incorporation of amendments and adaptation
4. facilitator training.
The programme was developed collaboratively by a team with expertise in the development of obesity and
lifestyle programmes, and mental health-care professionals and researchers with specialist knowledge of
schizophrenia and psychosis. Following the literature review, we sought the opinion of service users in
Sheffield and Leicester between January and September 2014. Three meetings were held in Leicester at
a user-led mental health support group; these were attended by 11 people with schizophrenia or other
mental health conditions, who provided input to discussions of the suggested prototype curriculum,
resources and subsequent iterations. Topics and suggestions were drawn directly from the group, but the
researchers also raised issues that they wished to explore with service users. In addition, other service
users, carers and investigators provided input at monthly meetings and in one-to-one interviews. We
sought advice from expert practitioners with experience of delivering lifestyle management groups for
people with psychosis in Salford, UK, and Sydney, Australia. The principles of the constant comparative
approach based on grounded theory were used to analyse these meetings.29
Six themes emerged from the service users:
1. transportation to and from the venue
2. venue and time
3. level of concentration
4. sessions
5. incentives and motivation
6. accompanying persons.
These are described in Testing the pilot intervention and informed the design of the prototype
intervention, its content, delivery and logistics.
DOI: 10.3310/hta22650 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 65
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Holt et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Development Pathway for Self Management Interventions: From Idea to Research
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• Training Programme
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• Research Q’s
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• Intervention Fidelity Process
• Cost Of Intervention
• Research Schedule
Establish  A Working Group
• Theories & Philosophies
• Potential Outcomes
• Describes Intervention
• Conﬁrm The Target Group
• Education Delivery 
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Observation Tool
1st Pilot
• Structure/Design
• Uptake/Recruitment
• Pilot Curriculum
• Intervention Receipt
• Piloting Resources
• Observe Delivery & 
Describe
• Recruit Pilot Educators
• Train Pilot educators
2nd Pilot
• 2nd Pilot Of Reﬁned 
Intervention
• Acquired Feedback  
(See 1st Pilot)
• Re-train Pilot educators
Training
• Skills & Knowledge Required
• Don’t Re invent   Wheel
• Scope Existing Training
• What do you want 
Educators to do/achieve
• Target intervention 
Behaviours
• Write /Deliver Training
• Trial Resources
Train or Retrain Educators
• Review Training and Reﬁne 
• Observe Delivery
• Re -Train in Relation To 
Intervention Changes
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6/12 Weeks 1/4 Weeks 1/4 Weeks
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FIGURE 2 The Leicester development pathway for self-management interventions. Reproduced with permission from Dr Sharon Spencer (Dr Sharon Spencer, University of
Leicester, November 2017, personal communication).
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Prototype
The user group specifically contributed to the intervention format and played an important role in refining
the logistics, content and delivery. The Sheffield mental health team and research team also suggested
further changes to the prototype curriculum and resources; for example, appropriate supporting tools
(incentives) for participants were introduced and the curriculum terminology was adjusted to improve
its acceptability.
The prototype intervention comprised four 90-minute core group education sessions, delivered to small
groups of six to eight participants over 4 consecutive weeks. A breakdown of each session can be found in
Figure 3. The curriculum included individual personal stories, taking control of weight, healthier food and
drink choices, the relationship between weight and medication, and the relationship between calories and
portions and physical activity. The intervention had a written curriculum to ensure consistency and resources
in line with its person-centred philosophy. Participants were not ‘taught’ in a formal way, but instead were
supported to discover and work out knowledge for themselves to inform their goals and plans.
Although the intervention was designed to be delivered by two local trained facilitators, the prototype
sessions were delivered in Sheffield by the development team and were watched by health-care professionals
who had been identified as potential facilitators. Feedback from the developers and potential facilitators
confirmed the appropriateness of content and resources, while challenging any assumptions made about
style and content. We envisaged that at least one facilitator would be a registered mental health professional,
whereas the other would have a professional background as a registered mental health professional, mental
health support worker, health-care assistant or similar. Current experience of working with people with
mental health issues and knowledge of antipsychotics were key facilitator attributes.
To provide ongoing support, a series of 110-minute follow-up ‘booster’ sessions were designed to occur
every 3 months after the end of the core sessions. Fortnightly support telephone calls from the facilitator
team were arranged and appropriate training was given to the facilitators.
Testing the pilot intervention
The pilot testing of the intervention was undertaken in a community setting and comprised a cycle of four
cohorts between May and December 2014 (Figure 4). Biomedical and lifestyle outcomes were not collected
during the pilot. The aims were to:
l test the components of the intervention
l assess the skills and knowledge required from facilitators and so inform the training
programme content
l understand the obstacles to, and enablers of, delivering the intervention in a real-world situation
in accordance with intervention mapping, as described by Bartholomew et al.,22 and following the
Medical Research Council framework for evaluating complex interventions.30
The participants were recruited through Sheffield Health and Social Care NHS Foundation Trust Community
Mental Health Teams (CMHTs). The eligibility criteria were identical to those proposed for the future RCT
(see Chapter 3, Participant selection and eligibility) to ensure that the intervention would meet the needs of
potential trial participants.
Participants were identified during routine clinic appointments and case note review and given brief
information about the study. A total of 103 service users with schizophrenia or first episode psychosis
were approached by the mental health team, of whom 44 did not meet the eligibility criteria, 16 were
non-contactable and 19 declined to participate. Twenty-four people consented to participate, and
20 attended at least one session.
DOI: 10.3310/hta22650 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 65
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Holt et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
Session 2Session 1
STEPWISE programme
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Supporting tool
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Supporting tool
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Supporting tool
Cookery book
Food scales
Supporting tool
Weighing scales
Tape measure
Sessions 5, 6 and 7
Your story
Your story
(20 minutes)
Sharing stories
(20 minutes)
Sharing stories
(20 minutes)
Sharing stories
(20 minutes)
Sharing stories
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Introduction
Introduction
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Introduction
(5 minutes)
Introduction
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Introduction
(5 minutes)
Introduction
(5 minutes)
Next steps
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Topic 1a 
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Next steps
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Next steps
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Topic 2b 
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Topic 3b 
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Sedentary 
behaviour
Topic 2a 
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Taking control of
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Topic 3a 
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Taking control of
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Taking control of
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Next steps
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Your plan
Next steps
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Follow-up
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FIGURE3 OutlineoftheSTEPWISEgroupsessions.ReproducedfromHoltetal.
23 ThisisanOpenAccessarticledistributedinaccordancewiththetermsoftheCreative
CommonsAttribution(CCBY4.0)license,whichpermitsotherstodistribute,remix,adaptandbuilduponthiswork,forcommercialuse,providedtheoriginalworkisproperly
cited.See:http://creativecommons.org/licenses/by/4.0/.TheGJHVSeincludesminoradditionsandformattingchangestotheoriginaltext.
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Cycle 1
(n = 5)
Identified as potentially eligible
(n = 103)a
Not contacted 
(n = 1)
(Reasons unknown)
Consented
(n = 24)
• Did not attend screening visit, n = 1
• Candidate not interested/not willing to participate,
   n = 10
• Unable to attend scheduled course, n = 1
• Alcohol dependence, n = 1
• Substance misuse, n = 1
• Too ill at present, n = 2
• Changed medication within 1 month, n = 1
• Bipolar disorder, n = 2
Candidate responded
(n = 43)
Unable to contact
(n = 15)
Attempts to contact by telephone
(n = 58)
Cycle 3
(n = 4)
Cycle 2
(n = 3)
• Engaged in weight management programme, n = 2
• Significant alcohol use, n = 4
• Tentative diagnosis of mania, n = 1
• Current inpatient/too ill, n = 3
• Not engaged with service, n = 2
• Substance/drug use, n = 6
• No weight gain or concern, n = 13
• Not taking antipsychotics, n = 5
• Out of city, n = 2
• New to service, n = 1
• < 18 years of age, n = 3
• Deaf, unable to participate, n = 1
• Does not like groups, n = 1
Eligible
(n = 36)
Session attendanceb Session attendance Session attendance Session attendance
• Week 1, n = 2
  (2 DNA – 1 had hospital
  appointment, 1 unknown)
• Week 2, n = 2
• Week 3, n = 1
   (1 DNA – unknown reason)
• Week 4, n = 2
• Week 1, n = 3
• Week 2, n = 1
   (2 DNA – 1 unwell, joined
   cycle 3, 1 unknown)
• Week 3, n = 0
   (1 DNA – unknown reason)
• Week 4, n = 0
• Week 1, n = 4
• Week 2, n = 5
   (1 joined from cycle 2)
• Week 3, n = 4
   (1 DNA – unknown reason)
• Week 4, n = 4
One could not 
attend – joined cycle 2 
• Week 1, n = 11
• Week 2, n = 9
   (2 DNA – unknown reasons)
• Week 3, n = 8
   (1 DNA – unknown reason)
• Week 4, n = 5
   (3 DNA – unknown reasons)
Cycle 4
(n = 12)
Not eligible
(n = 7)
Not eligible from face-to-face contact
(n = 44)
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The participants attended one of four pilot interventions at a local venue; these comprised the four weekly
core sessions, each lasting ≈2 hours, including a refreshment break. Observation notes were taken at
each session to supplement feedback from participants and facilitators in order to refine the programme
content, resources and delivery as necessary in an iterative process.
Recruitment and reminders for attendance
Recruitment and retention to the first two cohorts were difficult, and novel recruitment strategies, such as
the offer of transport, and text and telephone-call reminders, were needed to increase attendance. This led
to improved participation in the third and fourth iterations.
Logistical considerations
Participant feedback showed that they valued the intervention and discussion mostly focused on practical
ways of facilitating attendance and active engagement. Organisational issues were seen as key factors
(e.g. arranging taxis helped participants to arrive in a timely manner, while reducing the anxiety of using
public transport). The local mental health venue was described as a convenient and familiar place to reach.
The participants reported that the number of sessions was reasonable.
Many people with schizophrenia have altered sleep patterns, which make early-morning appointments
difficult, and so the time of the sessions (12.30 for a 13.00 start) was considered to be ideal. During the
first cohort, participants struggled to attend on time; this was partly solved by providing taxis, but we also
introduced a pre-session healthy lunch. This meant that the participants did not disrupt sessions if they
arrived late, and also provided a practical demonstration of how to eat healthily on a limited budget.
Many people with schizophrenia may experience cognitive deficits and limited ability to concentrate over
time. To overcome this, we incorporated sufficient and flexible breaks into the pilot intervention.
Sessions
Participants enjoyed the small-group setting, which enabled them to assimilate information more efficiently,
share experiences with fellow participants and reinforce existing messages. Participants and facilitators found
the resources, such as flipcharts, laminates and booklets, valuable and engaging. Participants commented
on the benefit of using the same facilitators throughout the intervention. Contrary to our expectations,
participants wished to attend alone and thought that they would not benefit from bringing an accompanying
person to the sessions. Participants felt that undertaking the intervention was something they could accomplish
on their own and that it would be easier to share information with fellow participants without the presence of
people who did not have mental illness.
The use of supporting tools (e.g. samples of low-calorie drinks and snacks, kitchen scales, cookery books
and pedometers) reinforced the messages provided to participants about the benefits of participation,
improved internal motivation and supported engagement and attendance.
FIGURE 4 Consolidated Standards of Reporting Trials flow diagram for the STEPWISE Intervention Development
Study. a, Sheffield Health and Social Care NHS Foundation Trust advised that approximately 100 patients (60 patients
at one Community Mental Health Team, 20 at another and 20 at a third Community Mental Health Team) from care
co-ordinator lists were prescreened and deemed not to meet the basic inclusion criteria. A further cohort of patients
was then prescreened for cycle 4, with a further 64 identified as potentially eligible; b, two participants recruited
prior to the first Intervention Development Study cycle were unable to attend but willing to take part in the second
cycle; however, they did not take part in the second cycle as a result of returning to work (n= 1) and not being
contactable (n= 1). DNA, did not attend.
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Chapter 3 Evaluation methods
Trial methods
Trial design
We undertook a multicentre, two-arm, parallel-group RCT of the STEPWISE structured lifestyle education
programme compared with usual care plus written lifestyle advice in 10 NHS Mental Health Trusts in
England. Participants were individually randomised to the STEPWISE programme or usual care. This report
is concordant with the Consolidated Standards of Reporting Trials (CONSORT) statement (2010).31
Important changes to methods after trial commencement
Trial recruitment commenced on 12 March 2015 (first patient, first visit) and, following this, in response to
early observations and feedback from the intervention development study, a number of changes were
made to the protocol. The protocol was published32 and the current version is available via the National
Institute for Health Research (NIHR) Journals Library website.33
Between the initial Research Ethics Committee approval and study commencement, there were two
substantial amendments. These revised the sample size, clarified the eligibility criteria, described the control
arm and updated the screening and consent process to ensure that recruitment could take place closer to
scheduled intervention sessions.
In March 2015 (substantial amendment 3, protocol version 4.0), following feedback from the intervention
development study, the option for participants in the intervention arm to bring along a friend, relative or
carer to the intervention sessions was removed. This amendment also added details about referring any
concerns or participant risk to the clinical care team. Amendments were made before delivery of the first
foundation session (23 April 2015).
In June 2015 (substantial amendment 4, protocol version 5.0), the data collection windows for the
Operational Criteria Checklist for Psychotic Illness and Affective Illness (OPCRIT+) and the outcome
assessments were increased, to provide more opportunity for sites to follow up participants, allowing
for missed appointments.
A further amendment in November 2015 (substantial amendment 5, protocol version 6.0) clarified the use
of ‘Community Mental Health Teams’ in the eligibility criteria. This allowed potential participants within a
variety of services, including those stepping down from inpatient to community services, to participate,
provided that they could fully implement the learning from the intervention. This amendment also allowed
1 additional week to obtain the fasting blood sample at the 12-month follow-up.
In February 2016 (substantial amendment 6, protocol version 8.0), changes were made to the protocol to
allow over-recruitment beyond the initial recruitment target, in order to allow centres to recruit in waves
and run intervention groups with sufficient participants.
Participant selection and eligibility
The trial was co-ordinated from the Clinical Trials Research Unit (CTRU) in the Sheffield School of Health
and Related Research (ScHARR). Delegated study staff located at participating centres identified and
gained consent from potential participants. Eight of the 10 centres [and their principal investigators (PIs)]
were involved at the proposal development stage, with two further centres identified through expressions
of interest via the NIHR Clinical Research Network.
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The trial was promoted within clinical teams and in community areas in which mental health services are
delivered. Clinicians used a standardised script to ensure that potential participants received consistent
information about the trial. The research team at participating sites worked with clinical teams to identify
potentially eligible patients from clinic lists and other caseloads. Self-referrals were also accepted, following
the use of information displayed on posters and leaflets.
The study took place within CMHTs, including early intervention services, in 10 mental health NHS trusts
in a range of locations, urban and rural, in Sheffield, Leeds, York, Bradford, Greater Manchester, South
London, Sussex, Hampshire, Devon, Somerset and Cornwall.
Adults were eligible for inclusion in the study if they:
l were aged ≥ 18 years
l had a diagnosis of schizophrenia or schizoaffective disorder [defined by the International Classification
of Diseases, Tenth Revision (ICD-10) codes F20 and F25] or first episode psychosis (defined as < 3 years
since presentation to the mental health team) using case note review
l were being treated with an antipsychotic
l were able to give written informed consent
l were able and willing to attend and participate in a group education programme
l were able to speak and read English
l had a body mass index (BMI) of ≥ 25 kg/m2 or were concerned about their weight (in the case of
participants from South Asian and Chinese backgrounds, the BMI threshold was reduced to ≥ 23 kg/m2).
People were excluded from the study if they:
l had a physical illness that could seriously reduce their life expectancy or ability to participate in the trial
l had a coexisting physical health problem that would, in the opinion of the PI, independently affect
metabolic measures
l had a mental illness that could seriously reduce their ability to participate in the trial
l had a current pregnancy or were < 6 months post partum
l had a condition associated with significant weight gain (e.g. Cushing syndrome)
l engaged in significant alcohol or substance misuse which, in the opinion of the PI, would limit the
patient’s ability to participate in the trial
l had a diagnosis or a tentative diagnosis of psychotic depression or mania
l had a primary diagnosis of a learning disability
l were currently (or within the past 3 months) engaged in a systematic weight management programme,
to ensure that other programmes did not have an impact on baseline measures.
During the trial, participants were not prevented from joining weight loss or physical activity programmes
(intervention arm participants were encouraged to make positive behaviour change); however, any uptake
of systematic programmes (other than STEPWISE) was captured at the 3- and 12-month follow-up by
asking all participants if they had taken up any other weight management or physical activity programme
outside the trial.
All potential participants had a minimum of 24 hours in which to decide whether or not they wished to
participate, before attending a consent visit.
The CTRU co-ordinated the follow-up and data collection in collaboration with centres. Participant study
data were collected and recorded on study-specific case report forms (CRFs) by site research staff and were
entered onto a remote web-based data capture system at each site.
Interventions
All participants received written lifestyle advice on diet, physical activity and alcohol and smoking use before
randomisation. Participants were randomised to receive either the STEPWISE education programme or usual care.
EVALUATION METHODS
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Research intervention (STEPWISE education programme)
Participants allocated to the research intervention were contacted by the session co-ordinator and provided
with pre-course information, which included an introductory letter and leaflet confirming when and where
the sessions would take place and what to expect.
The intervention took place over approximately a 12-month period post randomisation. Participants
allocated to STEPWISE received a foundation course of four weekly 2.5-hour (including breaks) group
sessions delivered by two trained facilitators. The protocol specified approximately 6–10 participants for
each course, to allow for a good group size and to account for likely attrition.
The foundation course was followed by one-to-one support contact lasting for around 10 minutes,
approximately every 2 weeks for the remainder of the intervention period. This contact was personalised
and was mostly conducted by telephone, although it also took place in person on some occasions. The
purpose of the support contact was to discuss participants’ progress towards their goals, highlight any
issues and try and motivate participants to change their behaviours in line with the group-based session.
When participants could not be contacted, a motivational postcard was sent to them to maintain this
contact. Support contact was undertaken by a trained facilitator to support behaviour change and obtain
feedback from the participant.
Participants were invited to attend 2.5-hour group-based booster education sessions at 4, 7 and 10 months
post randomisation. Attendance at all intervention sessions and receipt of support contact were recorded.
Participants who attended education sessions were invited by facilitators to complete a ‘session feedback’
form at the end of each session. This was completed independently and sealed in an envelope to maintain
anonymity. The envelopes were posted directly to the CTRU for data entry. Participants could choose
whether or not to include their name on the feedback form, and the aim was to capture a self-report of
empowerment and health belief during the intervention.
Between four and six health-care professionals or associated staff at each participating centre received
facilitator training to deliver the STEPWISE intervention. This training covered the core DESMOND philosophy
(3 days), specific content and delivery of the STEPWISE programme (1 day) and the content and delivery of
booster sessions (1 day).
Control arm
Participants allocated to the control arm received treatment as usual (TAU), enhanced by the provision of
written lifestyle advice. There is known variability in the provision of physical health care, despite NICE
guidelines on the treatment and management of schizophrenia regarding healthy eating and physical
health.14 To standardise usual care in both groups as far as possible, participating centres provided printed
guidance to all participants (regardless of allocation) before randomisation on the risk of weight gain and
lifestyle advice, regarding diet, physical activity, smoking and alcohol use, when appropriate.
Usual care
It is appropriate in pragmatic trials for the comparison intervention to involve ‘usual practice’, offering
study sites leeway in deciding what that should involve.34 As the content of usual care can influence effect
size,35 we undertook a survey of usual care at the participating centres at two time points. The methods
for this exercise have been reported previously,36 but, in brief, sites were surveyed on their current practices
regarding healthy eating and physical activity programmes offered to people with schizophrenia. The
survey was based on current NICE guidance14 and included questions about any trust-offered healthy
eating and physical activity programmes, what discussions take place with patients before antipsychotic
initiation, the availability of smoking cessation support and how physical health reviews are completed,
including what measures are reviewed and how often.
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Measurement of outcomes
Following consent but before randomisation, research staff completed CRFs for each participant, which
covered medical and psychiatric history, demographics and current medication information (Table 2).
All assessments and questionnaires were undertaken either at the participant’s home or in the NHS trust.
A fasting blood sample was taken, as well as measurements of vital signs and anthropometry. Baseline
self-report instruments were completed, with research staff encouraged to read questions aloud to
TABLE 2 Trial outcome measures
Outcome measure
Time point
Pre-baseline Baseline 3 months 12 months
Eligibility criteria assessed by the clinical care team ✗
Medical history ✗
Psychiatric history ✗
OPCRIT+37 ✗
Renal function ✗ ✗
Hepatic function ✗ ✗
Height (to calculate BMI) ✗
Weight ✗ ✗ ✗
Waist circumference ✗ ✗ ✗
Physical activity [7-day wrist-worn GENEActiv
(Activinsights, Kimbolton, UK) accelerometer]
✗ ✗ ✗
Adapted DINE questionnaire38 ✗ ✗ ✗
Blood pressure ✗ ✗ ✗
Fasting glucose ✗ ✗
Lipid profile ✗ ✗
Glycated haemoglobin ✗ ✗
EQ-5D-5L39 ✗ ✗ ✗
SF-3640 ✗ ✗ ✗
B-IPQ41 ✗ ✗ ✗
BPRS42 ✗ ✗ ✗
Smoking status ✗ ✗ ✗
CSRI43 ✗ ✗ ✗
Changes in medication (dose and side effects) ✗ ✗ ✗
PHQ-944 ✗ ✗ ✗
Use of weight loss programmes ✗ ✗
Adverse events ✗ ✗
Session feedback (intervention only; each group session) ✗
B-IPQ, Brief Illness Perception Questionnaire; BPRS, Brief Psychiatric Rating Scale; CSRI, Client Service Receipt Inventory;
DINE, Dietary Instrument for Nutrition Education; EQ-5D-5L, EuroQol-5 Dimensions, five-level version; PHQ-9, Patient Health
Questionnaire-9; SF-36, Short Form questionnaire-36 items.
Note
Adapted from Gossage-Worrall et al.32 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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participants, with all available answer options, to ensure understanding. Participants were provided with
a wrist-worn accelerometer to wear 24 hours per day for 7 days following the visit.
Additional information, such as medication details and details of hospital admissions, was obtained and/or
verified using the patient’s medical notes. At both the 3- and the 12-month follow-up visits, research staff
who were masked to treatment allocation confirmed medication information with participants, particularly
doses and side effects of antipsychotic medication. They took measurements of blood pressure, weight
and waist circumference (and a fasting blood sample at 12 months only) and provided the participant
with a wrist accelerometer to wear for the next 7 days. Participants were asked to complete the same
questionnaires as at baseline, with the addition of a form to capture the uptake of any weight loss
programmes outside the STEPWISE trial. The follow-up windows at 3 and 12 months were defined
as minus 2 weeks and plus 4 weeks to allow time for missed and rearranged appointments.
Biomedical measures
The biomedical outcomes were:
l Weight outcomes – change in weight, the proportion of participants who maintained or reduced
weight, percentage change in weight, waist circumference and BMI. Standard operating procedures
specified how to measure body weight (e.g. light clothing, shoes off) using the Class III approved
Marsden 430-C portable scales (Marsden Weighing Machine Group Limited, Rotherham, UK) to the
nearest 0.1 kg; height (e.g. standing tall, feet hip-width apart and head level) using the Class I approved
Marsden HM-250P stadiometer (Marsden Weighing Machine Group Limited, Rotherham, UK) to the
nearest 1 cm; and waist circumference (e.g. tape lying flat and level, taut but not tight) using the Class I
approved Seca 201 tape measure (Seca, Birmingham, UK) to the nearest 0.1 cm. Participants who
provided 12-month weight data in accordance with the protocol received a £20 shopping voucher.
l Vital signs and laboratory measurements:
¢ blood pressure (average of three measurements) and pulse, measured by electronic
sphygmomanometer in the non-dominant arm after 5 minutes’ rest
¢ fasting glucose, lipid profile and glycated haemoglobin (HbA1c) at baseline and 12 months only
(all blood samples were analysed by local laboratories).
Physical activity
Physical activity was assessed by wrist-worn accelerometer (GENEActiv, Activinsights Ltd, Kimbolton, UK).
Participants were asked to wear the accelerometer on their non-dominant wrist continuously (i.e. 24 hours
per day) for 7 days and data were derived using the approach reported in da Silva et al.45 The GENEActiv.bin
files were analysed with R-package GGIR, version 1.5 (Cran-R Project, the Netherlands).28,29 Signal processing
in GGIR includes the following steps:
l autocalibration, using local gravity as a reference28
l detection of sustained abnormally high values
l detection of non-wear
l calculation of the average magnitude of dynamic acceleration (i.e. the vector magnitude of acceleration
corrected for gravity [Euclidean norm minus one g (ENMO)] as:
ENMO = Σ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
x2 + y2 + z2
p
− g, (1)
over 5-second epochs, with negative values rounded up to zero.
DOI: 10.3310/hta22650 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 65
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Holt et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Files were excluded from all analyses if the post-calibration error was > 0.02 g30 or < 16 hours of wear
time as recorded by either monitor during the 24-hour day of interest. Detection of non-wear has been
described in detail previously.29 In brief, non-wear is estimated based on the standard deviation (SD) and
value range of each axis, calculated for 60-minute windows with 15-minute moving increments. If for at
least two out of the three axes the SD is < 13 mg (milligravity) or the value range is < 50 mg, the time
window is classified as non-wear.
The average magnitude of dynamic wrist acceleration (ENMO) and time accumulated in moderate or
vigorous physical activity (MVPA) were calculated. The threshold for determining MVPA was ≥ 100 mg.
Four measures were taken:
1. mean acceleration calculated per day
2. MVPA based on a 5-second epoch setting (i.e. total unbouted MVPA)
3. MVPA based on a 5-second epoch setting and a bout duration of 5 minutes, inclusion criteria based
on > 80%
4. MVPA based on a 5-second epoch setting and a bout duration of 10 minutes, inclusion criteria based
on > 80%.
Each of the above was calculated for weekdays (provided data were available for at least 3 of the 5 days),
weekends (provided data were available for at least 1 day) and all days (when data were available for at
least 4 of the 7 days).
Lifestyle factors
Three lifestyle measures were collected. These were the adapted Dietary Instrument for Nutrition Education
(DINE) questionnaire,38 smoking status and use of weight loss programmes:
l The adapted DINE questionnaire measures diet on six items – fibre intake, fat intake, unsaturated fat
intake, sugar intake, alcohol intake and meal type. Scores and ratings were calculated only when all
constituent items had been reported for the particular item.
l Smoking status was measured by the number and percentage of participants who smoke, smoking
category [light (< 10 cigarettes per day), moderate (10–19 cigarettes per day) or heavy (≥ 20 cigarettes per
day)], interventions offered to aid smoking cessation and interventions taken to aid smoking cessation.
l Use of weight loss programmes (follow-up only); the number and percentage of participants who
reported enrolling in any weight loss programme.
Patient-reported outcome measures
Four patient-reported outcome measures were collected:
1. EuroQol-5 Dimensions, five-level version (EQ-5D-5L) health utility,46 comprising a health state and
thermometer scale. Higher scores indicate a better health state.
2. The Short Form questionnaire-36 items (SF-36),47 from which eight domains of quality of life (QoL) were
derived. Higher scores indicate a higher QoL.
3. The Patient Health Questionnaire-9 (PHQ-9),44 a measure of depressive symptoms. Higher scores
indicate more severe depressive symptoms.
4. The adapted Brief Illness Perception Questionnaire (B-IPQ),41 a measure of illness perception. Higher
scores reflect a more threatening view of the obesity.
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Clinician-assessed outcome measure
Participants were assessed using the Brief Psychiatric Rating Scale (BPRS), a clinician-rated measure
that evaluates the psychopathology of patients with schizophrenia.42 Higher scores indicate greater
psychiatric concern.
The OPCRIT+ was completed by the research team, using case note review, within 10 weeks of the
baseline visit. This was to provide comparable baseline characteristics for all participants across the study.
The protocol allowed baseline fasting blood samples and accelerometry data to be collected after
randomisation when recruitment occurred close to a scheduled intervention course.
Cardiovascular and diabetes mellitus risk
The 10-year cardiovascular risk was calculated using the Framingham Cardiovascular Risk Score.48 An
analysis using a second cardiovascular risk score for people with severe mental illness (PRIMROSE)49 was
planned but not used, as a problem emerged with the algorithm during the analysis. The 10-year type 2
diabetes mellitus risk was calculated by the Leicester score.50
Derivation of outcome measures
The EuroQol-5 Dimensions (EQ-5D) tariff was scored using the EQ-5D-5L for UK population norms;51 no
score was calculated if any of the five items were missing. The eight subscales of the SF-36 were calculated
as per McHorney et al.;40 subscores were calculated when at least half of the questions within the domain
had been answered. When all eight domains were completed, the aggregate physical and mental
component scores were calculated. The adapted B-IPQ was scored by summing the responses to items into
a single score41 if at least six of the eight questions were answered. The BPRS was scored by summing up
the responses into a single score42 and was calculated if at least 14 of the 18 items had been answered.
Sample size
The sample size calculation was based on data from two sources, both of which assessed behavioural
interventions for weight loss in people prescribed antipsychotics for schizophrenia. First, a systematic review
undertaken by Das et al.52 examined both randomised and non-randomised controlled trials, and reported
between-group differences of 1.5–6 kg (SD ≈5 kg). Data on overweight and obese UK patients with severe
mental illness from a second study also contributed to the sample size calculation. A total of 51 people with
schizophrenia were followed up for at least 1 year, and the weight change reported was 7.7 kg (SD 6.5 kg).53
The sample size used in STEPWISE aimed to detect a difference of 4.5 kg, which is clinically meaningful
(average ≈5% reduction in body weight)54 and also appears to be compatible based on previous work.
A conservative estimate of a SD of 10 kg, 95% study power and a two-sided significance level of 5% was
assumed, meaning that 130 participants per intervention arm (260 participants in total) were required to
detect a minimum clinically important difference of 4.5 kg.
Owing to the group nature of the intervention, it is possible that the outcomes of participants within the
same group may be correlated. Therefore, an average group size of seven participants was assumed, with
an intraclass correlation of 5% in the intervention arm. For this reason, the sample size was inflated by a
design effect of 1.3 in the intervention arm, which gives revised sample sizes of 169 participants in the
intervention arm and 130 participants in the control arm (299 in total).
To ensure a 1 : 1 allocation, 158 participants were required per arm to reproduce this power. Assumptions
were made for a conservative dropout rate of 20%, which is higher than that observed in similar studies,55
giving a final sample size of 198 participants per trial arm. This equates to 40–50 participants at each
centre, with 20–25 of these receiving the intervention in up to four groups per site.
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Randomisation
Sequence generation
The randomisation list was generated using the CTRU’s web-based system, which provided central
randomisation and ensured that the study team was blinded to the allocation. The list was generated using
permuted blocks of random sizes to allocate participants to either TAU plus the STEPWISE lifestyle education
programme or TAU alone in a 1 : 1 ratio, stratified by site and time since the start of antipsychotic medication
(< 3 months or ≥ 3 months). When the exact duration was unknown, an approximate duration was
considered to be acceptable for the purposes of randomisation.
Implementation
After the baseline assessments were completed and consent was provided, participants were randomised
using the STEPWISE randomisation system. Once randomised, an unblinded member of the site research
team informed the participant and their general practitioner (GP) of the treatment allocation.
Blinding
All research team members performing outcome assessments were blind to treatment allocation. Blind
(or suspected) breaks were recorded. Owing to the nature of the intervention, participants were not blinded.
Ethics aspects
The study received a favourable opinion from the National Research Ethics Committee, Yorkshire & the
Humber – South Yorkshire on 4 February 2014 (reference 14/YH/0019).
Patient and public involvement
Angela Etherington (a person with severe mental illness and experience of taking antipsychotic medication)
and David Shiers (the carer of a family member with schizophrenia) were involved in the design of the
study and the intervention, management meetings, the qualitative research analysis and the drafting of the
report. They reviewed, made changes to and approved the final lay summary.
Statistical methods
Outcome measures
Primary outcome measure
The primary end point of the STEPWISE trial was the change in weight (kg) at 12 months after randomisation.
Secondary outcome measures
Secondary outcomes included biomedical measurements, physical activity, dietary components and
psychosocial factors, including QoL, health beliefs and cost-effectiveness. All secondary outcome measures
were assessed at baseline and after 3 and 12 months (except when stated), to measure if there was an
effect at the end of the intervention and, if so, whether or not this was sustained over the longer term.
Analysis of weight change
The primary objective (weight change at 1 year post randomisation) was assessed by fitting a marginal
generalised estimating equation (GEE) model using robust standard errors and an exchangeable correlation
structure. The difference between intervention and control arms was adjusted for baseline weight, site and
years since antipsychotic medication initiation. The intraclass correlation coefficient (i.e. the ‘cluster’ term)
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was derived from the correlation matrix of the GEE model. The following preplanned sensitivity analyses
were undertaken:
l alternative covariates (in which any imbalanced baseline characteristics were added into the GEE model)
l alternative model structure (multilevel model in place of the GEE to estimate the cluster effect)
l alternative assumptions for missing data.
The last of these analyses used approaches proposed by von Hippel,56 Carpenter et al.57 and White et al.58
The complete-case analyses were augmented with a reanalysis assuming a missing-at-random (MAR)
mechanism, achieved by incorporating all baseline covariates that were associated with the probability of
missing weight at 12 months and/or with weight change among those who were followed up; these
included baseline demographics, disease characteristics, recruiting site, treatment group, weight, BPRS
score, B-IPQ score and physical domains of the SF-36 at baseline and 3 months.
The first model incorporated baseline measures as covariates, following which the treatment effect was
re-estimated (model MAR 1). Following this, predictive mean matching multiple imputation via chained
estimation incorporated all available baseline and 3-month values to impute missing 12-month weight
using the original model covariates (model MAR 2). Thereafter, the sensitivity to missing not at random
(MNAR) was assessed by adding a range of fixed quantities (delta) to the MAR prediction; for example,
delta = 1 corresponds to the assumption that an individual with no 12-month data has a weight change of
1 kg more than predicted. The values of delta used ranged from –5 to + 5 kg and included different values
of delta for the two treatment groups.
The treatment comparison was calculated in the following preplanned subgroups:
l uptake of therapy (non-attender; attended one or two foundation sessions; attended three or four
foundation sessions but no booster sessions; attended at least three foundation sessions and one
booster session)
l recruiting centre
l clinical diagnosis (first episode vs. other diagnoses)
l time since starting antipsychotic medication (≤ 12 months, > 12 to ≤ 24 months and > 24 months)
l BMI (≤ 25 kg/m2, > 25 to ≤ 30 kg/m2, > 30 to ≤ 35 kg/m2, > 35 to ≤ 40 kg/m2 and > 40 kg/m2)
l principal reason for dietary concern, as assessed by the B-IPQ.
Analysis of other outcomes
Other outcomes were analysed using a GEE model, with the covariates being treatment group, site, years
since antipsychotic medication initiation and the baseline measurement of the respective outcome.
General considerations
A comprehensive statistical analysis plan was developed before the database freeze and while the
statistician was blinded to treatment allocation. Data were reported and presented in accordance with the
revised CONSORT statement.31,59 Analyses were performed on an intention-to-treat basis, unless otherwise
stated. Analyses of outcome in relation to protocol compliance were undertaken by looking at the level of
course attendance (a subgroup analysis in Analysis of other outcomes) and by complier-average causal
effect (CACE), using two-stage least squares regression; the latter defined compliance as attendance of at
least one foundation course.
All statistical tests were two-tailed at a 5% significance level and CIs were two-sided, with 95% intervals.
No adjustment was made for multiplicity, but the number of outcome measures used necessitates cautious
interpretation of statistical significance. All analyses were performed in the Stata® version 14.2 (StataCorp LP,
College Station, TX, USA) statistical software, using the user-written Stata package rctmiss for the first
MNAR model.60
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Process evaluation
Overview
The process evaluation was undertaken ‘to explain discrepancies between expected and observed outcomes,
to understand how context influences outcomes, and to provide insights to aid implementation’.30 Specifically,
we investigated whether or not (1) treatment is consistent with the underpinning behaviour change theories
(treatment theory or theory of change) and (2) contextual factors affected implementation. The process
evaluation used a pipeline logic model, showing causal links between resources, activities and outcomes,
integrating the National Institutes for Health Behaviour Change Consortium (NIHBCC)’s approach to treatment
fidelity24 and a modified version of Linnan and Steckler’s framework for process evaluation.61 We described
context qualitatively and took a mixed-methods approach to characterising recruitment, reach, dose delivered/
received and fidelity both qualitatively and quantitatively, with triangulation between data sources.62 Interviews
were held with intervention designers, health professionals and RCT participants, and the analyses were
combined with RCT data and quantitative fidelity data.
Researchers
The qualitative researchers, Rebecca Gossage-Worrall, a female graduate sociologist [Master of Arts (MA);
Research Associate], and Daniel Hind, a male graduate anthropologist [Doctor of Philosophy (PhD),
Reader], had 8 and 10 years’ experience of interviewing, respectively. No relationship was established with
any participant outside or before the interview. The interview purpose was explained to participants twice,
at consent to trial and at interview. Two facilitators had a prior relationship with Rebecca Gossage-Worrall
(through their study research role) before participating in the interviews. Daniel Hind knew two
intervention developers prior to interview via project meetings.
Theoretical and thematic framework
Rationale and worldview63/epistemology64
We incorporated qualitative research to understand the implementation of, and response to, the
intervention,65–67 to propose causal pathways to success or failure.65–68 However, our rationale was primarily
pragmatic rather than explanatory;69 we were pursuing a basis for ‘organising future observations and
experiences’70 by ‘investigating conceivable practical consequences’71 of future decisions, rather than
advancing, building or testing social science theory.68,72
Research design63/methodology64/approach73
We used a single-case design,74 with the unit of analysis variably at the participant level (n = 24 participants)
and at the level of the experimental intervention programme (n = 20 facilitator interviews). In participant
case studies, the embedded units of analysis were (1) post-course interview and (2) quantitative CRFs,
especially weight at 0, 3 and 12 months.
Theory
We used the International Classification of Functioning (ICF) as a conceptual framework for describing the
schizophrenia-specific context for implementation.75,76 We used an a priori framework, based on similar
studies,77,78 to inform the topic guide for interviews with participants (Table 3). Topic guides for interviews
with health professionals were designed around the normalisation process theory (NPT).80–83 We used the
theoretical domains framework (TDF)84 to characterise stakeholder understandings of the intervention.
Codes from the TDF were later mapped to constructs from the principal theories underpinning the
STEPWISE intervention: Bandura’s self-efficacy theory,85 the self-regulation theory of Leventhal et al.86 and
Marlatt and George’s relapse prevention model.87 We used the NIHBCC’s framework for understanding
intervention fidelity79 and the framework of Sekhon et al. for understanding the acceptability of health-care
interventions.88
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We developed a programme theory to identify essential elements for the successful replication and causes
of failure in the contracts, actions, interactions and emergent relationships between people and organisations
that surround the STEPWISE intervention.89–91 The programme theory development was deductive, through
literature review and by articulating mental models in discussion with the LDC team, and inductive, through
interviews with participants and professionals.92 To illustrate how sequences of events were to bring about
desirable outcomes, as per the programme theory, we developed a logic model (Figure 5).93,94
Participant selection and setting
Consent for participant interviews was requested, face to face, at the time of consent to the RCT (when
participants specified a preferred method of approach) and reconsented immediately before interview. The
majority of participants were approached by telephone. Professionals were approached directly by telephone,
e-mailed the information sheet and consented by telephone; intervention designers were approached during
project meetings and by e-mail. The RCT intervention arm participants were purposively sampled (n = 24)
from those consenting and allocated to the intervention (n = 188) to reflect different study centre, gender
and age (Table 4). A total of 63 participants (34%) were sampled, of whom 22 (35%) were non-responsive,
despite a minimum of three attempts to contact. Ten participants declined when invited to participate, one
declined at (re-)consent and six consented but did not attend the appointment. Forty professionals were
purposively sampled to reflect differences in site, occupation, sex and prior group facilitation characteristics
(derived from a short survey after completing facilitator training) for invitation to study, of whom 20 were
interviewed (Table 5); none formally declined, but many left their employment or were non-responsive, or it
became unnecessary to interview them because of accrual of the target sample. All those involved with the
intervention design were interviewed. All interviews were conducted by telephone.
TABLE 3 Example questions derived from the a priori framework
A priori theme Example interview question
Acceptability77,78 l How did you find the STEPWISE programme?
l Was there anything in particular that you liked about it?
l Was there anything in particular that you did not like about it?
l How easy or difficult would it be to pay for the travel to the sessions?
l How long were the sessions? Was that OK? How many sessions did you attend?
(Probe: if sessions were missed, why?)
l How do you feel now that it is the end of the weekly course?
Being in a group77,78 l How many people were in your group? (Probe: was this number OK?)
l How easy or difficult did you find talking in the group? (Prompt: talking about weight,
experience of attending other weight management programmes and how they differ)
Presentation of
content78
l Did you feel it got the balance right in terms of talking about both diet and physical activity?
l What did you think of the people who led your group?
Changes in
behaviour77,78
l Did you receive anything to help you to put into practice what you learned?
(Prompts: water bottle; scales; printed materials)
l How useful or not were these items?
Processes of change78 l Did the programme meet your needs?
Types of
interventions78
l Did you feel it got the balance right in terms of talking about both diet and physical activity?
Fidelity79 l Did you have any of the one-to-one contact with your facilitator?
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Resources Activities Immediate outcomes Intermediate outcomes Longer-term outcomes
STEPWISE programme
• Infrastructure
• Trainers
• Their mentors/managers
STEPWISE programme
Mentors frequently 
assess the competency 
of trainers
Trainers train and
periodically assess fidelity
of NHS trust-based group
facilitators
Programme management
(including identification
of staff, booking rooms)
‘Case’ management
(booking people on
course, sending letters,
follow-up)
• Health professionals
   motivated to become
   STEPWISE facilitators
   (ideally experienced in
   group facilitation)
• Appropriately
   resourced co-ordinator
• Buy-in from NHS trust
   chief executive and
   gatekeepers
Gatekeepers actively
refer people
Training course materials
and venue
People with
schizophrenia motivated
to attend the course
STEPWISE course
materials:
venue, leaflets, patient
handbook, refreshments,
travel costs
Eligible people invited to
attend the STEPWISE
programme (‘reach’)
Attendance at all
foundation and booster
sessions; one-to-one
telephone support 
sessions with 
demonstrable in-session
‘receipt’ of behaviour
change content  (‘dose
received’)
4 × weekly foundation
sessions and
3 ‘booster’ sessions; 
one-to-one telephone 
support calls made 
(‘dose delivered’)
Sessions delivered in line
with STEPWISE
philosophy (‘fidelity’)
Quality of STEPWISE training maintained
Trusts can monitor
patient-important
outcomes
Reduced:
• weight
• depression
• inappropriate
   service use
• blood pressure
• BMI
• incidence of smoking
Increased:
• physical activity
• health-related quality
   of life
Improved:
• nutrition
• enactment of health
   behaviours
Trusts sustain STEPWISE
Uptake sustained
Cost-effectiveness
demonstrated.
NICE recommend the
STEPWISE programme as
part of care pathway
Other trusts adopt the
STEPWISE programme
Obesity, type 2 diabetes
mellitus and
cardiovascular events
reduced in population
of people with
schizophrenia
FIGURE 5 Logic model for the implementation of the STEPWISE intervention.
E
V
A
L
U
A
T
IO
N
M
E
T
H
O
D
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
4
TABLE 4 Important characteristics of the qualitative sample (all intervention participants)
ID Sex
Age
(years) Diagnosisa Ethnicity
BPRS
score
Sessions Weight in kg Weight change in kg Interview took
place after
(session)Foundation Booster 0 months 3 months 12 months 0–3 months 3–12 months 0–12 months
Clinically important weight loss over 12 months
S03/Q06 M 35 F20 White British 34 4 3 115.5 111.7 98.3 –3.8 –13.4 –17.2 Booster 2
S01/Q01 F 40 F20 African 27 3 2 106.7 101.0 94.0 –5.7 –7.0 –12.7 Foundation
S08/Q05 F 28 F25 White British 41 4 3 103.4 104.9 94.1 1.5 –10.8 –9.3 Booster 1
S04/Q02 F 33 FEP African 34 4 0 92.2 93.4 86.1 1.2 –7.3 –6.1 Foundation
S06/Q01 M 23 F20 White British 27 3 2 92.7 92.6 87.5 –0.1 –5.1 –5.2 Foundation
S01/Q05 M 40 F20 White British 24 4 2 110.4 105.4 105.2 –5.0 –0.2 –5.2 Foundation
S02/Q04 F 40 F25 White British 31 4 3 74.0 71.0 69.3 –3.0 –1.7 –4.7 Booster 2
Weight loss that is not clinically important
S10/Q03 F 39 F20 White British 23 3 3 110.8 108.2 107.4 –2.6 –0.8 –3.4 Booster 1
S04/Q09 M 48 F20 White British 47 3 1 70.1 71.9 68.7 1.8 –3.2 –1.4 Foundation
S09/Q04 M 43 F20 White British 25 4 2 125.1 110.0 123.7 –15.1 13.7 –1.4 Foundation
S09/Q02 F 49 F25 White British 21 4 3 105.5 104.4 104.2 –1.1 –0.2 –1.3 Foundation
S08/Q06 F 44 F20 White British 28 2 2 92.0 93.6 90.8 1.6 –2.8 –1.2 Foundation
S01/Q04 M 43 F20 White British 33 3 3 96.7 97.0 96.6 0.3 –0.4 –0.1 Booster 1
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TABLE 4 Important characteristics of the qualitative sample (all intervention participants) (continued )
ID Sex
Age
(years) Diagnosisa Ethnicity
BPRS
score
Sessions Weight in kg Weight change in kg Interview took
place after
(session)Foundation Booster 0 months 3 months 12 months 0–3 months 3–12 months 0–12 months
Weight gain that is not clinically important
S05/Q03 F 54 F25 White British 53 4 3 92.4 90.0 92.9 –2.4 2.9 0.5 Foundation
S06/Q02 M 34 FEP White British 32 3 2 121.8 126.0 123.9 4.2 –2.1 2.1 Booster 1
S03/Q01 F 36 F20 Bangladeshi 24 4 2 101.5 103.3 103.7 1.8 0.4 2.2 Foundation
S04/Q10 M 19 FEP White British 36 2 0 84.6 83.9 87.7 –0.7 3.8 3.1 Foundation
S08/Q09 F 31 F25 White British 23 4 1 92.4 96.4 95.5 4.0 –0.9 3.1 Foundation
S09/Q01 M 54 F20 White British 29 3 3 86.3 87.3 90.4 1.0 3.1 4.1 Foundation
Clinically important weight gain
S04/Q12 M 30 FEP Indian 26 4 3 120.0 124.3 125.5 4.3 1.2 5.5 Foundation
S07/Q06 M 25 FEP White British 34 3 2 131.6 140.0 142.9 8.4 2.9 11.3 Foundation
S04/Q08 F 32 FEP White British 44 4 3 126.2 139.8 155.9 13.6 16.1 29.7 Booster 1
Qualitative participants without weight data
S04/Q06 F 25 FEP White British 34 4 0 86.0 94.0 ND 8.0 ND ND Booster 1
S06/Q06 M 21 FEP White other 39 3 2 91.3 79.0 ND –12.3 ND ND Booster 1
F, female; ID, identification; M, male.
a FEP, first episode psychosis; F20, schizophrenia; F25, schizoaffective disorder; ND, no data.
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TABLE 5 Characteristics of the qualitative sample (facilitators)
ID Professional category Education
Worked in
Groups
facilitated
Confidence in
skills (0= low;
5= high)
Mental health Physical health
Years Months Years Months
S01/F02 Support worker City and Guilds of London
Institute
29 0 ND ND 1 4
S01/F04 Mental health nurse PG degree 8 0 0 0 0 3
S02/F02 Healthy living advisor UG degree ND ND ND ND 10 4
S02/F03 Physiotherapist UG degree 2 4 4 3 10 4
S02/F06 Dietitian UG degree 3 4 3 4 99 4
S03/F02 Occupational therapist UG degree 5 0 0 0 24 4
S03/F04 Mental health nurse UG degree 11 4 ND ND ND 5
S03/F05 Community development UG degree 8 10 3 11 15 4
S04/F02 Support worker No data 38 4 14 ND ND 4
S04/F03 Clinical studies officer PG diploma 6 2 0 0 3 4
S05/F02 Mental health nurse PG degree 17 0 17 0 2 5
S06/F01 Research assistant PG degree 2 0 ND ND 0 3
S06/F04 Mental health nurse Diploma (college) 24 11 0 0 1 4
S06/F05 Mental health nurse PG diploma 7 8 ND ND 0 3
S07/F05 Mental health nurse UG degree 7 3 0 0 0 4
S08/F03 Mental health nurse UG degree 26 9 ND ND 0 4
S08/F05 Occupational therapist UG degree 20 0 ND ND ND 4
S09/F01 Mental health nurse Diploma (college) 25 4 ND ND 0 3
S09/F03 Occupational therapist UG degree 6 7 ND ND 5 4
S09/F04 Pharmacy technician BTEC degree in
Pharmaceutical Science
8 0 ND ND 1 3
BTEC, Business and Technology Education Council; ID, identification; ND, no data; PG, postgraduate; UG, undergraduate.
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Data collection
Semistructured interview guides for participants (see Appendix 1) and professionals (see Appendix 2) were
pilot-tested with the relevant project team members. No topic guide was used for the unstructured interviews
with intervention designers, although sections from the behaviour change wheel,95 the logic model and the
NIHBCC framework24 were used as prompts. Interviews were recorded on an encrypted digital recorder and
field notes were made during and after the interview. The median (range) length of the interviews was
18:57 minutes (13:06–30:33 minutes) for participant interviews, 46:13 minutes (29:29–76:32 minutes) for
facilitator interviews and 39:20 minutes (43:39–64:00 minutes) for intervention designer interviews. Data
saturation was achieved in the participant, professional and intervention designer data sets. No repeat
interviews were carried out and transcripts were not returned to participants for comment/correction.
Data analysis
Two coders (RG-W and DH) coded participant interviews systematically in NVivo version 11 (QSR International,
Warrington, UK) to behaviour change theory, intervention functions, theoretical domains95 and dimensions
of acceptability,88 as well as opportunistically to the NIHBCC framework79 (see Table 6) and logic model
constructs (see Figure 5). Staff interviews were coded systematically to NPT constructs and opportunistically
to the NIHBCC framework and logic model constructs. Developer interviews were coded systematically to
intervention functions, logic model and NIHBCC framework constructs (see Table 6).
Fidelity assessment
Leicester Diabetes Centre staff monitored the fidelity of intervention delivery through direct observation
of sessions, using two instruments. First, the STEPWISE Core Facilitator Behavioural Observation Sheet
assesses the relative presence or absence of 35 behaviours in six domains: non-judgemental engagement
of participants (five items); eliciting and responding to emotions/feelings (two items); facilitating reflective
learning (eight items); behavioural change, planning and goal-setting (nine items); overall group management
(nine items); and other behaviours (two items). Second, LDC staff objectively assessed participant–educator
interaction during observation visits by means of the DOT (DESMOND Observation Tool). The coder sat at
the back of the room, with a compact disc playing in a headphone, from which a beep sounded every
10 seconds, whereupon the coder recorded whether an educator or a participant was currently talking at
that point. Silence, laughter or multiple conversations were classed as ‘miscellaneous’. In self-management
programme research, a link has been proposed between less facilitator talk and a more effective participant
receipt of the education process, defined as a less didactic/more facilitative approach.96 The national and local
infrastructure available for quality control and mentoring in education programmes such as DESMOND was
not available for STEPWISE, so feedback of observations in pursuit of accreditation was conducted. Other
steps to ensure intervention fidelity are described in Table 6.
Triangulation protocol
Different methods and informants were used and a formal framework was employed for comparison of the
findings to comprehensively address different questions, increase confidence in findings and provide a basis
for feedback from participants and professionals on the project team.97 No priority was granted to either
quantitative or qualitative methods, which were used concurrently to assess the intervention. A modified
triangulation protocol62 was employed for the methodological triangulation of data sets, in five stages:
1. Data sets were reviewed to compare for presence and examples (‘sorting’) of logic model constructs.
2. The level of convergence between data types was coded for each of the 22 logic model components
as ‘agreement’ (full interpretive agreement between data sets); partial agreement (some disagreement
within/between data sets); silence (a logic mode component covered by only one data set); and
dissonance [disagreement between data sets (‘convergence coding’)].
3. The global level of convergence was characterised (‘convergence assessment’).
4. Differences in the data set contribution to the case study were summarised (‘completeness comparison’).
5. The triangulated results were shared and points of disagreement were discussed with stakeholders at a
face-to-face meeting on 14 July 2017 (‘feedback’), with changes in interpretation being incorporated
when supported by the data. A formal comparison of researcher coding was not conducted, owing to
time constraints and a rapidly evolving analysis strategy.
EVALUATION METHODS
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TABLE 6 Strategies within the STEPWISE programme that were intended to ensure fidelity
Goal STEPWISE fidelity strategies
Design
Ensure the same treatment
dose within conditions
l Theory-based scripted programme defined in the protocol
l Specified (and recorded) fixed number, duration, frequency and mode of delivery of
education sessions. Deviations logged
Ensure an equivalent dose
across conditions
Not applicable (no active control)
Plan for implementation
setbacks
l Providers ensured a pool of (a minimum of four) trained facilitators and attrition
track (with additional training needs met)
l Test intervention piloted and changes in design incorporated
Training
Standardise training l Standardised training programme
l Written facilitator training manual and materials
l Structured practice and (expert) trainers model the style of delivery
l Multiple providers trained together
Ensure provider skill acquisition l Role playing (trainees ‘have a go’)
l Trained to (self-) reflect on performance and make changes
Minimise ‘drift’ in provider skills Not applicable (no benchmark established)
Accommodate provider
differences
l Facilitator role defined. Providers advised to ensure that at least one facilitator had
adequate clinical skills
l Facilitator characteristics (experience of leading groups, level of education and
professional background) collected at training
l All providers received training, and more-experienced providers gave informal
support to less-experienced providers
Delivery
Control for provider differences l Session feedback invited on non-specific treatment effects (e.g. credibility
of facilitator)
l Qualitative interview, including perceptions of the intervention at the end of
the study
l Sessions were observed by intervention developers, who noted any effects
Reduce differences within
treatment
l Written treatment manual and standardised resource list (e.g. food models and
samples for each session)
Ensure adherence to treatment
protocol
l Facilitator self-reflection on content/delivery
l Central team monitored treatment dose delivered through attendance registers
l Providers monitored intervention delivery and adherence to varying degrees
(e.g. team meetings and co-ordination of courses)
l Sample of sessions observed (including facilitator behaviours) by the
intervention developers
l Qualitative interviews with participants, facilitators and intervention developers
explored the style and content of delivery
Minimise contamination
between conditions
l Providers trained in study design, including treatment and control conditions
(with separate documentation when applicable), and associated procedures, to
minimise contamination
l Training supported by a written training manual and trial protocol and regular
supervision of providers
l Providers were monitored frequently on site and remotely
l Facilitators and co-ordinators received separate manuals and the protocol
continued
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Health economic methods
Introduction
The economic evaluation of the STEPWISE trial was conducted using both health and social care and societal
perspectives. Individual participant data were used in the analysis to generate results for the cost-effectiveness
of the intervention regarding its impact on cost-relative quality-adjusted life-years (QALYs), derived from the
EQ-5D-5L and the SF-36 questionnaires, and weight change. The time horizon of the trial (3- and 12-month
follow-up) was the same in the economic evaluation. The economic analyses included all trial participants.
The comparison was between the group receiving the STEPWISE intervention and the group receiving a
leaflet with advice. This analysis determined cost-effectiveness using the £20,000-per-QALY-gained threshold
set by NICE. A sensitivity analysis was used to establish the effect of changes in costs and QoL measurement
(comparing results using utility values from the EQ-5D and the SF-36)51,98 on the results. Value sets for
health-related QoL measures related to value sets containing preferences from a population in England
for the EQ-5D-5L51 and in the UK for the SF-36.98
Health and social care costs
Health and social care resources were calculated using the unit costs from the Personal Social Services
Research Unit (PSSRU)99 and NHS reference costs,100 with service use data. Responses to the Client Service
Receipt Inventory (CSRI)101 questionnaire, which captured health and social care as well as other resource
use, were collected for the 3 months before the baseline assessment and the 3-month follow-up and the
9 months before the 12-month follow-up. The CSRI includes information on hospital care (inpatient and
outpatient), social care, primary care and criminal justice service contacts. Less frequently used health-care
professional contacts were reported in the ‘other health-care professional’ category, including drug
advisors, outreach workers, early intervention services, occupational therapists, drug service facilities and
communities, using the CSRI. Medication prices from the British National Formulary102 in March 2017 were
TABLE 6 Strategies within the STEPWISE programme that were intended to ensure fidelity (continued )
Goal STEPWISE fidelity strategies
Receipt
Ensure participant
comprehension
l Facilitators asked participants questions, discussed materials, used scripts to help to
summarise content; encouraged the use of activity logs; and structured content
around achievement-based objectives
l Qualitative interviews (sample) explored the experience and purpose of
the programme
Ensure participant ability to use
cognitive skills
l Facilitators encourage participants to consider strategies for overcoming obstacles to
changing their behaviours
l Session-specific (forms) and overall (qualitative interview) feedback
Ensure participant ability to
perform behavioural skills
l Programme encourages self-monitoring, self-reporting of success and adherence
l Programme encourages good practice to help overcome barriers (e.g. use of food
diaries and ‘triggers’ for making less-healthy choices, mindfulness) and obstacles
within sessions
l Facilitators provided follow-up telephone contacts
Enactment
Ensure participant use of
cognitive skills
l Facilitators checked progress (and provided an opportunity to discuss the ongoing
use of skills) during 1 : 1 interactions
l Printed materials with space to record group exercises or tasks and goals were
provided for use in, and between, sessions and after the course
l Qualitative interviews explored the achievement of goals (self-report)
Ensure participant use of
behavioural skills
l Frequency/duration of sessions and adherence monitored
l Programme maintained longitudinally (booster and telephone support)
l Qualitative interviews explored the use of skills that participants learned and their
use or not (self-report)
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applied to the data on medication use by the participants in the study. All drugs for physical and mental
health conditions, including those that could be bought over the counter, were included. Ongoing
medications recorded on the CRF were used as a source of medication data.
Intervention costs
The intervention comprised four foundation sessions (2.5 hours each), three booster sessions (at 4, 7 and
10 months, of 2.5 hours each) and support contacts (telephone calls, texts and postcards) every 2 weeks.
The base case was conducted to represent the scenario in which only four patients attended each session.
This was to reflect lower attendance than the seven full sessions for the intervention. The cost of the
accelerometer was omitted.
The foundation and booster sessions of the intervention were costed as group therapy sessions, using the
mental health nurse wage level and related oncosts, combined with capital costs and other costs of the
service at 2015–16 prices. The intervention unit costs, using the wages of a mental health nurse and a
dietitian, were costed for a 2.5-hour session of the intervention. For most analyses, the results are reported
for two mental health nurses facilitating a group session with six participants. The unit costs per person,
calculated using the costs of a mental health nurse, were £88 for a group of four, £59 for a group of six
and £44 for a group of eight (the costs for groups of six and eight were used in the sensitivity analyses).
Support contacts by telephone were costed at the price of one nurse or dietitian per minute, multiplied by
the length of the call. Text messages and postcards were costed at a nominal value of £5. The costs of the
intervention were split between time periods, as the intervention booster sessions and support contacts
continued after the 3-month period.
Societal costs
Average wage rates were applied to productivity losses and informal care time, which were obtained using
data from the Office for National Statistics.103 In the sensitivity analyses, we used minimum wage rates,104
which were also applied to productivity losses and informal care, and the unit costs for a home-care
worker for informal care using the figure from the PSSRU.99
Police officer contact time was calculated from police salary scales105 and workforce statistics.106 A cost of
police contacts was included, but no other criminal justice system costs were included. The cost of a lost
education day was calculated as the cost of a working day; as it was assumed that as the participants were
all adults, this was more appropriate. The CSRI also recorded time lost from work, education and informal
care from friends and family.
No discount rate was applied to the costs and QoL measures, as the follow-up period for participants was
1 year.
Health-related quality of life
Health-related QoL was measured using the EQ-5D-5L107 and the SF-36/Short Form questionnaire-6
Dimensions (SF-6D).98 The EQ-5D is the measure more commonly used in health technology assessments in
England and is recommended by NICE. However, the EQ-5D is known to have a ceiling effect in schizophrenia,
which is why the SF-6D was also used, as this measure is more likely to be normally distributed. The SF-36
questionnaire responses were converted to the SF-6D QoL measure for the analysis, using domain weightings
from Brazier and Roberts.108 QALYs were calculated from the tariff scores using the area under the curve
method for both the EQ-5D-5L and the SF-6D QoL measures. It was assumed that there was a linear change
between any two time points.
Statistical analyses
The net benefit approach was used in a cost–utility analysis of costs and both types of QALY data, and in
a cost-effectiveness analysis with health/social care and societal costs. The net benefit is derived from the
multiplication of a threshold value for a unit of outcome minus the cost.
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Service use and cost differences between the two groups were described. The analysis of costs and
outcomes was carried out in four combinations: (1) EQ-5D-5L QALY and health and social care costs;
(2) EQ-5D-5L QALY and societal costs; (3) SF-6D QALY and health and social care costs; and (4) SF-6D
QALY and societal costs.
Incremental cost-effectiveness ratios (ICERs) were computed by dividing incremental costs by incremental
outcomes. Cost-effectiveness planes were constructed by obtaining, through bootstrapped regression
models, 1000 pairs of cost and outcome differences and showing these on scatterplots. The proportion of
replications in each quadrant could then be obtained.
Cost-effectiveness acceptability curves
Cost-effectiveness acceptability curves (CEACs) show the probability that one group is more cost-effective
than the other for a chosen value of willingness to pay per unit of outcome. The STEPWISE economic
evaluation uses the net benefit approach109 with the 12-month follow-up results for these CEACs. The
willingness-to-pay value that is used is the £20,000 NICE threshold for total health and social care costs.
CEACs are also produced for societal costs at the 12-month follow-up; however, the relevant analysis for
NICE methodology is from the health and social care perspective. The value of the willingness-to-pay
threshold was also varied in values of £10,000 between £0 and £200,000, to show how the probability of
cost-effectiveness changes as the threshold rises.
Missing data
The multiple imputation (chained equations) method110 was applied to impute missing values for cost and
QoL data, assuming that data were MAR before bootstrapping to carry out the cost-effectiveness analysis.
Sensitivity analysis
Three types of sensitivity analysis will be reported in the final analysis, with varying costs. First, costs of the
intervention were used [mental health nurse (£1.18 per minute, £59 per session – two facilitators with a
group of four patients)]. Second, informal care costs were calculated using two alternative unit costs:
home care worker (£20 per weekday hour of a home care worker based on independent and social
services home care) and minimum wage rate (£7.20 per hour in 2016). Third, productivity losses (lost
employment time), valued using the average wage rate in the base case, are also calculated using the
minimum wage rate104 (£7.20 per hour in 2016). Each of these sensitivity analyses were carried out using
values from both the EQ-5D and the SF-6D. No adjustments were made to take into account deaths
during the study, as the numbers were so low.
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Chapter 4 Results of the trial
Recruitment and participant flow
The first participant consented to the trial on 10 March 2015 and was randomised on 14 March 2015. The
trial closed as scheduled on 31 March 2017, when the last 12-month follow-up was completed (Figure 6).
A total of 414 participants were randomised, of whom two were not included in any analyses: one was
erroneously randomised, having previously withdrawn consent to randomisation, and a second withdrew
all consent to use their data. Therefore, 412 participants (207 intervention, 205 control) were included in
the following summaries.
Figure 7 shows that completion was slightly higher in the control group. There were three deaths, all in
the intervention arm, owing to pulmonary embolism (n = 1), myocardial infarction (n = 1) and diabetic
ketoacidosis in a person with type 2 diabetes mellitus previously treated with oral antidiabetes agents,
leading to cardiac arrest (n = 1).
Intervention arm participants were categorised as non-attenders, attending one or two foundation (‘core’)
sessions, attending three or four core sessions without any boosters or attending three or four core sessions
with at least one booster. A total of 47 participants (22.7%) attended all core and booster sessions (Table 7).
The mean number of sessions attended was 2.7 foundation sessions and 1.4 booster sessions (Table 8).
The mean intervention group size as randomised was 6.3, but the mean number of participants who actually
attended ranged from 4.0 to 4.4 during the foundation course and dropped to 2.7 to 3.0 during the booster
sessions (see Table 9).
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FIGURE 6 Randomisation by month. IDS, Intervention Development Study.
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Assessed for eligibility
(n = 1223)
• Not meeting inclusion criteria, n = 221
• Not interested, n = 391
• Not contactable, n = 32
• Declined consent, n = 15
• Unable to give informed consent, n = 13
• Other reasons, n = 128a
Enrolment
Allocated to intervention
(n = 208)
Allocated to intervention
(n = 206)
Allocation
Follow-up
Analysis
Completed 12-month follow-up
(n = 168)
Lost to follow-up
(n = 11)
Withdrew
(n = 25)
Completed 12-month follow-up
(n = 173)
Lost to follow-up
(n = 10)
Withdrew
(n = 22)
Randomised
(n = 414)
Analysed
(n = 167)
Excluded from analysis
(n = 1)
Analysed
(n = 173)
Withdrew prior to randomisation
(n = 9)
Did not receive allocated intervention
(n = 36)b
Excluded
(n = 800)
  • Withdrew consent, n = 4
  • Deterioration in mental health, n = 4
  • Scheduled for surgery, n = 1
  • Withdrew consent and randomised in error,
     n = 1
  • Intention-to-treat population, n = 207
  • Time commitment, n = 6
  • Ill health, n = 6
  • Felt that the course was unhelpful, n = 2
  • Did not attend/not stated, n = 22
  • Ill health, n = 5
  • Too time-consuming, n = 5
  • Did not find intervention helpful, n = 4
  • No reason given, n = 9
  • Other, n = 2
Died
(n = 3)
  • Weight not recorded, n = 1
  • Ill health, n = 3
  • Too time-consuming, n = 5
  • Preference for intervention, n = 4
  • No reason given, n = 7
  • Other, n = 3
  • Withdrew all consent to use their data,
     n = 1
  • Intention-to-treat population, n = 205
FIGURE 7 Consolidated Standards of Reporting Trials flow diagram. a, Referred but not contacted before end of
recruitment (n= 27), current inpatient (n= 18), work (n= 9), Intervention Development Study participant (n= 9),
discharged from CMHT (n= 8), too busy/away a lot (n= 7), not able to travel/out of area (n= 5), did not attend
consent/baseline visit (n= 5), mental health problem relating to weight (n= 5), unknown (n= 4), other (specified
reasons) (n= 31). b, Receipt of intervention defined as attending at least one foundation. Reproduced from Holt
et al.23 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original text.
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Overall, there were 3218 support contacts made with participants outside the group sessions, of which
three-quarters were made by telephone. A total of 169 participants (81.6%) had one or more support
contact; 167 participants (81%) had at least one telephone contact, among whom the average number of
received telephone calls was 15, and 105 (50.7%) had at least one mail contact, with the average number
being five. Face-to-face contact was less common, but 68 participants (32.9%) attended at least one
session, with the average number of contacts being three and the average duration of these being just
under 1 hour.
Table 9 compares support contact (i.e. contact other than group sessions) at the recruiting sites.
Manchester made the most contacts overall, with the vast majority being by telephone (93.8%), with only
one contact being face to face. Cornwall made the smallest percentage of contacts by telephone (41.1%),
but had the largest percentage of contacts by mail and electronically. Leeds and York and Somerset had
the largest percentages of face-to-face contacts – 11.5% and 12.6%, respectively, almost three times the
sites’ average of 4.4%.
TABLE 7 Uptake of intervention
Attendance n (%)
Non-attender 36 (17.4)
One or two core sessions 34 (16.4)
≥ 3 core and 0 booster sessions 26 (12.6)
≥ 3 core and ≥ 1 booster sessions 111 (53.6)
Attended all courses 47 (22.7)
TABLE 8 Attendance and average group size
Attendance and group size
Group size
Mean Median Minimum Maximum
Group size at randomisation 6.3 6 3 11
Foundation coursesa
Week 1 4.4 4 2 9
Week 2 4.2 4 1 8
Week 3 4.2 4 2 9
Week 4 4.0 4 1 9
Booster sessionsa
Month 4 3.0 3 0 8
Month 7 2.8 3 0 7
Month 10 2.7 3 0 6
a Average number attending per course (at least 60 minutes).
Note
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original text.
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Baseline data
The characteristics of the randomised participants are given in Tables 10 and 11. The groups were largely
well balanced, but the intervention arm participants were, on average, 3 kg heavier at baseline, which is
partially explained by the higher proportion of men in the intervention arm (55.6% vs. 46.3%; the average
weight among men was 109 kg vs. 98 kg among women). The prevalence of type 2 diabetes mellitus was
higher in the intervention arm (16.4% vs. 11.7%), whereas the control group included a larger proportion
of participants with current depression (30.2% vs. 26.1%) and previous depression (28.3% vs. 24.2%).
TABLE 9 Number of contacts outside group sessions by site, overall and by contact type
Site
Contact type, n (%)
All contactsElectronic Face to face Mail Telephone
Overall 88 (2.7) 141 (4.4) 555 (17.3) 2434 (75.6) 3218
Bradford 5 (2.5) 7 (3.5) 2 (1.0) 189 (93.1) 203
Cornwall 63 (15.2) 22 (5.3) 159 (38.4) 170 (41.1) 414
Devon 11 (4.2) 10 (3.8) 49 (18.6) 193 (73.4) 263
Leeds and York 0 30 (11.5) 61 (23.3) 171 (65.3) 262
Manchester 0 1 (0.2) 38 (6.1) 588 (93.8) 627
Sheffield 0 1 (0.4) 43 (18.5) 189 (81.1) 233
Somerset 0 17 (12.6) 34 (25.2) 84 (62.2) 135
South London 3 (1.4) 20 (9.1) 0 196 (89.5) 219
Southern Health 5 (1.1) 14 (3.0) 126 (26.9) 324 (69.1) 469
Sussex 1 (0.3) 19 (4.8) 43 (10.9) 330 (84.0) 393
Mean contact time (minutes) 1.8 59.4 0.4 5.2 6.3
TABLE 10 Baseline characteristics
Characteristic
Trial arm
Intervention (N= 207) Control (N= 205)
Site, n (%)
Bradford 17 (8.2) 19 (9.3)
Cornwall 21 (10.1) 21 (10.2)
Devon 21 (10.1) 21 (10.2)
Leeds and York 22 (10.6) 20 (9.8)
Manchester 31 (15.0) 29 (14.1)
Sheffield 18 (8.7) 17 (8.3)
Somerset 12 (5.8) 14 (6.8)
South London 16 (7.7) 14 (6.8)
Southern Health 27 (13.0) 27 (13.2)
Sussex 22 (10.6) 23 (11.2)
Age (years)
Number of participants 207 205
Mean (SD) 40.0 (11.3) 40.1 (11.5)
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TABLE 10 Baseline characteristics (continued )
Characteristic
Trial arm
Intervention (N= 207) Control (N= 205)
Sex, n (%)
Male 115 (55.6) 95 (46.3)
Female 92 (44.4) 110 (53.7)
Ethnicity, n (%)
White 179 (86.5) 170 (82.9)
Asian 9 (4.3) 7 (3.4)
Black 12 (5.8) 19 (9.3)
Mixed 4 (1.9) 7 (3.4)
Other 3 (1.4) 2 (1.0)
Smoking status, n (%)
Ex-smoker 55 (26.6) 52 (25.4)
Never smoked 54 (26.1) 45 (22.0)
Current smoker 98 (47.3) 108 (52.7)
Light smoker 18 (8.7) 20 (9.8)
Moderate smoker 37 (17.9) 32 (15.6)
Heavy smoker 43 (20.8) 55 (26.8)
Missing 0 1 (0.5)
Weight (kg)
n 206 204
Mean (SD) 105.2 (22.2) 102.1 (22.1)
Median (IQR) 104.2 (89.0–116.2) 99.3 (88.0–113.0)
BMI (kg/m2)
n 206 204
Mean (SD) 36.1 (7.2) 35.3 (7.2)
Median (IQR) 35.1 (31.0–39.5) 34.2 (29.9–39.1)
Waist circumference (cm)
n 205 204
Mean (SD) 117.8 (15.6) 116.1 (17.4)
Median (IQR) 118.0 (106.0–128.2) 116.8 (104.5–125.5)
Systolic blood pressure (mmHg)
n 205 203
Mean (SD) 126.4 (15.9) 124.0 (16.8)
Median (IQR) 126.0 (116.0–135.0) 123.0 (112.0–134.0)
Diastolic blood pressure (mmHg)
n 205 203
Mean (SD) 82.5 (11.0) 81.9 (12.5)
Median (IQR) 82.0 (74.0–89.0) 81.0 (74.0–90.0)
continued
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TABLE 10 Baseline characteristics (continued )
Characteristic
Trial arm
Intervention (N= 207) Control (N= 205)
Pulse (b.p.m.)
n 204 203
Mean (SD) 84.5 (13.9) 83.8 (13.6)
Median (IQR) 84.5 (75.0–95.0) 84.0 (75.0–93.0)
HbA1c (mmol/mol)
n 171 170
Mean (SD) 41.5 (13.3) 39.9 (10.9)
Median (IQR) 37.0 (35.0–42.0) 38.0 (35.0–41.0)
HbA1c (%)
Mean (SD) 5.9 (1.2) 5.8 (1.0)
Median (IQR) 5.5 (5.4–6.0) 5.6 (5.4–5.9)
HbA1c category
< 6% (42mmol/mol) 133 (64.3%) 139 (67.8%)
6–6.5% (42–47mmol/mol) 10 (4.8%) 17 (8.3%)
6.5–7.5% (48–57mmol/mol) 9 (4.3%) 7 (3.4%)
7.5–8.5% (58–68mmol/mol) 9 (4.3%) 2 (1.0%)
≥ 8.5% (69 mmol/mol) 10 (4.8%) 6 (2.9%)
Missing 36 (17.4%) 34 (16.6%)
Total cholesterol (mmol/l)
n 175 179
Mean (SD) 5.0 (1.2) 5.1 (1.2)
Median (IQR) 4.9 (4.2–5.8) 4.9 (4.2–5.7)
HDL cholesterol (mmol/l)
n 170 173
Mean (SD) 1.2 (0.5) 1.2 (0.4)
Median (IQR) 1.2 (1.0–1.4) 1.2 (1.0–1.3)
Non-HDL cholesterol (mmol/l)
n 169 174
Mean (SD) 3.8 (1.3) 3.9 (1.4)
Median (IQR) 3.8 (2.9–4.6) 3.8 (2.9–4.6)
Triglycerides (mmol/l)
n 172 172
Mean (SD) 2.5 (2.0) 2.2 (1.7)
Median (IQR) 1.9 (1.4–2.8) 1.7 (1.2–2.8)
Fasting glucose (mmol/l)
n 170 172
Mean (SD) 5.9 (2.2) 5.8 (2.3)
Median (IQR) 5.2 (4.8–6.1) 5.3 (4.7–6.0)
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TABLE 10 Baseline characteristics (continued )
Characteristic
Trial arm
Intervention (N= 207) Control (N= 205)
eGFR (ml/minute/1.73m2), n (%)
≤ 60 2 (1.0) 3 (1.5)
60–90 58 (28.0) 55 (26.8)
> 90 15 (7.2) 9 (4.4)
Missing 132 (63.8) 138 (67.3)
Evidence of hepatic disease?, n (%)
No 167 (80.7) 167 (81.5)
Yes 5 (2.4) 7 (3.4)
Missing 35 (16.9) 31 (15.1)
b.p.m., beats per minute; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range.
TABLE 11 Medical history
Diagnosis
Trial arm
Intervention (N= 207) Control (N= 205)
Schizophrenia diagnosis type, n (%)
ICD-10: F20 145 (70.0) 138 (67.3)
ICD-10: F25 30 (14.5) 36 (17.6)
First episode psychosis 32 (15.5) 31 (15.1)
OPCRIT+ diagnosis, n (%)
Schizophrenia [F20] 37 (17.9) 37 (18.0)
Schizoaffective disorder [F25.X] 8 (3.9) 7 (3.4)
Other non-organic psychosis [F28.X] 72 (34.8) 69 (33.7)
Affective disorder [F3X.X, F30X, F31, F32] 11 (5.3) 14 (6.8)
Other 60 (29.0) 62 (30.2)
Not met 12 (5.8) 12 (5.9)
Missing 7 (3.4) 4 (2.0)
Diabetes mellitus status, n (%)
Type 1 1 (0.5) 1 (0.5)
Type 2 34 (16.4) 24 (11.7)
Diagnosed chronic kidney disease, n (%)
Current 0 (0.0) 1 (0.5)
Atrial fibrillation, n (%)
Current 0 (0.0) 0 (0.0)
Past 2 (1.0) 1 (0.5)
Hypertension, n (%)
Current 21 (10.1) 17 (8.3)
continued
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TABLE 11 Medical history (continued )
Diagnosis
Trial arm
Intervention (N= 207) Control (N= 205)
Rheumatoid arthritis, n (%)
Current 9 (4.3) 5 (2.4)
Heart attack, n (%)
Past 0 (0.0) 3 (1.5)
Angina, n (%)
Ongoing 1 (0.5) 5 (2.4)
Past 2 (1.0) 1 (0.5)
Stroke or TIA, n (%)
Past 4 (1.9) 3 (1.5)
Peripheral vascular disease, n (%)
Ongoing 0 (0.0) 1 (0.5)
Past 0 (0.0) 0 (0.0)
Depression, n (%)
Current 54 (26.1) 62 (30.2)
Past 50 (24.2) 58 (28.3)
Any other relevant medical conditions, n (%)
Yes 72 (34.8) 70 (34.1)
Has a first-degree relative who has had angina or a heart attack before the age of 60 years, n (%)
No 170 (82.1) 158 (77.1)
Yes 36 (17.4) 44 (21.5)
Unknown 1 (0.5) 2 (1.0)
Has a first-degree relative with diabetes mellitus, n (%)
No 158 (76.3) 146 (71.2)
Yes 47 (22.7) 56 (27.3)
Unknown 2 (1.0) 2 (1.0)
Has a history of heavy drinking or an alcohol problem,a n (%)
No 157 (75.8) 153 (74.6)
Yes 50 (24.2) 52 (25.4)
Time since first contact with psychiatric services (years)
Median (IQR) 14 (6–22) 15 (6–22)
Time since first contact with psychiatric services (years), n (%)
< 1 7 (3.4) 9 (4.4)
1–2 8 (3.9) 16 (7.8)
2–5 29 (14.0) 20 (9.8)
5–10 27 (13.0) 27 (13.2)
10–20 66 (31.9) 65 (31.7)
≥ 20 70 (33.8) 68 (33.2)
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Medication use on entry is given in Table 12. All bar one participant were recorded as being currently
prescribed antipsychotic medication and over half reported use of antidepressant medication, all of which
factors were reasonably well balanced between the groups.
Course delivery and protocol non-compliance
Although the courses were designed to be delivered by two trained facilitators, 16 of the 231 courses
(eight foundation and eight booster) were led by a single facilitator owing to staff unavailability. At one
centre, the wave 2 7-month booster session (with five participants allocated to the group) did not take
place owing to lack of facilitator availability. At another centre, two booster sessions were delivered by
the external (fully trained NHS employee) fidelity assessor who delivered the session on the day because
neither facilitator was available owing to sickness. In addition, the support contacts were not always at the
intended intervals of approximately every 2 weeks; 8% of contacts occurred within 1 week of the previous
contact and 10% occurred more than 3 weeks after the previous contact.
Of the 54 individuals who facilitated at least one course, 47 completed a short survey describing their
qualifications and experience before delivering the intervention. Twenty-two were mental health nurses
(47%), six were support workers (13%), five were occupational therapists (11%) and the remainder were
TABLE 11 Medical history (continued )
Diagnosis
Trial arm
Intervention (N= 207) Control (N= 205)
Years since started antipsychotics
Median (IQR) 13 (5–20) 12 (5–20)
Time since started antipsychotic medication (years), n (%)
< 1 12 (5.8) 12 (5.9)
1–2 11 (5.3) 20 (9.8)
2–5 28 (13.5) 19 (9.3)
5–10 28 (13.5) 33 (16.1)
10–20 71 (34.3) 69 (33.7)
≥ 20 57 (27.5) 52 (25.4)
Time since first symptoms of psychosis (years)
Median (IQR) 15 (7–22) 15 (6–23)
Time since first symptoms of psychosis (years), n (%)
< 1 8 (3.9) 9 (4.4)
1–2 5 (2.4) 11 (5.4)
2–5 26 (12.6) 20 (9.8)
5–10 27 (13.0) 26 (12.7)
10–20 70 (33.8) 70 (34.1)
≥ 20 66 (31.9) 69 (33.7)
Not recorded 5 (2.4) 0 (0.0)
IQR, interquartile range; TIA, transient ischaemic attack.
a Based on the opinion of the site PI.
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from other disciplines. Thirty-three (70%) were trained to graduate or postgraduate level; with the
remainder mostly having vocational qualifications (n = 11, 23%). Facilitators had spent, on average,
13 years working in mental health (range 2–40 years); 13 facilitators reported a career of between 1 and
17 years (mean 6 years) working in physical health. Facilitators were asked to rate their confidence in
group facilitation skills on a 5-point scale; the majority rated their abilities as ‘3’ (n = 16, 34%) or ‘4’
(n = 24, 51%), with six rating their confidence as ‘5’ (very confident) and one scoring themselves as ‘2’.
Of the 230 foundation and booster courses delivered, 162 (71%) included a mental health nurse as a
facilitator, 80 (35%) involved a support worker and 31 (13%) involved an occupational therapist. Eight of
the 10 sites utilised facilitators with substantial experience of mental health (> 10 years’ experience).
By contrast, only two sites utilised facilitators with experience of physical health; the average experience
(summed across all courses) was 10 years in Manchester, 7 years in London and < 2 years elsewhere.
Outcomes and estimation
Weight change (primary end point)
Among participants completing follow-up, the weight change was almost identical for the intervention and
control arms. At 3 months, there was a reduction of 0.2 kg in the intervention arm and an increase of 0.4 kg
in the control arm (difference= –0.55 kg, 95% CI –1.44 to 0.35 kg; p = 0.230). At 12 months (the timing of
TABLE 12 Medications at baseline
Psychiatric medication
Participants in each trial arm, n (%)
Intervention (N= 207) Control (N= 205)
Antipsychotic medication at baseline
Any antipsychotic 207 (100.0) 204 (99.5)a
Haloperidol 7 (3.4) 3 (1.5)
Amisulpride 21 (10.1) 16 (7.8)
Aripiprazole 40 (19.3) 34 (16.6)
Clozapine 89 (43.0) 81 (39.5)
Olanzapine 31 (15.0) 31 (15.1)
Quetiapine 28 (13.5) 24 (11.7)
Risperidone 10 (4.8) 21 (10.2)
Flupentixol 8 (3.9) 11 (5.4)
Zuclopenthixol 10 (4.8) 21 (10.2)
Paliperidone 7 (3.4) 8 (3.9)
Other antipsychotic 19 (9.2) 9 (4.4)
Antidepressant medication at baseline
Any antidepressant 131 (63.3) 129 (62.9)
Citalopram 19 (9.2) 13 (6.3)
Lithium 8 (3.9) 9 (4.4)
Mirtazepine 9 (4.3) 10 (4.9)
Other antidepressant 107 (51.7) 115 (56.1)
a One participant had no antipsychotics listed at baseline either on the CRF or self-reported medications. This was most
likely a data error rather than an ineligible participant.
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the primary comparison), the mean reduction in weight was 0.47 kg in the intervention group and 0.51 kg in
the control group (difference = 0.04 kg, 95% CI –1.59 to 1.67 kg; p = 0.964). The distributions are shown
in Figure 8 and further summaries are presented in Table 13. There was considerable variation in the weight
change in both groups, ranging from –24 kg to +30 kg in the intervention arm and from –25 kg to +30 kg in
the control arm.
Figure 9 shows the mean and 95% CI for the adjusted mean weight change by time point and group.
The means are adjusted for the primary covariates (recruiting site, years since starting antipsychotics, baseline
weight and course identifier). The mean weight loss was similar between arms and was some distance from
the 4.5 kg defined as the minimally clinically important difference in the sample size calculation.
The weight change by recruiting centre is displayed in Figure 10. The difference between the intervention
and control arms ranged from –2.6 kg to +7.0 kg. Adding an interaction term between site and treatment
to the primary model gave a test statistic of χ2(9) = 14.9 (p = 0.094), indicating some evidence of a variation
in the size of intervention effect between sites.
Other weight-related end points
The weight, BMI and waist circumference outcomes are also presented in Table 13. Although the
proportion of participants reporting any weight reduction was slightly higher in the intervention arm, the
magnitude of the difference was almost identical between the two trial arms. None of the comparisons
reached statistical or clinical significance.
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FIGURE 8 Weight change. (a) 3 months and (b) 12 months. Reproduced from Holt et al.23 This is an Open Access
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Sensitivity analyses of weight change
A number of sensitivity analyses were undertaken for weight change with regard to alternative model types,
covariates and missing data assumptions (Figure 11). The weight change at 12 months was refitted with sex
included as a covariate, as the groups were imbalanced in this; doing so made little difference, as sex was not
associated with weight loss. The model assumptions were also reassessed using a mixed-effects model, by
CACE (using the same covariates) to assess the impact of uptake, and with missing data assumed to be MAR
using predictive mean matching imputation. In all cases, the difference between groups remained small.
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TABLE 13 Weight change
Characteristic
Trial arm
Mean differencea (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Weight (kg)
Baseline
n 206 204
Mean (SD) 105.2 (22.2) 102.1 (22.1)
3 months
n 178 180
Mean (SD) 104.7 (21.5) 103.1 (23.5)
Change mean (SD) –0.2 (4.4) 0.4 (4.7) –0.55 (–1.44 to 0.35) 0.230
12 months
n 167 173
Mean (SD) 104.1 (21.1) 101.3 (23.7)
Change mean (SD) –0.5 (7.9) –0.5 (8.3) 0.04 (–1.58 to 1.66) 0.963
Change in weight (%)
3 months
n 178 180
Mean (SD) –0.0 (4.3) 0.4 (4.4) –0.4 (–1.3 to 0.5) 0.350
12 months
n 167 173
Mean (SD) –0.4 (7.9) –0.5 (8.2) 0.0 (–1.6 to 1.7) 0.964
Maintained or lost weight
3 months 93 (52.2%) 80 (44.2%) 1.35 (0.88 to 2.05)b 0.169
12 months 98 (58.3%) 88 (50.9%) 1.35 (0.85 to 2.14)b 0.206
BMI (kg/m2)
Baseline
n 206 204
Mean (SD) 36.1 (7.2) 35.3 (7.2)
3 months
n 178 180
Mean (SD) 35.8 (7.1) 35.5 (7.4) –0.15 (–0.47 to 0.16) 0.337
12 months
n 167 173
Mean (SD) 35.6 (7.2) 34.8 (7.3) 0.05 (–0.51 to 0.60) 0.869
continued
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It is possible that some participants did not remain in the study because of their weight (i.e. informative dropout
or MNAR), and the above models do not account for this. As a final sensitivity analysis, missing weight was
imputed in which those who withdrew were assigned weights up to 5 kg more than their predicted value; this
was done in the intervention arm only, the control arm only and both. Although this affected the estimated
treatment differences, the differences remained small and were not statistically significant.
TABLE 13 Weight change (continued )
Characteristic
Trial arm
Mean differencea (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Waist circumference (cm)
Baseline
n 205 204
Mean (SD) 117.8 (15.6) 116.1 (17.4)
3 months
n 178 180
Mean (SD) 116.8 (15.2) 115.4 (17.0) 0.79 (–0.65 to 2.22) 0.284
12 months
n 164 170
Mean (SD) 116.4 (16.1) 114.0 (17.7) 1.23 (–0.74 to 3.20) 0.222
a Mean difference derived from GEEs model in which the covariates were treatment group, time since started antipsychotic
medication and baseline measure.
b Odds ratio derived from GEEs model in which the covariates were the treatment group, time since started antipsychotic
medication and baseline weight.
– 3 – 2 – 1 0 1 2 3
Mean difference (kg)
Favours intervention Favours control
MNAR, + 5 kg in control arm
MNAR, + 5 kg in both arms
MNAR, + 5 kg in intervention arm
GEE and multiple imputation (PMM)
CACE
Multilevel regression
Primary GEE model and sex
Primary GEE model
FIGURE 11 Sensitivity analyses for weight change. PMM, predictive mean matching.
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The impact of the intervention by subgroup was estimated in four subgroups, as described in Chapter 3,
Analysis of other outcomes. In all cases, the difference between groups was small and not of clinical or
statistical significance (Figure 12).
Predictors of weight change
A series of linear regressions were undertaken to assess whether or not any participant characteristics were
associated with weight change. The univariate analyses are presented in Table 14. Few of the characteristics
appeared to systematically explain weight gain or loss. Weight loss was modestly associated with age, with
weight reduction increasing by 0.8 kg per 10 additional years (95% CI 0.0 to 1.5 kg; p = 0.042), participants
with a diagnosis of schizoaffective disorder had a greater mean weight loss (2.7 kg) than those with first
episode psychosis (0.3 kg) or schizophrenia (0.01 kg gain; global test, p = 0.075). Weight loss was greater
among female participants and was, on average, greater among those with higher baseline weight and
longer duration on antipsychotics, but none of these findings was statistically significant. Additional analyses
based on non-linear associations, using fractional polynomial regression and multivariable regression
models, did not reveal any important predictors of weight change. There was no association between total
(group, telephone and face-to-face) contact time and weight change (see Figure 13).
Participants who were prescribed lithium had a statistically significantly greater weight reduction than those
who were not (mean difference = 4.4 kg, 95% CI 0.4 to 8.5 kg; p = 0.033), although this accounted for
only 16 participants completing the trial. Among participants taking antipsychotics, weight loss was greatest
among participants on paliperidone (n = 12, average weight loss 3.4 kg) and lowest among those on
aripiprazole (n = 63, 1.2-kg gain) and other antipsychotics (n = 20, 1.6 kg gain). Participants who changed
medication within 3 months of randomisation had a higher average weight gain than those who did not
(antipsychotic change: n = 29, mean difference = 3.4 kg, 95% CI 0.3 to 6.5 kg; p = 0.031; antidepressant
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FIGURE 12 Weight change by subgroup.
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TABLE 14 Predictors of weight loss at 12 months
Predictor Mean difference (95% CI) p-value
Baseline demographics
Age (per 10-year increase) –0.8 (–1.5 to –0.0) 0.042
Sex (female vs. male) –1.2 (–2.9 to 0.6) 0.182
Weight at baseline (per 10 kg) –0.1 (–0.5 to 0.3) 0.587
Disease characteristics and comorbidities
Diagnosis
Schizoaffective disorder vs. schizophrenia –2.7 (–5.1 to –0.4) 0.023
First episode psychosis vs. schizophrenia –0.4 (–2.8 to 2.1) 0.774
Time since started antipsychotics (per 10 years) –0.5 (–1.3 to 0.4) 0.253
Presence of diabetes mellitus –2.1 (–4.6 to 0.5) 0.109
Evidence of hepatic disease –1.5 (–6.2 to 3.2) 0.532
Mental health at baseline
Diagnosis of clinical depression 0.7 (–0.3 to 1.7) 0.194
BPRS 0.0 (–0.1 to 0.1) 0.845
B-IPQ overall total score –0.4 (–0.9 to 0.1) 0.134
PHQ-9 score –0.0 (–0.2 to 0.1) 0.525
SF-36 QoL at baseline
Physical functioning 0.0 (–0.0 to 0.1) 0.106
Role limitations owing to physical health 0.0 (–0.0 to 0.0) 0.746
Role limitations owing to emotional problems –0.0 (–0.0 to 0.0) 0.529
Energy/fatigue score –0.0 (–0.1 to 0.0) 0.469
Emotional well-being –0.0 (–0.1 to 0.0) 0.380
Social functioning 0.0 (–0.0 to 0.0) 0.763
Bodily pain 0.0 (–0.0 to 0.0) 0.462
General health –0.0 (–0.0 to 0.0) 0.876
Antipsychotic medication at baseline
Amisulpride –1.8 (–5.1 to 1.5) 0.274
Aripiprazole 2.1 (–0.1 to 4.3) 0.061
Clozapine 0.3 (–1.5 to 2.0) 0.757
Flupentixol –2.1 (–6.0 to 1.7) 0.276
Haloperidol –0.9 (–5.8 to 4.0) 0.725
Paliperidone –3.1 (–7.7 to 1.6) 0.199
Olanzapine –0.6 (–2.9 to 1.8) 0.642
Quetiapine 0.1 (–2.4 to 2.6) 0.941
Risperidone –0.2 (–3.6 to 3.1) 0.893
Zuclopenthixol –1.2 (–4.5 to 2.1) 0.471
Other antipsychotic 2.2 (–1.5 to 5.9) 0.237
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change: n = 18, mean difference = 6.1 kg, 95% CI 2.3 to 9.9 kg; p = 0.002), but changes over the full
12 months were not associated with weight change.
Finally, there was no association between total contact time (summed across foundation sessions, booster
sessions and support contact) and weight loss (Figure 13).
TABLE 14 Predictors of weight loss at 12 months (continued )
Predictor Mean difference (95% CI) p-value
Antidepressant medication at baseline
Any antidepressant –0.2 (–2.0 to 1.6) 0.811
Citalopram 1.3 (–1.9 to 4.5) 0.415
Lithium –4.4 (–8.5 to –0.4) 0.033
Mirtazepine 0.4 (–3.7 to 4.5) 0.851
Other antidepressant –0.4 (–2.1 to 1.4) 0.666
Post-baseline medication and change in medication
Changed antipsychotics by 3 months 3.4 (0.3 to 6.5) 0.031
Changed antipsychotics by 12 months –0.2 (–2.6 to 2.2) 0.856
On antidepressants at 3 months 0.4 (–1.4 to 2.2) 0.660
Changed antidepressants by 3 months 6.1 (2.3 to 9.9) 0.002
On antidepressants at 12 months 0.0 (–1.8 to 1.8) 0.963
Changed antidepressants by 12 months 1.5 (–0.9 to 3.8) 0.220
Weight loss programme
Attended any weight loss programme over 12 months –0.1 (–2.8 to 2.7) 0.965
Intervention uptake
Total contact time (hours) –0.1 (–0.4 to 0.2) 0.607
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FIGURE 13 Weight loss at 12 months vs. total contact time (group session and support contact). The line is a locally
weighted scatterplot smoother with bandwidth 0.4.
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Other vital signs
The vital signs (blood pressure and pulse) at baseline, 3 months and 12 months are presented in Table 15.
Systolic (but not diastolic) blood pressure was significantly higher in the intervention group at 3 months
(difference = 2.4 mmHg, 95% CI 0.1 to 4.6 mmHg), but otherwise no change was apparent either
between groups or across time points.
TABLE 15 Vital signs
Vital sign
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Systolic blood pressure (mmHg)
Baseline
n 205 203
Mean (SD) 126.4 (15.9) 124.0 (16.8)
3 months
n 178 179
Mean (SD) 126.9 (16.2) 122.8 (15.7) 2.4 (0.1 to 4.6) 0.040
12 months
n 164 168
Mean (SD) 124.7 (15.2) 122.2 (16.4) 1.7 (–1.1 to 4.6) 0.237
Diastolic blood pressure (mmHg)
Baseline
n 205 203
Mean (SD) 82.5 (11.0) 81.9 (12.5)
3 months
n 178 179
Mean (SD) 82.2 (11.0) 81.4 (12.2) 0.4 (–1.5 to 2.3) 0.696
12 months
n 164 168
Mean (SD) 82.2 (10.3) 81.1 (10.5) 1.1 (–0.7 to 3.0) 0.231
Pulse (b.p.m.)
Baseline
n 204 203
Mean (SD) 84.5 (13.9) 83.8 (13.6)
3 months
n 178 180
Mean (SD) 86.1 (13.7) 83.6 (16.0) 2.1 (–0.5 to 4.6) 0.108
12 months
n 164 168
Mean (SD) 84.4 (13.9) 82.2 (14.0) 1.2 (–0.8 to 3.3) 0.245
b.p.m., beats per minute.
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Laboratory measurements
The laboratory measurements at baseline and 12 months are presented in Table 16. No change was
apparent either between groups or across time points.
TABLE 16 Laboratory measurements
Laboratory measurement
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
HbA1c (mmol/mol)
Baseline
n 171 171
Mean (SD) 41.5 (13.3) 39.9 (10.9)
12 months
n 134 132
Mean (SD) 42.8 (15.4) 41.1 (14.1)
Change from baseline
n 119 118
Mean (SD) 0.7 (7.9) 0.6 (5.6) 0.2 (–1.5 to 1.9) 0.807
HbA1c (%)
Baseline
n 171 171
Mean (SD) 5.9 (1.2) 5.8 (1.0)
12 months
n 134 132
Mean (SD) 6.1 (1.4) 5.9 (1.3)
Change from baseline
n 119 118
Mean (SD) 0.1 (0.7) 0.1 (0.5)
Fasting glucose (mmol/l)
Baseline
n 170 172
Mean (SD) 5.9 (2.2) 5.8 (2.3)
12 months
n 137 132
Mean (SD) 6.4 (3.0) 6.0 (2.8)
Change from baseline
n 123 122
Mean (SD) 0.3 (2.1) 0.1 (1.5) 0.3 (–0.2 to 0.8) 0.242
Total cholesterol (mmol/l)
Baseline
n 175 179
Mean (SD) 5.0 (1.2) 5.1 (1.2)
continued
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TABLE 16 Laboratory measurements (continued )
Laboratory measurement
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
12 months
n 143 138
Mean (SD) 4.9 (1.2) 5.1 (1.1)
Change from baseline
n 129 127
Mean (SD) –0.2 (1.2) –0.1 (0.9) –0.2 (–0.4 to 0.1) 0.176
HDL cholesterol (mmol/l)
Baseline
n 170 173
Mean (SD) 1.2 (0.5) 1.2 (0.4)
12 months
n 143 137
Mean (SD) 1.2 (0.6) 1.2 (0.3)
Change from baseline
n 125 122
Mean (SD) 0.0 (0.7) –0.0 (0.3) 0.0 (–0.1 to 0.1) 0.824
Triglycerides (mmol/l)
Baseline
n 172 172
Mean (SD) 2.5 (2.0) 2.2 (1.7)
12 months
n 139 135
Mean (SD) 2.4 (1.4) 2.4 (2.2)
Change from baseline
n 124 120
Mean (SD) –0.2 (1.8) 0.2 (1.7) –0.2 (–0.6 to 0.1) 0.203
Non-HDL cholesterol (mmol/l)
Baseline
n 169 174
Mean (SD) 3.8 (1.3) 3.9 (1.4)
12 months
n 143 136
Mean (SD) 3.7 (1.2) 3.8 (1.2)
Change from baseline
n 124 121
Mean (SD) –0.2 (1.4) –0.2 (0.9) –0.1 (–0.4 to 0.2) 0.428
HDL, high-density lipoprotein.
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Accelerometry
Table 17 shows the results of the accelerometry. A total of 352 participants had baseline recordings for
the primary accelerometry end point [(ENMO) i.e. average acceleration], of whom 302 had worn the
GENEActiv for at least 4 days and therefore had a valid baseline measure. Of these, valid ENMO data were
available in 222 participants at 3 months and in 209 participants at 12 months, meaning that the change in
accelerometry could be estimated in 54% and 51% of the trial population at 3 and 12 months, respectively.
Overall baseline physical activity was low in both groups. Intervention arm participants were, on average,
more active than control arm participants both before randomisation and after randomisation, but, after
adjusting for baseline, few of the differences were statistically significant. The exception was MVPA,
measured at weekends at the 3-month follow-up, which was modestly greater in the intervention group.
The mean length of MVPA in the intervention and control groups was 70 versus 58 minutes per day
(difference of 9.2 minutes per day, 95% CI 1.7 to 16.7 minutes per day; p = 0.016) for 5-minute bouts
and 11 versus 7 minutes per day for 10-minute bouts (difference of 5.6 minutes per day, 95% CI 2.0
to 9.3 minutes per day; p = 0.003). The corresponding outcome for acceleration was not statistically
significant (20 vs. 19 mg, difference = 1.0 mg, 95% CI –0.3 to 2.4 mg; p = 0.140). None of the remaining
outcomes was different between the trial arms.
TABLE 17 Accelerometry (all data)
Measure of physical activity
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Mean acceleration magnitude, mg (ENMO)
Baseline
n 160 152
Mean (SD) 21.3 (7.9) 20.8 (7.3)
3 months
n 123 130
Mean (SD) 21.7 (9.0) 19.8 (7.1) –0.3 (–1.4 to 0.9) 0.654
12 months
n 120 134
Mean (SD) 22.4 (8.1) 20.5 (8.5) 0.1 (–1.5 to 1.6) 0.947
Mean acceleration magnitude (all days measured)
Baseline
n 160 152
Mean (SD) 21.3 (7.9) 20.8 (7.4)
3 months
n 123 130
Mean (SD) 21.7 (9.0) 19.8 (7.1) –0.4 (–1.5 to 0.8) 0.555
12 months
n 120 134
Mean (SD) 22.4 (8.2) 20.5 (8.5) 0.2 (–1.4 to 1.7) 0.844
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TABLE 17 Accelerometry (all data) (continued )
Measure of physical activity
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Mean acceleration magnitude (weekends)
Baseline
n 167 154
Mean (SD) 19.6 (8.0) 19.8 (8.3)
3 months
n 128 139
Mean (SD) 20.4 (9.6) 18.7 (6.9) 1.0 (–0.3 to 2.4) 0.140
12 months
n 126 137
Mean (SD) 20.9 (8.6) 19.4 (8.8) 0.3 (–1.5 to 2.1) 0.708
Mean acceleration magnitude (weekdays)
Baseline
n 159 153
Mean (SD) 22.1 (8.3) 21.1 (7.1)
3 months
n 125 129
Mean (SD) 22.1 (9.2) 20.2 (7.5) –0.7 (–2.0 to 0.6) 0.278
12 months
n 124 136
Mean (SD) 23.0 (8.5) 20.9 (8.6) 0.0 (–1.6 to 1.6) 0.994
MVPA, based on 5-second epochs (all days)
Baseline
n 160 152
Mean (SD) 75.6 (45.9) 72.4 (42.2)
3 months
n 123 130
Mean (SD) 77.5 (53.3) 64.1 (39.4) –0.5 (–7.7 to 6.8) 0.902
12 months
n 120 134
Mean (SD) 79.8 (50.3) 68.9 (47.2) 0.4 (–8.6 to 9.3) 0.939
MVPA, 5-second bout duration (weekends)
Baseline
n 167 154
Mean (SD) 65.7 (44.7) 67.5 (47.0)
3 months
n 128 139
Mean (SD) 70.3 (55.1) 57.9 (37.5) 9.2 (1.7 to 16.7) 0.016
12 months
n 126 137
Mean (SD) 71.9 (50.0) 63.0 (48.3) 2.1 (–7.9 to 12.1) 0.677
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TABLE 17 Accelerometry (all data) (continued )
Measure of physical activity
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
MVPA, based on 5-second epochs (weekdays)
Baseline
n 159 153
Mean (SD) 21.6 (22.8) 17.6 (17.8)
3 months
n 125 129
Mean (SD) 20.6 (25.8) 14.3 (17.7) –2.3 (–10.0 to 5.5) 0.563
12 months
n 124 136
Mean (SD) 23.6 (28.7) 18.0 (23.3) –0.4 (–9.7 to 8.8) 0.926
MVPA, > 5-minute bout duration, 80% inclusion (all days)
Baseline
n 160 152
Mean (SD) 19.8 (20.7) 16.8 (16.5)
3 months
n 123 130
Mean (SD) 19.9 (25.5) 13.5 (15.8) 1.7 (–1.8 to 5.2) 0.350
12 months
n 120 134
Mean (SD) 22.0 (25.5) 17.0 (22.4) 1.0 (–3.6 to 5.6) 0.675
MVPA, ≥ 5-minute bout duration, 80% inclusion (weekends)
Baseline
n 167 154
Mean (SD) 14.7 (19.6) 14.9 (18.7)
3 months
n 128 139
Mean (SD) 17.2 (28.9) 11.5 (15.5) 7.0 (2.7 to 11.4) 0.002
12 months
n 126 137
Mean (SD) 17.3 (25.2) 14.2 (22.2) 2.3 (–2.3 to 6.9) 0.333
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TABLE 17 Accelerometry (all data) (continued )
Measure of physical activity
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
MVPA, > 5-minute bout duration, 80% inclusion (weekdays)
Baseline
n 159 153
Mean (SD) 21.6 (22.8) 17.6 (17.8)
3 months
n 125 129
Mean (SD) 20.6 (25.8) 14.3 (17.7) 0.2 (–3.4 to 3.7) 0.924
12 months
n 124 136
Mean (SD) 23.6 (28.7) 18.0 (23.3) 0.4 (–5.0 to 5.9) 0.871
MVPA, ≥ 10-minute bouts, 80% inclusion (all days)
Baseline
n 160 152
Mean (SD) 13.3 (16.8) 11.0 (13.1)
3 months
n 123 130
Mean (SD) 13.3 (20.4) 8.8 (12.6) 2.0 (–0.9 to 4.9) 0.183
12 months
n 120 134
Mean (SD) 15.4 (21.7) 11.8 (19.3) 1.5 (–2.5 to 5.5) 0.473
MVPA, ≥ 10-minute bouts, 80% inclusion (weekends)
Baseline
n 167 154
Mean (SD) 9.6 (16.6) 9.6 (14.8)
3 months
n 128 139
Mean (SD) 11.3 (24.9) 7.4 (12.4) 5.6 (2.0 to 9.3) 0.003
12 months
n 126 137
Mean (SD) 11.9 (22.1) 9.5 (19.2) 2.2 (–1.8 to 6.2) 0.274
MVPA, ≥ 10-minute bouts, 80% inclusion (weekdays)
Baseline
n 159 153
Mean (SD) 14.4 (18.5) 11.6 (14.8)
3 months
n 125 129
Mean (SD) 13.8 (20.3) 9.5 (14.3) 0.9 (–2.0 to 3.8) 0.552
12 months
n 124 136
Mean (SD) 16.6 (24.5) 12.6 (20.1) 1.0 (–3.9 to 6.0) 0.680
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Dietary intake as assessed by the Dietary Instrument for Nutrition
Education questionnaire
Figures 14–18 depict food intake as assessed by the DINE questionnaire (blue lines denote mean values).
The measures (including the categorisations as low, medium and high) are reported in Table 18. The
baseline self-reported diet of the participants in both groups indicated a high consumption of refined
sugar from sugary drinks and low fibre. There was some evidence that alcohol intake had reduced in the
intervention arm, although the intake was highly skewed and not robust to alternative models, including
non-parametric analyses. No other dietary changes were observed as a result of the intervention or
trial participation.
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FIGURE 14 Dietary Instrument for Nutrition Education fibre intake. (a) Baseline; (b) 3 months; and (c) 12 months.
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FIGURE 15 Dietary Instrument for Nutrition Education fat intake. (a) Baseline; (b) 3 months; and (c) 12 months.
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FIGURE 16 Dietary Instrument for Nutrition Education unsaturated fat intake. (a) Baseline; (b) 3 months; and
(c) 12 months.
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FIGURE 17 Dietary Instrument for Nutrition Education daily sugar intake from drinks (g). (a) Baseline; (b) 3 months;
and (c) 12 months.
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FIGURE 18 Dietary Instrument for Nutrition Education weekly alcohol intake (units). (a) Baseline; (b) 3 months;
and (c) 12 months.
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TABLE 18 Dietary Instrument for Nutrition Education nutritional intake questionnaire
Dietary intake
Trial arm
Intervention (N= 207) Control (N= 205)
DINE fibre intake
Baseline
n 207 205
Mean (SD) 27.6 (11.3) 28.3 (12.6)
Median (IQR) 26.0 (19.0 to 34.0) 26.0 (20.0 to 36.0)
3 months
n 178 180
Mean (SD) 28.2 (12.0) 28.0 (12.4)
Median (IQR) 26.0 (19.0 to 36.0) 26.5 (19.5 to 36.0)
12 months
n 165 172
Mean (SD) 28.6 (12.1) 28.1 (10.6)
Median (IQR) 28.0 (20.0 to 35.0) 28.0 (21.0 to 36.0)
Baseline, n (%)
Low 122 (58.9) 120 (58.5)
Medium 55 (26.6) 50 (24.4)
High 30 (14.5) 35 (17.1)
3 months, n (%)
Low 101 (56.7) 103 (57.2)
Medium 41 (23.0) 53 (29.4)
High 36 (20.2) 24 (13.3)
12 months, n (%)
Low 90 (54.5) 93 (54.1)
Medium 52 (31.5) 61 (35.5)
High 23 (13.9) 18 (10.5)
DINE fat intake
Baseline
n 207 205
Mean (SD) 31.5 (11.0) 32.2 (11.9)
Median (IQR) 31.0 (23.0 to 39.0) 30.0 (23.0 to 39.0)
3 months
n 178 180
Mean (SD) 30.1 (11.4) 30.2 (11.6)
Median (IQR) 28.0 (22.0 to 36.0) 29.0 (21.0 to 37.0)
12 months
n 165 172
Mean (SD) 30.6 (12.7) 30.6 (11.6)
Median (IQR) 28.0 (22.0 to 37.0) 30.0 (22.0 to 37.5)
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TABLE 18 Dietary Instrument for Nutrition Education nutritional intake questionnaire (continued )
Dietary intake
Trial arm
Intervention (N= 207) Control (N= 205)
Baseline, n (%)
Low 96 (46.4) 96 (46.8)
Medium 65 (31.4) 63 (30.7)
High 46 (22.2) 46 (22.4)
3 months, n (%)
Low 99 (55.6) 97 (53.9)
Medium 49 (27.5) 52 (28.9)
High 30 (16.9) 31 (17.2)
12 months, n (%)
Low 90 (54.5) 80 (46.5)
Medium 41 (24.8) 62 (36.0)
High 34 (20.6) 30 (17.4)
DINE unsaturated fat intake
Baseline
n 207 204
Mean (SD) 9.5 (1.6) 9.2 (1.9)
Median (IQR) 10.0 (9.0 to 11.0) 9.0 (8.0 to 11.0)
3 months
n 178 179
Mean (SD) 9.6 (1.9) 9.3 (1.9)
Median (IQR) 10.0 (9.0 to 11.0) 9.0 (9.0 to 11.0)
12 months
n 164 171
Mean (SD) 9.7 (1.8) 9.4 (1.9)
Median (IQR) 10.0 (9.0 to 11.0) 10.0 (9.0 to 11.0)
Baseline, n (%)
Low 6 (2.9) 12 (5.9)
Medium 93 (44.9) 94 (45.9)
High 108 (52.2) 98 (47.8)
3 months, n (%)
Low 6 (3.4) 9 (5.0)
Medium 65 (36.5) 81 (45.0)
High 107 (60.1) 89 (49.4)
12 months, n (%)
Low 3 (1.8) 7 (4.1)
Medium 68 (41.2) 78 (45.3)
High 93 (56.4) 86 (50.0)
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Patient-reported outcome measures and disease severity
Health utility (EQ-5D) and QoL (SF-36) are reported in Tables 19 and 20. Self-reported QoL post randomisation
was generally slightly higher in intervention participants (physical functioning, role limitations), but emotional
well-being was slightly higher in the control group participants.
Health utility (EuroQol-5 Dimensions)
The main measure of the EQ-5D-5L showed little difference between groups at either time point, although
the ‘thermometer’ health scale showed a greater improvement among control participants at 12 months,
with a difference of 4.4 points (p = 0.028).
Health utility (Short Form questionnaire-6 Dimensions)
Self-reported QoL using the SF-36 suggested higher QoL post randomisation in intervention participants for
physical functioning and bodily pain, but emotional well-being was higher in the control group (Table 20).
TABLE 18 Dietary Instrument for Nutrition Education nutritional intake questionnaire (continued )
Dietary intake
Trial arm
Intervention (N= 207) Control (N= 205)
Daily sugar intake from drinks (g)
Baseline
n 207 205
Mean (SD) 76.2 (73.1) 85.4 (85.1)
Median (IQR) 53.0 (25.0 to 102.0) 56.0 (29.0 to 104.0)
3 months
n 178 180
Mean (SD) 70.9 (78.9) 74.2 (81.0)
Median (IQR) 49.0 (19.0 to 86.0) 50.0 (22.0 to 93.0)
12 months
n 165 172
Mean (SD) 71.8 (90.6) 66.3 (77.9)
Median (IQR) 37.0 (12.0 to 90.0) 41.0 (19.0 to 91.0)
Weekly alcohol intake (units)
Baseline
n 207 205
Mean (SD) 4.6 (12.6) 3.0 (7.4)
Median (IQR) 0.5 (0.0 to 3.5) 0.5 (0.0 to 3.0)
3 months
n 178 180
Mean (SD) 3.5 (10.3) 3.5 (12.8)
Median (IQR) 0.0 (0.0 to 2.5) 0.0 (0.0 to 2.5)
12 months
n 165 172
Mean (SD) 3.7 (9.9) 4.5 (12.2)
Median (IQR) 0.5 (0.0 to 2.5) 0.0 (0.0 to 3.5)
IQR, interquartile range.
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TABLE 19 The EuroQol-5 Dimensions
Dimension
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
EQ-5D-5L health utility
Baseline
n 206 203
Mean (SD) 0.793 (0.201) 0.783 (0.187)
3 months
n 178 180
Mean (SD) 0.815 (0.165) 0.785 (0.214) 0.02 (–0.02 to 0.05) 0.259
12 months
n 165 170
Mean (SD) 0.793 (0.237) 0.793 (0.239) –0.02 (–0.06 to 0.03) 0.495
EQ-5D-5L ‘thermometer’ health state
Baseline
n 207 204
Mean (SD) 57.9 (20.3) 54.4 (20.4)
3 months
n 178 180
Mean (SD) 60.3 (19.8) 57.7 (19.8) 0.1 (–3.1 to 3.3) 0.956
12 months
n 164 170
Mean (SD) 58.5 (21.3) 61.6 (21.1) –4.4 (–8.4 to –0.5) 0.028
TABLE 20 Short Form questionnaire-6 Dimensions
Dimension
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Physical functioning
Baseline
n 207 204
Mean (SD) 72.8 (25.6) 71.9 (24.6)
3 months
n 178 180
Mean (SD) 76.9 (23.1) 70.9 (26.2) 4.4 (1.0 to 7.9) 0.012
12 months
n 164 170
Mean (SD) 76.5 (25.6) 70.9 (26.8) 4.1 (0.2 to 8.0) 0.038
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TABLE 20 Short Form questionnaire-6 Dimensions (continued )
Dimension
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Role limitations owing to physical health
Baseline
n 207 204
Mean (SD) 54.6 (42.0) 54.2 (41.0)
3 months
n 178 179
Mean (SD) 63.8 (39.7) 60.2 (41.3) 3.3 (–4.8 to 11.4) 0.425
12 months
n 164 169
Mean (SD) 65.9 (41.8) 60.8 (40.7) 4.8 (–3.0, 12.7) 0.226
Role limitations owing to emotional problems
Baseline
n 207 204
Mean (SD) 46.2 (42.6) 44.0 (42.3)
3 months
n 178 179
Mean (SD) 52.2 (43.8) 50.1 (44.0) 1.3 (–7.3 to 9.8) 0.770
12 months
n 164 170
Mean (SD) 58.5 (43.9) 52.5 (45.4) 5.1 (–3.6 to 13.8) 0.251
Energy/fatigue score
Baseline
n 207 204
Mean (SD) 43.2 (21.8) 40.5 (23.1)
3 months
n 178 180
Mean (SD) 44.9 (21.6) 42.8 (23.6) –0.6 (–3.6 to 2.5) 0.720
12 months
n 164 170
Mean (SD) 44.9 (22.2) 45.0 (24.6) –2.7 (–6.3 to 0.9) 0.140
Emotional well-being
Baseline
n 207 204
Mean (SD) 58.3 (21.4) 56.4 (23.9)
3 months
n 178 180
Mean (SD) 58.8 (22.3) 57.0 (25.3) –0.1 (–3.5 to 3.3) 0.957
12 months
n 164 170
Mean (SD) 58.8 (23.4) 62.2 (23.4) –5.3 (–9.0 to –1.7) 0.004
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TABLE 20 Short Form questionnaire-6 Dimensions (continued )
Dimension
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Social functioning
Baseline
n 207 204
Mean (SD) 60.5 (29.1) 61.2 (28.7)
3 months
n 178 180
Mean (SD) 64.5 (29.6) 62.7 (31.5) 2.8 (–2.7 to 8.4) 0.311
12 months
n 164 170
Mean (SD) 66.1 (30.0) 65.7 (29.5) 1.5 (–4.2 to 7.1) 0.615
Bodily pain
Baseline
n 207 204
Mean (SD) 71.6 (28.8) 74.8 (27.4)
3 months
n 178 180
Mean (SD) 75.2 (25.5) 71.3 (28.4) 5.5 (0.9 to 10.2) 0.020
12 months
n 164 170
Mean (SD) 71.6 (30.7) 70.6 (29.1) 1.4 (–2.9 to 5.7) 0.534
General health
Baseline
n 207 204
Mean (SD) 45.0 (20.3) 44.8 (20.7)
3 months
n 178 180
Mean (SD) 48.0 (21.8) 46.8 (20.3) –0.3 (–3.4 to 2.8) 0.846
12 months
n 164 170
Mean (SD) 49.8 (23.1) 46.8 (21.4) 2.1 (–1.5 to 5.6) 0.249
Health change
Baseline
n 207 204
Mean (SD) 57.4 (30.2) 57.4 (29.0)
3 months
n 178 180
Mean (SD) 62.1 (26.7) 58.6 (28.9)
12 months
n 164 170
Mean (SD) 62.5 (25.3) 63.4 (26.7)
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Condition perception (Brief Illness Perception Questionnaire)
The B-IPQ measured participants’ perceptions of their ‘weight’ condition. The total score showed a small
improvement in both groups over time, although the changes on the eight dimensions of the B-IPQ were
mixed. There were no significant differences between groups on the total score or for each of the eight
dimensions (Table 21).
TABLE 21 Brief Illness Perception Questionnaire
Perception
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
B-IPQ overall total
Baseline
n 207 204
Mean (SD) 5.5 (1.5) 5.5 (1.7)
3 months
n 178 180
Mean (SD) 5.0 (1.7) 5.3 (1.7) –0.2 (–0.4 to 0.0) 0.110
12 months
n 164 170
Mean (SD) 5.0 (1.9) 5.0 (1.7) –0.0 (–0.3 to 0.3) 0.973
How much does your weight problem affect your life?
Baseline
n 207 204
Mean (SD) 6.1 (2.7) 6.2 (2.8)
3 months
n 178 180
Mean (SD) 5.9 (2.8) 6.1 (2.9)
12 months
n 164 170
Mean (SD) 5.9 (3.0) 5.7 (2.9)
How long do you think your weight problem will continue?
Baseline
n 206 202
Mean (SD) 6.1 (2.5) 6.0 (2.7)
3 months
n 176 180
Mean (SD) 5.9 (2.4) 5.9 (2.6)
12 months
n 163 169
Mean (SD) 5.7 (2.7) 5.6 (2.9)
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TABLE 21 Brief Illness Perception Questionnaire (continued )
Perception
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
How much control do you feel you have over your weight problem?
Baseline
n 207 204
Mean (SD) 4.4 (2.6) 4.1 (2.9)
3 months
n 178 180
Mean (SD) 5.4 (2.5) 4.7 (2.8)
12 months
n 164 170
Mean (SD) 5.4 (2.6) 4.9 (3.0)
How much do you think lifestyle programmes can help your weight problem?
Baseline
n 206 203
Mean (SD) 7.2 (2.1) 6.7 (2.6)
3 months
n 178 180
Mean (SD) 6.8 (2.7) 5.9 (2.7)
12 months
n 163 170
Mean (SD) 6.5 (2.7) 6.0 (3.0)
How much do you experience symptoms from your weight problem?
Baseline
n 207 204
Mean (SD) 5.4 (3.0) 5.2 (3.1)
3 months
n 178 180
Mean (SD) 4.6 (3.0) 4.7 (3.2)
12 months
n 162 170
Mean (SD) 4.9 (3.2) 4.5 (3.2)
How concerned are you about your weight problem?
Baseline
n 207 204
Mean (SD) 7.6 (2.6) 7.4 (2.7)
3 months
n 178 180
Mean (SD) 7.0 (2.9) 7.0 (2.8)
12 months
n 164 170
Mean (SD) 6.8 (2.8) 6.4 (3.2)
continued
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Psychiatric well-being (Brief Psychiatric Rating Scale and Patient Health Questionnaire-9)
Tables 22 and 23 show scores on the observer-rated BPRS and the patient-completed PHQ-9. The baseline
scores of the BPRS of around 30 indicate ‘mild illness’, and the differences between the groups and
over time were not clinically significant (see Table 22). Table 23 shows the percentage of participants
who scored above the clinical cut-off point (i.e. ≥ 10) for depression on the PHQ-9 at each time point.
Although the percentage who scored above the cut-off point reduced in both groups between baseline
TABLE 21 Brief Illness Perception Questionnaire (continued )
Perception
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
How well do you feel you understand your weight problem?
Baseline
n 207 204
Mean (SD) 6.4 (2.8) 6.7 (2.8)
3 months
n 178 180
Mean (SD) 7.2 (2.6) 6.8 (2.8)
12 months
n 164 170
Mean (SD) 7.1 (2.7) 6.8 (2.9)
How much does your weight problem affect you emotionally?
Baseline
n 207 204
Mean (SD) 6.1 (2.9) 6.1 (3.4)
3 months
n 178 180
Mean (SD) 5.5 (3.3) 6.0 (3.4)
12 months
n 164 170
Mean (SD) 5.3 (3.2) 5.2 (3.2)
TABLE 22 Brief Psychiatric Rating Scale
BPRS
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Baseline
n 207 204
Mean (SD) 30.9 (8.8) 31.5 (9.4)
3 months
n 178 180
Mean (SD) 30.3 (9.0) 30.4 (9.4) 0.2 (–1.3 to 1.7) 0.827
12 months
n 165 170
Mean (SD) 29.1 (9.7) 28.3 (9.5) 1.0 (–0.9 to 2.9) 0.303
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and 12 months, there were no significant differences between the groups. The mean baseline scores on
the PHQ-9 were in the moderate depressive symptom range, and again the differences between the
groups and over time were not clinically significant (see Table 23).
Smoking status
At baseline, approximately half of the participants were current smokers (Table 24). Smoking rates did not
change during the trial in either group.
TABLE 23 Patient Health Questionnaire-9
PHQ-9 scores
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Baseline
n 207 204
Mean (SD) 10.6 (6.3) 11.0 (6.8)
PHQ-9 score of ≥ 10, n (%) 106 (51.2) 116 (56.9)
3 months
n 178 180
Mean (SD) 10.3 (6.3) 10.1 (7.1) 0.5 (–0.4 to 1.3) 0.314
PHQ-9 score of ≥ 10, n (%) 94 (52.8) 94 (52.2)
12 months
n 165 170
Mean (SD) 9.9 (7.0) 9.6 (6.6) 0.5 (–0.4 to 1.5) 0.299
PHQ-9 score of ≥ 10, n (%) 74 (44.8) 79 (46.5)
TABLE 24 Smoking status
Smoking status
Trial arm, n (%)
Intervention (N= 207) Control (N= 205)
Baseline
Smoking status N = 207 N = 205
Current smoker 98 (47.3) 108 (52.7)
Light smoker 18 (8.7) 20 (9.8)
Moderate smoker 37 (17.9) 32 (15.6)
Heavy smoker 43 (20.8) 55 (26.8)
Amount not reported 0 (0.0) 1 (0.5)
Offered help to stop smoking 89 (47.3) 90 (47.1)
Brief intervention 38 (20.2) 53 (27.7)
Nicotine replacement 58 (30.9) 61 (31.9)
Drug treatment 3 (1.6) 4 (2.1)
Electronic cigarettes/vape 5 (2.7) 3 (1.6)
Other types 8 (4.3) 6 (3.1)
continued
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TABLE 24 Smoking status (continued )
Smoking status
Trial arm, n (%)
Intervention (N= 207) Control (N= 205)
Currently using therapy to stop smoking 24 (12.8) 25 (13.1)
Nicotine replacement 15 (8.0) 013 (6.8)
Drug treatment 0 0
Electronic cigarettes/vape 10 (5.3) 12 (6.3)
Other types 9 (4.8) 12 (6.3)
3 months
Smoking status N = 178 N = 180
Current smoker 85 (47.8) 96 (53.3)
Light smoker 13 (7.3) 19 (10.6)
Moderate smoker 28 (15.7) 31 (17.2)
Heavy smoker 44 (24.7) 46 (25.6)
Offered help to stop smoking 78 (47.0) 71 (42.5)
Brief intervention 39 (23.5) 39 (23.4)
Nicotine replacement 55 (33.1) 54 (32.3)
Drug treatment 4 (2.4) 2 (1.2)
Electronic cigarettes/vape 5 (3.0) 1 (0.6)
Other types 2 (1.2) 2 (1.2)
Currently using therapy to stop smoking 21 (12.7) 19 (11.4)
Nicotine replacement 11 (6.6) 13 (7.8)
Drug treatment 0 0
Electronic cigarettes/vape 10 (6.0) 6 (3.6)
Other types 9 (5.4) 6 (3.6)
12 months
Smoking status N = 166 N = 172
Current smoker 75 (45.2) 88 (51.2)
Light smoker 17 (10.2) 13 (7.6)
Moderate smoker 29 (17.5) 27 (15.7)
Heavy smoker 29 (17.5) 48 (27.9)
Offered help to stop smoking 64 (45.1) 63 (42.9)
Brief intervention 27 (19.0) 27 (18.4)
Nicotine replacement 47 (33.1) 42 (28.6)
Drug treatment 1 (0.7) 3 (2.0)
Electronic cigarettes/vape 3 (2.1) 3 (2.0)
Other types 6 (4.2) 2 (1.4)
Currently using therapy to stop smoking 22 (15.4) 11 (7.5)
Nicotine replacement 12 (8.4) 6 (4.1)
Drug treatment 0 0
Electronic cigarettes/vape 10 (7.0) 4 (2.7)
Other types 9 (6.3) 5 (3.4)
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Weight loss programmes
During the trial, 25 participants [(7.4%) eight control, 17 intervention] reported attending one or more
weight loss programmes outside the trial (Table 25).
Ten-year cardiovascular and diabetes risk
The Framingham cardiovascular risk scores are presented in Table 26. Twenty-six participants in each trial
arm had a pre-existing cardiovascular diagnosis and 84 (40 intervention, 44 control) were aged < 30 years;
the Framingham risk score is not defined for these subgroups. The mean ‘desk’ Framingham 10-year risk
(which does not incorporate laboratory measures) was 10.9% for the intervention group and 10.6%
for the control group at baseline, and remained similar at both 3 months and 12 months. The mean
laboratory-based Framingham scores were substantially lower in the control group at baseline (7.7% vs. 8.6%),
and both demonstrated minor change (< 1%) at 12 months. Only one participant in the intervention arm
developed a cardiac event during the trial; this individual died.
Table 27 shows that 60 participants (35 in the intervention group and 25 in the control) group had
diabetes on entry to the trial. Among the remainder, the 10-year risk of developing diabetes was 17.2% in
both trial arms at baseline, with over half being in the ‘moderate’ risk category. By 12 months, the risk had
decreased by 0.5% in the intervention arm and by 0.4% in the control arm. No participant was recorded
as having developed diabetes during the trial, although one participant (intervention arm) was hospitalised
twice because of diabetes-related complications.
Change in medications
During the trial, the vast majority of participants remained on antipsychotics (Table 28), although around
one-fifth of participants in both groups experienced a change of antipsychotic treatment. Approximately
TABLE 25 Weight loss programmes
Use of weight loss programme
Trial arm
Intervention (N= 207) Control (N= 205)
3 months
Followed up N = 178 N = 180
Attended any weight loss programme 4 (2.5%) 8 (4.4%)
Slimming World® (Alfreton, UK) 2 1
Weight Watchers® (New York, NY, USA) 0 3
Structured programme organised by GP/care team 1 3
Other 1 1
12 months
Followed up N = 165 N = 170
Attended any weight loss programme 17 (10.3%) 8 (4.7%)
Slimming World 8 3
Weight Watchers 4 1
Structured programme organised by GP/care team 3 4
Other 4 0
Notes
Some participants attended more than one weight loss programme.
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
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TABLE 26 Ten-year cardiovascular risk (Framingham)
Risk measure
Trial arm
Mean difference
(95% CI) p-value
Intervention
(N= 207)
Control
(N= 205)
Aged 30–74 years and no cardiovascular
condition, n (%)
142 (68.6) 136 (66.3)
Framingham % cardiovascular risk score (excluding laboratory measures)
Baseline
n 142 135
Mean (SD) 10.9 (9.5) 10.6 (10.9)
3 months
n 123 120
Mean (SD) 10.8 (8.6) 10.7 (10.5)
Change at 3 months
n 123 120
Mean (SD) –0.5 (3.8) –0.5 (4.4) 0.0 (–0.8 to 0.9) 0.986
12 months
n 114 123
Mean (SD) 10.9 (9.6) 10.5 (10.5)
Change at 12 months
n 112 118
Mean (SD) –0.3 (3.9) –0.3 (4.4) –0.1 (–1.1 to 1.0) 0.905
Framingham % cardiovascular risk score: including laboratory measures
Baseline
n 120 117
Mean (SD) 8.7 (8.2) 7.6 (6.3)
12 months
n 100 105
Mean (SD) 8.6 (7.7) 7.6 (6.3)
Change at 12 months
n 87 90
Mean (SD) –0.7 (4.0) –0.4 (4.1) –0.2 (–1.2 to 0.8) 0.690
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TABLE 27 Ten-year diabetes mellitus risk
Risk measure
Trial arm
Mean difference (95% CI) p-valueIntervention (N= 207) Control (N= 205)
Has diabetes mellitus, n (%) 35 (16.9) 25 (12.2)
Diabetes UK 10-year diabetes mellitus risk (%)
Baseline
n 171 180
Mean (SD) 17.2 (6.2) 17.2 (6.2)
Diabetes UK 10-year diabetes mellitus risk group, n (%)
Low 3 (1.5) 6 (2.9)
Increased 65 (31.6) 68 (33.3)
Moderate 111 (53.9) 109 (53.4)
High 27 (13.1) 21 (10.3)
Diabetes UK 10-year diabetes mellitus risk (%): 3 months
n 150 159
Mean (SD) 16.8 (6.1) 17.3 (6.2)
Change at 3 months
n 150 159
Mean (SD) –0.1 (1.8) –0.1 (1.8) –0.0 (–0.4 to 0.3) 0.940
Diabetes UK 10-year diabetes mellitus risk group: 3 months, n (%)
Low 5 (2.8) 5 (2.8)
Increased 57 (32.0) 58 (32.0)
Moderate 97 (54.5) 100 (55.2)
High 19 (10.7) 18 (9.9)
Diabetes UK 10-year diabetes mellitus risk (%): 12 months
n 141 154
Mean (SD) 16.6 (6.6) 16.9 (6.6)
Change at 12 months
n 141 154
Mean (SD) –0.5 (2.8) –0.4 (2.9) 0.0 (–0.7 to 0.8) 0.896
Diabetes UK 10-year diabetes mellitus risk group: 12 months, n (%)
Low 9 (5.4) 10 (5.8)
Increased 54 (32.1) 54 (31.2)
Moderate 86 (51.2) 89 (51.4)
High 19 (11.3) 20 (11.6)
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half of participants in both groups were treated with antidepressants. By the end of the trial, 17% of
intervention arm participants and 15% of control arm participants had experienced a change of
antidepressant medication.
Session feedback forms and centre outcomes
Session feedback
Intervention group participants could provide anonymous feedback following each group session. It was
not possible to link feedback to their clinical outcomes, but the feedback could be linked to the study
centre results. Seven hundred and eight session feedback forms were returned after the seven group
sessions across the 10 centres, although we did not know who responded or on how many occasions.
Therefore, the numbers and percentages in the tables below are based on ‘forms returned’ rather than
on ‘participants’. Five of the returned forms had no study centre identifiers and were excluded. When
two responses were indicated (n = 3), the higher score was taken, and missing responses (n = 10) were
replaced with the mean of the participants’ other responses.
Table 29 shows that the vast majority of responses were positive for all six statements, with almost 90%
‘agreeing’ with each statement either ‘strongly’ or scoring ‘2’ on a Likert scale of 5. A total of 87.2% of
participants strongly agreed or agreed that the sessions had met their needs.
Participants had the opportunity to add comments to their forms, although only four did so. Three of these
comments were positive:
I felt this has been a fantastic group and really looking forward to meeting up in 3 months’ time.
One thing that went well? Talking together about different weight control.
What went well. Everything except the cold.
The only negative comment made was:
Mental health as bad as ever which affects my answer.
TABLE 28 Changes in medication
Psychiatric medication
Trial arm, n (%)
Intervention (N= 207) Control (N= 205)
Antipsychotics
Antipsychotics changed by 3 months 9 (5.0) 21 (11.6)
Antipsychotics changed by 12 months 24 (14.3) 29 (16.7)
Antidepressants
On antidepressants at 3 months 112 (62.9) 111 (61.3)
Antidepressants changed by 3 months 11 (6.1) 10 (5.5)
On antidepressants at 12 months 111 (66.1) 105 (60.7)
Antidepressants changed by 12 months 29 (17.3) 27 (15.4)
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Session feedback by study centre
Session feedback scores could range from 6 to 30, with 6 indicating the most positive response on all five
items and 30 indicating the most negative response on all items. Table 29 shows the average feedback
scores across the 10 centres and Table 30 shows the average scores by centre. Feedback was similar across
the centres: in most centres > 50% of forms recorded the most positive score of 6 and in all centres at
least 75% of forms recorded scores below 12 (equivalent to scoring 2 for each statement). There were no
TABLE 30 Session feedback scores (n= 703) by centre
Site
Number
of forms
returned
Total score
IQR
Score of, %
Mean (SD) Median
6 (most
positive)
> 24 (most
negative)
Sheffield 51 7.9 (4.3) 7 6–8 47.1 3.9
Leeds and York 39 8.1 (4.2) 6 6–10 64.1 2.6
Bradford 70 10.6 (8.5) 6 6–11 58.6 15.7
Manchester 84 7.7 (3.6) 6 6–9 61.9 1.2
South London 61 10.1 (7.1) 6 6–11 54.1 8.2
Sussex 105 9.6 (5.8) 7 6–11 45.7 5.7
Southern Health 116 9.2 (6.3) 6 6–9 57.8 7.8
Devon 69 9.7 (7.0) 6 6–10 56.5 10.1
Somerset 26 7.6 (3.0) 6 6–8 65.4 0
Cornwall 82 9.9 (6.1) 8 6–11 41.5 7.3
Overalla 703 9.2 (6.1) 6 6–10 54.1 6.8
IQR, interquartile range.
a All centres have at least 75% of forms scoring below 12 (equivalent to scoring 2 for each statement).
Note
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
TABLE 29 Session feedback questions and responses overall (n= 703 for each question)
Question
Responses (%)
1 2 3 4 5
(strongly
agree)
(neither
agree nor
disagree)
(strongly
disagree)
The facilitator listened to me 77.1 12.5 2.0 2.0 6.4
I understood what we talked about 74.4 13.9 3.0 2.3 6.4
I found what we talked about useful 71.8 17.1 2.7 2.6 5.8
I felt the facilitator understood the challenges I face 66.1 20.3 5.1 3.0 5.4
What we talked about made sense to me 76.7 12.4 2.4 3.3 5.3
Overall the session met my needs 67.3 19.9 4.7 3.1 5.0
Note
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
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significant correlations between mean weight change and mean feedback scores for centres, at 3 months
or 12 months (Spearman’s rank-order correlation = –0.20; p = 0.476, and Spearman’s rank-order
correlation = 0.042; p = 0.454, respectively).
Adverse events
The adverse events are summarised in Table 31. Most were expected and related to the psychiatric illness.
The majority were hospitalisations for psychiatric reasons. Serious adverse events were assessed for
relatedness and two were considered to be possibly related to the intervention, as described below.
Thirty-six participants (20 in the intervention group and 16 in the control group) were admitted to hospital
for mental health reasons (specified as ‘expected’ in the protocol) during the trial. One admission was
deemed to be possibly trial related; the patient was admitted following a relapse after stopping their
medication in an attempt to control their weight. The participant was randomised to the intervention arm,
but did not attend any of the sessions.
Four participants (two in each trial arm) were reported to have attempted suicide (specified as ‘expected’
in the protocol) and 21 participants were hospitalised (11 in the intervention group and 10 in the control
group) for non-mental health-related reasons. None of these events was considered to be related to the
study procedures.
Participant deaths
Four deaths were reported, all in the intervention group. Three deaths occurred during the trial and one
occurred several months after the trial ended. Detailed information is given below.
Patient 1 was a 53-year-old white man with a BMI of 34 kg/m2 and concurrent diagnoses of asthma and
depression, who had been on antipsychotic medication for 32 years. His death occurred 264 days after
randomisation, after he had attended four foundation sessions and two booster sessions. The cause of death
was a pulmonary embolism, which is likely to have developed secondarily to a ruptured Achilles tendon.
TABLE 31 Adverse events summary
Adverse event
Trial arm
Intervention (N= 207) Control (N= 205)
Number
of events
Number (%)
of participants
Number
of events
Number (%)
of participants
Any adverse event 46 37 (17.9) 34 26 (12.7)
Psychiatric hospitalisation 23 20 (9.7) 17 16 (7.8)
Self-harm 0 1 1 (0.55)
Suicide attempt 2 2 (1.0) 2 2 (1.0)
Hospitalisation (not mental health related) 13 11 (5.3) 11 10 (4.9)
Death 3 3 (1.4) 0
Skin reaction to accelerometer 4 4 (1.9) 0
Other 1 1 (0.5) 3 3 (1.5)
Note
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original text.
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Prior to the study, the participant reported walking a lot, achieving more than 10,000 steps per day, as
assessed by pedometer. Objective accelerometry data indicated that he had not changed his physical
activity after the intervention. Nevertheless, as a ruptured Achilles tendon could have occurred as a result
of following advice from the intervention, the relationship was reported to the ethics committee as
possibly intervention related. This death was therefore reported within 15 days to the research ethics
committee, which determined that no further action was required.
Patient 2 was a 48-year-old white woman with a BMI of 40 kg/m2 and concurrent diagnoses of hypertension
and dyslipidaemia. She had been taking antipsychotic medication for 22 years. Her death occurred 260 days
after randomisation, after she had attended three foundation sessions. The cause of death was determined
by the coroner as 1a) left ventricular hypertrophy, 1b) hypertension and obesity. The death was unrelated to
the intervention.
Patient 3 was a 35-year-old black woman with a BMI of 38 kg/m2 and a concurrent diagnosis of type 2
diabetes mellitus who had been on antipsychotic medication for 7 years. Her death occurred 57 days after
randomisation after four foundation sessions. Her diabetes mellitus had been treated with oral antidiabetes
agents, but not sodium–glucose co-transporter-2 inhibitors. She was found unresponsive at her home and
the death was determined as resulting from diabetic ketoacidosis leading to cardiac arrest. The death was
unrelated to the intervention.
Patient 4 was a 36-year-old Asian woman with a BMI of 36 kg/m2 and a concurrent diagnosis of type 2
diabetes mellitus who had been taking antipsychotic medication for 10 years. She died from a myocardial
infarction 1 month after she completed the study, while she was detained under section 3 of the Mental
Health Act 1983.111 She had been under the care of the local cardiology team, which advised that she stop
taking clozapine, which precipitated the deterioration in her mental health. The death was unrelated to
the intervention.
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Chapter 5 Results of the process evaluation
Context
Context, sometimes defined as ‘settings, roles, interactions and relationships’,112 affects the implementation
of complex interventions. Figure 19 shows contextual factors that affect the implementation of, and
engagement with, the STEPWISE intervention, coded in accordance with the ICF conceptual framework.76
Health condition: schizophrenia, 
with antipsychotic-induced weight gain
Body structure/function
Impairment
Activity
Activity limitation
Participation
Participation restriction
• d155 Acquiring skills
• d166 Reading
• d175 Solving problems
• d210 Undertaking a single
   task
• d310 Communicating with –
   receiving – spoken messages
• d330 Speaking
• d470 Using transportation
• d5701 Managing diet and
   fitness
• d5702 Maintaining one’s 
   health
• d620 Acquisition of goods
   and services
• d630 Preparing meals
• d730 Relating with strangers
• d7200 Forming relationships
• d750 Informal social
   relationships
• d7504 Informal relationships
   with peers
• d850 Remunerative employment
• d870 Economic self-sufficiency
Personal factors
• Age
• Gender
• Socioeconomic status
• Region
• Family status
• Coping styles
• Personality traits
Environmental factors
• e325 Support from peers
• e410 Individual attitudes of
   immediate family members
• e450 Individual attitudes of
   health professionals
• e460 Societal attitudes
• e580 Health services,
   systems and policies
Many people with
schizophrenia function well
most of the time, but some will
be dealing with impairments
of the following functions:
• b117 Intellectual
• b122 Global psychosocial
• b130 Energy and drive
• b132 Emotional
• b140 Attention
• b144 Memory
• b156 Perceptual
• b160 Thought
• b164 Higher-level cognitive
• b167 Language
FIGURE 19 Context understood through the ICF conceptual framework. Reprinted from the WHO’s Towards a
Common Language for Functioning, Disability and Health ICF;76 diagram entitled ‘model of disability’ on page 9.
WHO reference number: WHO/EIP/GPE/CAS/01.3. Copyright 2002.
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Body functions
Half of the facilitators interviewed commented that, although most participants were receptive to the
intervention, an individual’s psychosocial functioning could affect how well they could engage with
STEPWISE. Facilitators discussed this most frequently in terms of the transient severity of hallucinatory or
delusional symptoms associated with paranoid schizophrenia; some also spoke of comorbid learning
disabilities, implying problems with attention, memory, goal-directed/logical thought, insight, executive
function or language, which are commonly associated with disorganised-type schizophrenia:
. . . when we’ve gone out together we’ve all been discussing . . . university degrees they’ve got . . .
they are really quite intelligent people but they still do have a psychotic illness . . . they could be
distracted if there’s something on their mind, or if they’re paranoid at the time . . . that has to be
taken into consideration a little bit more when you’re planning.
Facilitator S03/F02
We’ve got quite a small group and one of the persons in the group . . . he has a mild learning
difficulty and I’m not sure that he’s quite sort of clear about what, why he’s there particularly
sometimes, which is difficult.
Facilitator S06/F05
I think some of them have mild learning disabilities and umm I’m not sure that you know they take in
everything we tell them in the session.
Facilitator S09/F01
There could be like mild learning disabilities running alongside their mental illness as well and that,
I have definitely noticed that that’s hindered . . . someone’s ability to engage.
Facilitator S09/F03
In addition, developers characterised this group as sometimes less interactive than other populations and
occasionally somnolent or impulsive:
. . . there’s been a couple of occasions where people do seem a bit overmedicated . . . Asleep . . . or
saying very random things that really have no you know no connection to what is being talked about.
Developer D05
We all said that the medication that we’re on, different people different reactions, but quite a few of
them said you know, I’m sluggish from the sedation. And it’s hard to wake you up in the morning.
Participant S08/Q06
. . . so when the sandwiches came out there was definitely some people [sic.] it was literally . . .
automatic that reaching for sandwiches and eating and reaching for another sandwich . . . and
thinking do you know, ‘have you noticed how many of those sandwiches that you’ve eaten?’.
Developer D03
Activities and participation
Cognitive problems meant that some participants had problems learning and applying knowledge, specifically,
acquiring skills, reading and problem-solving. Undertaking tasks could take longer than expected, and that
could be difficult:
We did have to sort of adjust to the people that were in the group . . . the ones that were struggling
with the reading . . . we would just sort of put more time in with them.
Facilitator S09/F01
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Costs notwithstanding, facilitators felt that the use of taxis was essential for attendance; the barriers to
using transportation were great for those with severe symptoms or poor cognition, and many lived in areas
that were poorly served by public transport. Aside from managing diet and fitness, the principal objective
of STEPWISE, a self-care theme that often arose was the importance of adherence to antipsychotic
medication in the face of weight gain:
Quite a few service users get put off continuing to take their medication because of the side effects
and this gives them a way to control it so it isn’t only kind of benefiting their physical health, but it will
benefit their mental health as well if it’s helping them to stay on the medication.
Facilitator S06/F01
In some cases, family or residential care staff were responsible for shopping and food preparation. Meeting
strangers and forming and conducting informal social relationships could cause anxiety. Some had never
met others with their condition; others talked about the difficulty of discussing antipsychotic-induced
weight gain at Weight Watchers owing to the stigma of mental illness:
. . . they are finally coming in to a group of people they have never met. It’s quite anxiety provoking
for them, isn’t it?
Facilitator S06/F04
So, the STEPWISE programme was really the first time I had had exposure to other service users.
Participant S09/Q01
I would never have said anything [at Weight Watchers] about my medication sort of being a contributor
to me putting on weight because they’d say ‘What is it?’ and . . . I would’ve felt pressure to tell them.
And then it was like a ‘oh no I’ve told them I’m mentally ill now’ sort of thing.
Participant S10/Q03
Many STEPWISE attendees were not in remunerative employment and some were living in economically
difficult circumstances:
You end up having more of a sedentary lifestyle because you’re told you’re not fit to work.
Participant S08/Q09
I was struck by some of the levels of deprivation . . . there was somebody who was living in a caravan.
Their caravan had been washed away in the floods so they actually didn’t have anywhere to live . . .
they were there at the group, which was pretty amazing, but if you think about . . . where this fits on
their . . . continuum of needs . . . some people are just getting by.
Developer D03
Environmental factors
The attitudes of family members were not always supportive vis-à-vis lifestyle changes, and stigmatising
treatment by other members of the public was reported:
They found these sessions were the opportunity for them do it for themselves instead of having
someone else there . . . [one of] the participants brought someone with them . . . it was a relative
and you could see, there was a lot of . . . judgemental attitude, like, ‘oh, you should be doing this,’
or, ‘you shouldn’t be doing that,’ and . . . ‘why are you doing this?’ and it was a lot of pressure on
that participant.
Developer 01
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The individual attitudes of facilitators were characterised by developers as being generally sensitive to the
needs of an autonomy-enabled approach to behaviour change, with only a small minority being overly
didactic in delivery. The following quotation from a facilitator is illustrative of how many facilitators
characterised their roles, interactions and relationships with clients:
Going to an acute [psychiatric] ward and you’re saying to the person take these tablets, they’ll turn
around and say to you, ‘why should I?’ Whereas, if you’ve got somebody who’s got a general illness
they just sit there and put them in their mouth [laughs] . . . you get used to having to discuss things
with people and in that respect I suppose it was natural for me to do things that way [i.e. in
accordance with the STEPWISE philosophy] . . . you’ve got to be more open-minded, I think, with
people with mental health . . . a lot of the people you’re talking to are extremely intelligent people
and so therefore you do respect them . . . they’re not an illness, they’re a person [with] need, wants
feelings, ways of doing things . . .
Facilitator S03/F02
However, some facilitators thought that health professionals who were meant to be referring patients to
STEPWISE (‘gatekeepers’) sometimes erected barriers to patient engagement:
A lot of clinicians have said their clients don’t like group work or they don’t like to leave their home
and they’ve put a lot of barriers in the way of people engaging.
Facilitator S06/F01
Interviewees described the availability of, and referral patterns associated with, existing lifestyle interventions
as ad hoc, fragmented and locally idiosyncratic, often involving referral to other organisations. This was
confirmed by our survey of usual care.36 Monitoring of weight was not systematic for this population in all
trusts, and, although all trusts talked about physical health as a priority, scarcity of resources was a problem,
although quality-improvement initiatives were changing this in some cases (see also Sense-making,
Operational work and Appraisal work).
How context might affect the success of the intervention
Facilitator views of STEPWISE and Implementation process concentrate on how organisational context
affects outcome. To more vividly illustrate and explore potential context effects (see also Table 4), we
present six vignettes of interviewees from the intervention arm who experienced clinically important weight
gain (Box 1) and weight loss (Box 2). These vignettes suggest that, although weight control is possible in
people with first episode psychosis and in people living in the most deprived neighbourhoods (S04/Q02), it is
particularly difficult for those with first episode psychosis (S04/Q08, S04/Q12, S07/Q06). Those with clinically
important weight loss may have less severe psychiatric symptoms and comorbidities (S04/Q02; BPRS score of
34) than those with clinically important weight gain (S04/Q08; BPRS score of 44). Those who experienced
clinically important weight loss generally talk about needing more ongoing support or, especially, closer
monitoring of behaviour change enactment and outcomes, as if they are more alert to the risk of relapse.
The intervention’s theory of change
As part of the process evaluation, the intervention development team at LDC was asked to use a behaviour
change techniques taxonomy25,95 to identify active ingredients within the STEPWISE intervention (Table 32).95,113
Although the STEPWISE intervention is inspired by a range of behaviour change theories, in conversation
with LDC staff, we established that it has a systematic basis in three in particular.114 The first is self-efficacy
theory (Figure 20), which posits that the central mechanism behind behaviour change is a person’s belief that
they can change.85 Interventions can boost those beliefs by confronting someone with personal experiences
of their success, other people’s experiences of success, verbal persuasion about their capability and arousing
their emotions. The second theory, the self-regulatory model of illness behaviour (Figure 21), proposes that the
interpretation of symptoms and social messages, coping strategies and the appraisal of their effectiveness
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BOX 1 Intervention interviewees who experienced clinically important weight gain
S04/Q08
Woman, 32 years old, ethnic white British, unemployed, neighbourhood in the 20% most deprived. Gained
13.6 kg in the first 3 months and a further 16.1 kg thereafter (total weight gain of 29.7 kg). Diagnosed
comorbidities: depression, asthma and an alcohol problem; first-degree relatives with diabetes mellitus or a
heart condition. First episode psychosis (2 years since diagnosis). BPRS score of 44 (moderately ill). Moderately
severe somatic concern, anxiety and hallucinatory behaviour. Moderate depressive mood. Mild suspiciousness.
Very mild emotional withdrawal, conceptual disorganisation, tension, mannerisms, hostility, motor retardation,
unco-operativeness, blunted affect and excitement. Reported a high level of acceptability of the intervention,
focusing on self-monitoring and social support elements, but wanted more sessions. Enjoyed small group size
owing to self-reported anxiety. Reported losing weight during the foundation course but putting on weight
thereafter. Reported using the taxis provided, despite living 5 minutes’ drive from the venue.
S04/Q12
Man, 30 years old, ethnic Indian, unemployed, neighbourhood in the 10% most deprived. Gained 4.3 kg in
the first 3 months and a further 1.2 kg thereafter (total weight gain of 5.5 kg). No comorbidities. First episode
psychosis (2 years since diagnosis). BPRS score of 26 (mildly ill). Moderate motor retardation. Mild emotional
withdrawal and blunted affect. Very mild unco-operativeness. Reported finding the intervention acceptable,
but remarked ‘I think it needed more talking about . . . all you can do in the gym, like, to lose weight faster’.
Preferred smaller groups.
S07/Q06
Man, 25 years old, ethnic white British, unemployed, neighbourhood in the 50% most deprived. Gained 8.4 kg
in the first 3 months and a further 2.9 kg thereafter (total weight gain of 11.3 kg). First episode psychosis
(9 months since diagnosis). Diagnosed with depression and irritable bowel syndrome. BPRS score of 34 (mildly ill).
Severe hallucinatory behaviour. Moderate anxiety, guilty feelings, depressive mood. Mild somatic concern.
Focused on dietary aspects of the intervention only.
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all interact, and are all targets for intervention.115 The third and final theory, the relapse prevention model
(Figure 22), aims to maintain abstinence from problem behaviours by helping the client to develop coping
responses and perceived self-efficacy.116 On a day-to-day basis, the LDC team talked rather more about
empowerment philosophy than the three behaviour change theories. Empowerment philosophy is ‘based on
the premise that human beings have the capacity to make choices and are responsible for the consequences of
their choices’.117 It is also the difference between what drives the style of delivery; empowerment philosophy
maintains that people are autonomous decision-makers and not purely driven by information provision.
Self-reflection supports change, whereas behaviour change theory supports the content of the intervention.
It is better understood as a conceptual model rather than a middle-range theory118 of the kind associated with
health psychology and behaviour change,114,119 being comparatively vague in terms of how change is to be
effected. The section above, How context might affect the success of the intervention, and the vignettes in
Box 2 suggest that some participants might welcome more sustained support, so care must be taken to ensure
that empowerment does not translate to a demand for patients to self-manage in isolation.120,121
BOX 2 Intervention interviewees who experienced clinically important weight loss
S04/Q02
Woman, 33 years old, ethnic African, unemployed, neighbourhood in the 10% most deprived. Gained 1.2 kg
in the first 3 months and lost 7.3 kg thereafter (total weight loss of 6.1 kg). Diagnosed with hypertension and
depression. First episode psychosis (7 months since diagnosis). BPRS score of 34 (mildly ill). Moderate somatic
concern and blunted affect. Mild anxiety, emotional withdrawal, unco-operativeness. Very mild guilty feelings,
mannerisms, depressive mood, suspiciousness. ‘It needs to be longer . . . maybe like 10 weeks . . . give us
updates on how we are coping, on what we are doing . . . to monitor us more closely . . . it was becoming a
routine and then it just stopped . . . the questions were important because they, we needed to know if there’s
any downfalls . . . challenges . . .’.
S03/Q06
Man, 35 years old, ethnic white British, unemployed, neighbourhood in the 10% most deprived. Lost 3.8 kg in
the first 3 months and lost a further 13.4 kg thereafter (total weight loss of 17.2 kg). Diagnosed with asthma.
ICD-10 F20. BPRS score of 34 (mildly ill). Moderate emotional withdrawal, blunted affect. Mild somatic concern,
anxiety, conceptual disorganisation, depressive mood. Very mild guilty feelings, tension. ‘It helped . . . [to] be
aware of my eating habits . . . it’s important to do exercise in order to lose the weight . . . it’s been quite a lot
of time in between doing the course and the refresher course . . . so I’m feeling a bit less motivation with
the dieting’.
S08/Q05
Woman, 28 years old, ethnic white British, unemployed, neighbourhood in the 50% most deprived. Gained
1.5 kg in the first 3 months and lost a further 10.8 kg thereafter (total weight loss of 9.3 kg). Diagnosed with
having an alcohol problem. ICD-10 F25. BPRS score of 41 (moderately ill). Moderately severe anxiety, hallucinatory
behaviour, unusual thought content. Mild somatic concern, hostility. Very mild emotional withdrawal, guilt
feelings, tension, grandiosity, depressive mood, suspiciousness, blunted affect. Talked in compelling detail about
enactment of exercise strategies, demonstrating understanding and application of STEPWISE content; also,
talked about the need for, ‘more regular support . . . see how you’re doing, because . . . the next session’s quite
far away’.
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TABLE 32 Behaviour change techniques/theoretical constructs mapped to the STEPWISE programme components
Behaviour change
techniques
Behaviour change theory:
construct Demonstrated in the programme
1. Goals and planning
1.1 Goal-setting
behaviour
SET: VE (modelling)
SET: VP (suggestion; self-instruction)
SET: OE
CSM: coping procedures (approach)
RP: coping
l Next steps (sessions 1–3)
l Next steps (session 4)
l Booster sessions 1–3
1.2 Problem-solving SET: VE (modelling)
SET: VP (suggestion; self-instruction)
CSM: coping procedures (approach)
RP: coping
l Sharing stories (sessions 2–4)
l Sharing stories (booster sessions 1–3)
l Keeping it going (booster sessions 1–3)
l Next steps (session 4)
l Next steps (booster sessions 1–3)
1.4 Action-planning SET: VE (modelling)
SET: VP (suggestion; self-instruction)
CSM: coping procedures (approach)
RP: coping
l Next steps (session 4)
l Booster sessions next steps 1–3
1.5 Review behaviour
goals
SET: VE (modelling)
SET: VP (suggestion; self-instruction)
SET: EA (symbolic exposure/
desensitisation)
CSM: appraisal
RP: review behaviour goals
Sharing stories asks to review goals but not specifically
reset unless it is revisited in the ‘next steps’ (sessions 2–4,
booster sessions 1–3)
2. Feedback and monitoring
2.3 Self-monitoring of
behaviour
SET: EME (performance exposure;
self-instructed performance)
SET: VP (self-instruction)
SET: EA (symbolic exposure)
CSM: appraisal
CSM: coping procedures (approach)
RP: self-monitoring
RP: behaviour assessment
Encourage use of food diaries/pedometers and physical
activity diaries
l Session 1: topic 1B – food diary
l Session 2: topic 2B – physical activity diary and
pedometer
Encouraged to complete and use these tools
throughout the whole programme
l Revisited in booster sessions 1–3
l Revisited in telephone calls
2.4 Self-monitoring of
outcomes of behaviour
SET: EME (performance exposure;
self-instructed performance); VP
(self-instruction)
CSM: appraisal
CSM: coping procedures (approach)
l Given weighing scales and encouraged to record
their weight weekly (session 1)
continued
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TABLE 32 Behaviour change techniques/theoretical constructs mapped to the STEPWISE programme components
(continued )
Behaviour change
techniques
Behaviour change theory:
construct Demonstrated in the programme
3. Social support
3.1 Social support
(unspecified)
CSM: coping procedures (approach) l Telephone calls to provide direct support
l Promote the person to work out where they can
get support (query if coded here)
4. Shaping knowledge
4.1 Instruction on how
to perform the
behaviour
SET: VE (symbolic modelling)
SET: VP (suggestion)
l Pedometer use (from session 2 onwards)
l Provide recipes in handbook: for booster session 1
4.2 Information about
antecedents
SET: EME (performance exposure)
SET: VE (live and symbolic
modelling)
CSM: emotion (food diary)
CSM: emotion (high risk)
RP: self-monitoring
l Food diary (from session 2 onwards)
l High-risk situations in booster sessions 1–4
4.4 Behavioural
experiments
SET: EME (self-instructed
performance)
SET: OE
SET: VE (live and symbolic
modelling)
CSM: appraisal
l Explore how people have tested new behaviours
l Sharing stories (sessions 2–4, booster sessions 1–3);
new behaviours explored through programmes –
snacks (topic 2, session 4), drinks (topic 1b, session 1),
eating out (topic 4a, session 4)
5. Natural consequences
5.1 Information about
health consequences
SET: VE (symbolic modelling)
SET: PAS (symbolic exposure)
SET: OE
CSM: illness representations
RP: education about effects of
substance
l Your story: consequences of weight gain elicited
(session 1)
l Physical activity: benefits elicited (session 2)
l Sedentary behaviour: benefits (session 3)
l Booster session 2: physical activity
5.6 Information about
emotional consequences
SET: VE (symbolic modelling)
SET: VP (suggestion)
SET: PAS (attribution, symbolic
exposure)
SET: OE
CSM: ER
l Benefits of increased physical activity and
decreased sedentary behaviour (sessions 2 and 3
and booster session 2)
l Improved mood
l Gains: elicited in ‘next steps’ (sessions 1–4 and
booster sessions 1–3). Query if coded
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TABLE 32 Behaviour change techniques/theoretical constructs mapped to the STEPWISE programme components
(continued )
Behaviour change
techniques
Behaviour change theory:
construct Demonstrated in the programme
6. Comparison of behaviour
6.2 Social comparison SET: VE (live and symbolic
modelling)
SET: OE
l Sharing stories: various comparisons with others in
the group (sessions 2–4, booster sessions 1–3)
l Next steps: others’ plans (all sessions)
l In other sessions [e.g. drinks/snacks/physical
activity (topic 1b, 2a and 2b, sessions 1–2)]
7. Associations
7.1 Prompts CSM: coping procedure (approach)
RP: coping
l Mindfulness stickers (booster sessions 3)
l Food diaries (session 2)
7.4 Remove access to
the reward
SET: VE (live and symbolic
modelling)
VP (self-instruction)
RP: reminder – what to do if you slip
l Keeping it going: strategies on avoiding high-risk
situations (booster sessions 1–3)
8. Repetition and substitution
8.2 Behavioural
substitution
SET: VP (suggestion; self-instruction)
CSM: coping procedure (approach)
Prompt group to come up with these throughout
programme:
l snacks (session 2)
l drinks (session 1)
l sedentary behaviour (session 3)
l mindfulness (booster session 3)
l eating out (session 4)
8.4 Habit reversal SET: VP (suggestion; self-instruction)
CSM: coping procedure (approach)
Elicit from group/person alternatives to behaviours:
snack, drinks, physical activity, sedentary behaviour
(sessions 1, 2 and 3)
8.6 Generalisation of
target behaviour
SET: EME
CSM: coping procedure (approach)
Mindfulness – advised to put the magnet on the fridge
Looking at menus (session 3 or 4)
8.7 Graded tasks SET: EME (performance exposure)
SET: VP (suggestion; self-instruction)
l 100-calorie game (session 3)
l Physical activity: increasing steps/intensity/
frequency (session 2)
TheraBand (TheraBand® resistance band; TheraBand,
Akron, OH, USA): physical activity revisited (booster
session 2)
9. Comparison of outcomes
9.1 Credible source SET: VP (suggestion) l National guidelines: physical activity sessions
(session 2, booster sessions 2); sedentary
behaviour (session 3); plate model (session 3)
l Health-care professionals
10. Reward and threat
10.7 Self-incentive SET: INCENTIVE
CSM: coping procedure (approach
coping)
l Session 4: making a plan
l All booster sessions
10.9 Self-reward SET: VP (suggestion; self-instruction)
CSM: coping procedure (approach
coping)
Encourage self-praise in the ‘sharing stories’ section
continued
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TABLE 32 Behaviour change techniques/theoretical constructs mapped to the STEPWISE programme components
(continued )
Behaviour change
techniques
Behaviour change theory:
construct Demonstrated in the programme
11. Regulation
11.2 Reduce negative
emotions
SET: VE (live and symbolling
modelling)
EA: (attribution; symbolic exposure;
symbolic desensitisation)
CSM: ER
CSM: coping procedure (approach
coping)
RP: stress management
l Sharing stories: strategies elicited (sessions 2–4,
booster sessions 1–3)
l Challenges and what might help (all sessions)
l Flip charts: medication and your weight (topic 1a,
session 1)
12. Antecedents
12.1 Restructuring
physical environment
RP: skills training Keeping it going (booster sessions 1–3)/sharing stories –
high-risk situations – strategies to manage (not having
a big bag of crisps – not buying things in the first place)
Magnet on the fridge
12.2 Restructuring social
environment
RP: skills training Keeping it going (booster sessions 1–3)
12.3 Avoidance/reducing
exposure to cues for
behaviour
SET: VP (self-instruction)
Relapse prevention model
RP: skills training
Keeping it going (booster sessions 1–3)
12.4 Distraction SET: VP (self-instruction; suggestion)
RP
Keeping it going (booster sessions 1–3); sharing stories
(sessions 1–4; all booster sessions)
13. Identity
13.2 Framing/reframing CSM: IR
RP: cognitive restructuring
Keeping it going (booster sessions 1–3)
14. Self-belief
14.1 Verbal persuasion
about capacity
SET: VP (suggestion; self-instruction)
RP: cognitive restructuring
Elicit (not tell) how they might challenge self-doubts
l Sharing stories (sessions 2–4, booster sessions 1–3)
l Next steps (sessions 1–4, booster sessions 1–3)
l Keeping it going (booster sessions 1–3)
14.3 Focus on past
success
SET: EME
CSM: appraisal
RP: behaviour assessment
l Sharing stories: elicit past successes (sessions 2–4,
booster sessions 1–3)
l Next steps (sessions 1–4)
CSM, common-sense model; EA, emotional arousal; EME, enactive mastery experience; ER, emotional representations; IR, illness
representations; OE, outcome expectancy; PAS, physical and affective states; RP, relapse prevention model; SET, self-efficacy
theory; VE, vicarious experience; VP, verbal persuasion.
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Sources of self-efficacy
Performance
accomplishments
Vicarious experience
Verbal persuasion
Emotional arousal
Self-efficacy theory
Person
Efficacy
expectations
Behaviour
Outcome
Outcome
expectations
Modes of induction with BCTs
Participant modelling
Performance desensitisation
Performance exposure
Symbolic desensitisation
Symbolic exposure
Self-instructed performance
Live modelling
Symbolic modelling
Symbolic modelling
Self-instruction
Self-instruction
• 15.3 Focus on past success
• 15.3 Focus on past success
• 1.5 Review behaviour goals  • 5.6 Information about
emotional consequence  • 11.2 Reduce negative emotion
• 1.5 Review behaviour goals  • 5.1 Information about
health consequence  • 5.6 Information about emotional 
consequences  • 11.2 Reduce negative emotion
• 1.1 Goal-setting behaviour  • 1.2 Problem-solving
 • 1.4 Action-planning  • 1.5 Review behaviour goals
• 4.2 Information about antecedents
• 4.4 Behavioural experiments  • 6.2 Social
comparison  • 7.4 Remove access to the reward
• 1.1 Goal-setting behaviour  • 1.2 Problem-solving
 • 1.4 Action-planning  • 1.5 Review behaviour goals
• 4.1 Instruction on how to perform the behaviour
• 4.2 Information about antecedents
• 4.4 Behavioural experiments  • 5.1 Information
about health consequences  • 5.6 Information 
about emotional consequences  • 6.2 Social 
comparison • 7.4 Remove access to the reward
• 1.1 Goal-setting behaviour  • 1.2 Problem-solving
 • 1.4 Action-planning  • 1.5 Review behaviour goals
• 4.1 Instruction on how to perform the behaviour
• 5.6 Information about emotional consequences  
• 8.2 Behavioural substitution  • 8.4 Habit reversal
• 8.7 Graded tasks  • 9.1 Credible source
• 10.7 Self-incentive  • 10.9 Self-reward
• 11.2 Reduce negative amotion  • 12.4 Distraction
• 15.1 Verbal persuasion about capacity
• 1.1 Goal-setting behaviour  • 1.2 Problem-solving
 • 1.4 Action-planning  • 1.5 Review behaviour goals
• 2.3 Self-monitoring of behaviour  • 2.4 Self-monitoring
of outcomes of behaviour  • 7.4 Remove access to
the reward • 8.2 Behavioural substitution  • 8.4 Habit
reversal • 8.7 Graded tasks  • 10.7 Self-incentive
• 10.9 Self-reward • 11.2 Reduce negative emotion
• 12.3 Avoidance/reducing exposure to cues 
for behaviour • 12.4 Distraction
• 15.1 Verbal persuasion about capacity
• 2.3 Self-monitoring of behaviour
• 2.4 Self-monitoring of outcomes of behaviour
• 4.2 Information about antecedents
• 8.7 Graded tasks • 15.3 Focus on past success
• 2.3 Self-monitoring of behaviour 
• 2.4 Self-monitoring of outcomes of behaviour
• 4.4 Behavioural experiments
• 15.3 Focus on past success
• 11.2 Reduce negative emotion
• 1.1 Goal-setting  
• 4.4 Behavioural experiments
• 5.1 Information about
   health consequences  
• 5.6 Information about 
   emotional consequences 
• 6.2 Social comparison
FIGURE 20 Use of self-efficacy theory in the STEPWISE intervention. BCT, behaviour-change theories.
DOI: 10.3310/hta22650 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 65
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Holt et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
When we mapped participant views on the intervention to behaviour change wheel intervention functions
(Table 33), we found that the majority focused on education, enablement (concordant with the developers’
views) and environmental restructuring (reflecting the fact that the topic guide asked about the support tools).
A minority of participants (n = 8) talked about STEPWISE in terms of persuasion, but four of these were from
the subset of people who experienced clinically important weight loss (n = 7).
When we mapped participant views on the intervention to behaviour change technique categories (Table 34),
we found that the majority of interviews could be coded to feedback and monitoring, social support, shaping
knowledge and antecedents (again, reflecting the salience of the support tools). The only participants for whom
behaviour change techniques in the ‘identity’ category were salient were again from the subset of people who
experienced clinically important weight loss (n = 3/7).
Participant acceptability
Affective attitude
The majority of participants felt that the intervention was acceptable, mentioning that lunch, support tools
(e.g. weighing scales) and being in a group were helpful.
Interpretation
Representation of
health threat
Emotional response
Coping procedures
Appraisal
• 5.1 Information about
   health consequences
• 13.2 Framing/reframing
• 4.2 Information about
   antecedents
• 5.6 Information about
   emotional consequences
• 11.2 Reduce negative
   emotion
• 1.1 Goal-setting
   behaviour
• 1.2 Problem-solving
• 1.4 Action-planning
• 2.3 Self-monitoring of
   behaviour
• 2.4 Self-monitoring of
   outcomes of behaviour
• 3.1 Social support
   (unspecified)
• 7.1 Prompts
• 8.2 Behavioural
   substitution
• 8.4 Habit reversal
• 8.6 Generalisation of
   target behaviour
• 10.9 Self-reward
• 11.2 Reduce negative
   emotion
• 1.5 Review behaviour
   goals
• 2.3 Self-monitoring of
   behaviour
• 2.4 Self-monitoring of
   outcomes of behaviour
• 4.4 Behavioural
   experiments
• 15.3 Focus on past
   success
FIGURE 21 Use of the common-sense model in the STEPWISE intervention.
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High-risk situation No coping response Lapse
Reminder card
Abstinance
violation effect
Cognitive
restructuring
Decreased self-efficacy
positive outcome
expectancies
Education about effects
• 7.1 Prompts
• 7.4 Remove access to
   the reward
• Cognitive dissonance
• Internal attributions
• 13.2 Framing/
   reframing
• 15.1 Verbal
   persuasion about
   capacity
• 5.1 Information about
   health consequences
• 1.1 Goal-setting
   behaviour
• 1.2 Problem-solving
• 1.4 Action-planning
• 1.5 Review behaviour
   goals
• 12.1 Restructuring
   physical environment
• 12.2 Restructuring
   social environment
• 12.3 Avoidance/reducing
   exposure to cues for
   behaviour
• 11.2 Reduce
   negative emotions
• 2.3 Self-monitoring of behaviour
• 4.2 Information about antecedents
• 15.3 Behaviour assessment
Skills training
Stress management
Self-monitoring
behaviour assessment
FIGURE 22 Use of the relapse prevention model in the STEPWISE intervention.
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TABLE 33 Intervention functions discussed by interviewed participants
Study
identifier
Function
Education Enablement
Environmental
restructuring Incentivisation Modelling Persuasion Training
Intervention developers
D01 • • ? ? • ? •
D02 • • – – • ? •
D03 • • • ? • ? •
D04 • • ? • • • •
D05 • • • • • • •
D06 • • – • • • •
D07 • • ? ? • ? •
Participants
Clinically important weight loss over 12 months
S03/Q06 • • – – – • •
S01/Q01 • • • – • • •
S08/Q05 • • • – • • –
S04/Q02 • • – – – – –
S06/Q01 – • • – – – •
S01/Q05 • • • – • – •
S02/Q04 • • • – • • •
Weight loss that is not clinically important
S10/Q03 • • • – • – •
S04/Q09 • • – – – – –
S09/Q04 • • • – – – –
S09/Q02 • • • – • – –
S08/Q06 • • • – – • •
S01/Q04 • • • – • – •
Weight gain that is not clinically important
S05/Q03 • • • – • • –
S06/Q02 • • – – • – –
S03/Q01 • • • – – – •
S04/Q10 • – – – – – •
S08/Q09 • • • • – – •
S09/Q01 – • • – • – –
Clinically important weight gain
S04/Q12 • • – – • • –
S07/Q06 • • • – – – –
S04/Q08 • • – – – – –
Qualitative participants without weight data
S04/Q06 • • – – • • –
S06/Q06 • • – – • – •
•, Present; –, absent; ?, uncertain.
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TABLE 34 Behaviour change theory categories discussed by interviewed participants
Study
identifier
Category
01.
Goals and
planning
02.
Feedback
and
monitoring
03.
Social
support
04.
Shaping
knowledge
05. Natural
consequences
06.
Comparison
of behaviour
07.
Associations
08.
Repetition
and
substitution
09.
Comparison
of outcomes
10.
Reward
and threat
11.
Regulation
12.
Antecedents
13.
Identity
14.0
Scheduled
consequences
15.0
Self-belief
16.
Covert
learning
Clinically important weight loss over 12 months
S03/Q06 • • • • – – – – – – – • • – – –
S01/Q01 • – • • – • • • – – – • • – – –
S08/Q05 • • • • • • • – – – – • • – – –
S04/Q02 – – • • – – – – – – – – – – – –
S06/Q01 – • • – – – – • – – – • – – – –
S01/Q05 • • • • • • – • – – – • – – – –
S02/Q04 • • • • – • – – – – – • – – – –
Weight loss that is not clinically important
S10/Q03 – • • – • • – • – – – • – – – –
S04/Q09 – • • – – – – – – – – – – – – –
S09/Q04 – • – • • – • • – – – • – – – –
S09/Q02 – • • • • • – • – – – • – – – –
S08/Q06 – • – • • – – • – – – • – – – –
S01/Q04 • • – • • – – • – – – • – – – –
Weight gain that is not clinically important
S05/Q03 • – • – • • – – – – – • – – – –
S06/Q02 • • • • • • – – – – – • – – – –
S03/Q01 – • – • • – – • – – – • – – – –
S04/Q10 – – – • • – – – – – – – – – – –
S08/Q09 – • • • • – – • – – – • – – – –
S09/Q01 – • – – – • – – – – – • – – – –
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TABLE 34 Behaviour change theory categories discussed by interviewed participants (continued )
Study
identifier
Category
01.
Goals and
planning
02.
Feedback
and
monitoring
03.
Social
support
04.
Shaping
knowledge
05. Natural
consequences
06.
Comparison
of behaviour
07.
Associations
08.
Repetition
and
substitution
09.
Comparison
of outcomes
10.
Reward
and threat
11.
Regulation
12.
Antecedents
13.
Identity
14.0
Scheduled
consequences
15.0
Self-belief
16.
Covert
learning
Clinically-important weight gain
S04/Q12 • • • – • – • – – – – • – – – –
S07/Q06 – • – • • – – • – – – • – – – –
S04/Q08 – • • – – – – – – – – – – – – –
Qualitative participants without weight data
S04/Q06 • • • – • • – – – – – • – – – –
S06/Q06 • • • • • – • • – – – • – – – –
•, Present; –, absent.
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Intervention coherence
Participants described the facilitators as welcoming, realistic and flexible and that they appeared to
be confident. Some participants said that the facilitators helped their understanding and made the
intervention more accessible:
Well it’s very friendly and informal, um and you could ask questions at any time. Um, I’ve tried to go
to Weight Watchers . . . in the past, and it is quite awkward to sort of stop and say hang on a minute,
what, ‘what did you mean about that’ . . . STEPWISE was really easy to understand and was put in a
way that you could sort of take away with you sort of thing.
Participant S10/Q03
Burden
Participants generally felt that the length and frequency of sessions was acceptable and the intervention
did not require significant effort to take part; however, several participants wanted more sessions (8–12)
or more time within a session (≈3 hours):
Interviewer: Yeah. And what might that have erm, obviously if you’d have had the sessions for a
couple of months, what would that have . . . given you?
Participant S04/Q08: Erm a bit more of a boost, erm like because at the minute I’ve been like, when I
was going there, I was losing weight and since I’ve like not been going I’ve been like putting weight
on. And like, not been like sticking to my routine and me diet and stuff like that, so it was giving me
more confidence and more help and getting me out of me house and me flat and stuff like that so.
Erm this month’s not been going, I’ve been like comfort eating, so, it got me out more.
Yeah it’s a bit tedious . . . too much time teaching people how to cook eggs to be fair . . . Not
knocking the facilitators, they delivered it quite well but the material was patronising . . .
Participant S04/Q09
. . . the way that it was set out and done was good, you just weren’t given enough time on
certain subjects.
Participant S02/Q04
Those who travelled by taxi to and from the venue reported how this made it easy to attend sessions,
especially for those participants who travelled a long way.
Coherence
Generally, participants said that they understood the intervention and how it works:
Well I think it was useful, as I say, to reinforce what you’re doing . . . and also it was useful to have
lunch as well because . . . and it also broke the silence . . .
Participant S01/Q04
Perceived effectiveness
Most participants felt that they benefited from participating in the programme, reporting (varying degrees
of) weight loss, improved nutrition and increased exercise. Participants felt that being in a group with
those in a similar situation was particularly useful. Several participants would have liked more content
about physical activity (S04/Q12; S05/Q03):
Oh, yes, definitely, I’ve lost quite a bit of weight and I’m in much better shape. Like, I’m healthier
because it’s taught me do a bit of exercise as well, yeah. Quite helpful. I’m in much better shape
as well.
Participant S06/Q06
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I found it quite useful, there’s been some interesting thoughts as well seeing what other people
thought of the . . . what we was trying to aim for . . . like-minded and had similar views on medication
and stuff as well [as] on gaining weight.
Participant S06/Q02
Yeah . . . I think it needed more talking about the gym like. You know. Like . . . you know to lose
weight . . . and, evidence for like towards how you should go to the gym a lot more often.
Participant S04/Q12
Facilitator views of STEPWISE
Sense-making
Staff distinguished STEPWISE from other interventions (‘differentiation’) in terms of its use of the
biopsychosocial (rather than the medical) model, with an autonomy-enabling, rather than a paternalistic,
didactic, approach;122–124 its comparatively structured character (the commonest response); its content,
including attention to antipsychotic weight gain; the group and peer-support elements; a greater time
commitment; a comparatively short programme duration; its use of boosters and telephone calls; its
external management; and its internal delivery – as lifestyle interventions often involve an external referral:
They’re encouraged to do our physical checks and look after people’s physical health including their
weight but . . . it’s done more in a medicalised sort of way rather than the way the STEPWISE project
offered which is better . . . it’s looking at a much more individualised person-centred approach.
Facilitator S06/F05
We don’t sort of tell them you can’t eat this . . . It’s more . . . giving them the opportunity to do what
works for them. We are giving them the information for them to work it out for themselves.
Facilitator S04/F02
Only one facilitator, a community development worker, compared STEPWISE unfavourably with another
manualised intervention:
[The other intervention] was more thorough in that it went right to the basics starting with food groups,
etc. and then moving up, you know, into like portion sizes, about sugars . . . because there’s more time
you’ve got more to explain . . . [whereas, with STEPWISE] the background information wasn’t there.
Facilitator S03/F05
Facilitators reported understanding what the intervention required of them (‘individual specification’)
and sharing a sense of the aims of STEPWISE with other health professionals (‘communal specification’).
This understanding was not immediately or always grasped by participants, either because of learning
difficulties, cognitive deficit or an expectation of something more didactic involving closer monitoring:
And their functioning is quite different, you know, there’s really quite a high-level functioning lady
there who sort of understood the thing straight away, and another guy . . . it’s very difficult to find
out what his understanding actually is. Because he tends to talk in slightly psychotic terms.
Facilitator S05/F02
We do repeat, you know . . . it’s a lifestyle choice . . . we’re not saying that you’ve got to ban all bad
food . . . they think they’re going to go there, get weighed, and they’ll go on a diet, we’re going to
give them a diet sheet. And for some people that would work, and for other people empowering
them works . . . sometimes the like peer pressure and going to Weight Watchers and knowing that
you know there’s some expectation you’ve lost some weight, because it’s been marked down, that
works very well for some people but not others.
Facilitator S01/F02
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Although most facilitators constructed potential value for STEPWISE (‘internalisation’), this was conditional
on the trial demonstrating an important difference in participant weight compared with usual care.
Anticipated benefits, apart from lifestyle changes and broadly defined well-being, included:
l the opportunity for often isolated individuals to interact, receive peer support, improve their social skills
and grow new interests
l an improved understanding of the participant’s own situation through modelling (intervention function)
and self-esteem
l better adherence to antipsychotics in the face of weight gain
l mental health improvements brought on by improvements in physical health
l improving the skillset, confidence and attitude toward physical health of health professionals
l meeting local or national quality improvement targets and
l downstream participant and health-system gains in terms of diabetes mellitus prevention.
Most facilitators agreed that STEPWISE fitted well with the goals of their organisation, although in some
trusts they had faced apathy toward referral and scepticism that the intervention would be sustained
beyond the end of the study:
I think it’s for the whole NHS really, because we are spending a lot of money on things like diabetes
. . . it’s a good opportunity for service users to come together . . . they talk to each other and they
share their own views, how they lost the weight, and again like engagement for them to get the
social skills . . . when people are quite lonely they can’t talk to anybody . . . you can go there you can
sit down, you can do a little bit of parkrun [parkrun Ltd, Twickenham UK] in the local park and you
can talk to each other. So, it does benefit, it does benefit to the physically, mentally and socially.
Facilitator S03/F04
Quite a few service users get put off continuing to take their medication because of the side effects
and this gives them a way to control it so it is not only kind of benefiting their physical health but it
will benefit their mental health as well if it’s helping them to stay on the medication.
Facilitator S06/F01
Relational work
The key individuals who drove the intervention forward (‘initiation’) were different between organisations.
Although many facilitators discussed having supportive clinical management, they frequently commented
that the trust research departments, rather than clinical managers, were the drivers of implementation. In
most trusts, the facilitators presented themselves as ultimately responsible for making STEPWISE happen
and one developer flagged the general absence of effective change agents – individuals who influence
innovation decisions:125
I know that people who are key in those sites are people who take part in [research project] meetings
. . . they probably do not really see it as their job . . . to be that link with people on the ground . . .
you do need senior people, very senior people in the trust to be supportive and to want something to
happen . . . at [trust name] . . . the people who sat round that table were on board but practically
speaking they were all a bit you know disconnected . . . you have got to have buy-in but you have got
to have communication between all levels.
Developer 03
The facilitators all believed that it was right to deliver a structured lifestyle programme (‘legitimation’),
reporting that they and most of their colleagues considered that it should be part of their work. One
facilitator commented that this was now externally reinforced by the Commissioning for Quality and
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Innovation (CQUIN) payments framework, which was incentivising the promotion of physical health in
mental health trusts during the study:
There is nobody who doesn’t perceive it as actually a very useful intervention and a useful way
of working.
Facilitator S05/F02
Completely compatible really . . . it’s very valid . . . It’s not reinventing the wheel it’s just putting things
in place that you need to know to make changes.
Facilitator S02/F03
I think that’s [STEPWISE is] definitely something that we haven’t been doing. And I think it’s
something that we should be doing.
Facilitator S02/F06
By and large, motivated trust employees put themselves forward for intervention training and delivery
(‘enrolment’), seeing it as a development opportunity as well as being good for patients; there were some
instances in which this was not the case, although the first quotation here is comparably extreme:
I felt that a colleague was being slightly, mildly bullied into it . . . I had quite a threatening e-mail
[after resigning] saying how . . . I was letting down the trust.
Facilitator S05/F02
There were some people who were ‘volunteered’ and . . . who were less positive but my general
feeling when we did the training was that most people had seen STEPWISE and thought ‘oh,
this looks really interesting, this would be nice thing to do, it fits’, you know, ‘I’m interested in
health promotion’.
Developer 03
At some trusts, participants were easily engaged; at others, clinical ‘gatekeepers’ and patients presented
barriers to filling STEPWISE course places. Although the current research context may have aggravated
gatekeeping, health professionals in other settings employ tacit and ‘informal criteria when selecting
individuals’ for routine clinical services.126 Such gatekeeping was also reported to service user co-authors
David Shiers and Angela Etherington, in their previous roles as project team members on the National
Audit of Schizophrenia:127
We’ve got more people wanting to do it than we are able to put into our group.
Facilitator S08/F03
A lot of clinicians have said their clients don’t like group work or they don’t like to leave their home
and they’ve put a lot of barriers in the way of people engaging . . . service users . . . the people who
do want to take part are really positive about it . . . it’s something that they’ve been looking for . . .
though you do also get some people who say . . . they wouldn’t want to talk about it in front of a
group of other people, or . . . they don’t have the time to kind of stick to it . . . they’ve already
engaged in other activities [gym or nutritionist] . . . the clinician has referred them because they know
they’re overweight, but actually they don’t have concerns themselves . . . a lot of people live quite far
away and that’s what puts them off.
Facilitator S06/F01
Service users are slightly put off by the thought of engaging in a research project, but I think that
there would be a lot more individuals who’d be interested in engaging in STEPWISE if it wasn’t part of
research, if it was just something that we’d rolled out.
Facilitator S09/F03
RESULTS OF THE PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
Although many facilitators continued to support STEPWISE (‘activation’), developers noted that there were
high levels of facilitator attrition (Figure 23) compared with other interventions on the LDC portfolio. Although
most of the facilitators had group facilitation experience and relevant experience of the clinical population,
there were still concerns among the developers that staff selection was not always well considered:
There’s no point in training 10 facilitators if they only get to deliver one session . . . obviously at any
one time you’ve only got a certain number of people with capacity and they may not be the right
people and, obviously, there were some people who trained and then they went on and got other
jobs . . . there was an awful lot of attrition in facilitators. I would have expected quite a bit anyway
perhaps not quite as much as we had.
Developer 02
Facilitators saw the availability of transport costs as critical to maintaining participant engagement during
the initial four sessions (see Table 7). Thereafter, there were problems with keeping participants involved
during the follow-up telephone calls (see Table 9), because of participants’ social commitments and staff
annual or sick leave:
A lot of times you speak to people about attending the sessions, they say ‘well, where’s it going to
be? And, how am I gonna get there?’. So I think that’s been a really good way of keeping people
attending the groups, knowing that they can get a taxi and not have to worry about going and
getting a bus . . .
Facilitator S06/01
It tends to seem to have worked better . . . where they had one person that kind of took ownership of
doing all of the calls . . . in most areas it tends to be either one of the facilitators . . . then takes them
through their calls and things.
Developer D05
No one picks up, you know. And it’s how many times really do you try and get through to someone.
Erm, but I’ve always left messages, erm. But I’ve tried to contact them if I haven’t got through. But it’s
usually about half, we’ve managed to actually contact.
Facilitator S02/F06
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FIGURE 23 Time to facilitator attrition from foundation training (weeks).
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It’s been quite mixed . . . some of the . . . service users that you’d speak to I think find it really useful
. . . to actually reflect back on how the last few weeks have been for them . . . Whereas a couple of
people it almost feels like you’re pestering them a little bit and they do not have so much of an
interest in talking about their diet and exercise levels and it’s quite a short conversation that they just
say yes everything’s fine, no I do not need support with anything else. So it is quite mixed in the
response that you get from people.
Facilitator S06/F01
Operational work
Facilitators could perform the tasks required by the intervention (‘interactional workability’). They were
universally complimentary about the training and printed materials they received, although:
It was a lot to take in just those 3 days initially . . . quite intense.
Facilitator S08/03
Facilitators described how they translated or adapted instructions from the manual to support participants
to perform particular tasks. Although most found that delivering their first sessions was tricky, they
reported becoming happier with group facilitation over time. Some reflected on the challenges of an
autonomy-enabled, rather than a paternalistic, communication style, all believing that they were adapting
well to this requirement. However, many facilitators complained about the logistical burden of programme
management, in particular the purchase, transport, setting up, taking down and storage of materials,
including sandwiches, other foodstuffs and flip charts. Intervention delivery and broader programme/case
management could be made more difficult by sick leave or staff attrition. The workability of materials was
problematic. For instance, one exercise involved showing pictures of foodstuffs to participants and asking
them to discuss how many calories they contained; however, it did not say in the materials and facilitators
who were not themselves dietitians did not know the right answer:
Had it not been for her [the administrator] . . . I don’t think half of the time I would have turned
up with the right stuff. And it would have took me a full day. It’s only because she had everything
organised . . . on a Wednesday morning she was getting me the stuff together. Erm, now some of the
stuff was out of date. That meant that we then had to go to the shops and go and buy replacements,
which we’re still waiting for the money, we paid for it out of our own pockets. And er I know £10,
£13, doesn’t seem like a lot but erm when you’re waiting 4 months for it . . .
Facilitator S01/F02
Facilitators sometimes alluded to the repetitive nature of aspects of the intervention causing problems with
some participants. They mentioned the problems of dealing with a client group in whom concentration
could be poor. Sometimes, one facilitator had to break off discreetly to support participants who were
struggling because of learning difficulties or symptoms. Small groups (≈4 participants) seemed to allow
enough time for the delivery of course content and for participants to come up with their own solutions,
whereas larger groups often felt rushed. One facilitator found that supporting participants to complete the
action-planning task was the most difficult part, but that retaining flip chart notes from across the sessions
helped to prompt and persuade participants to engage with the task. The timing of content delivery during
the sessions, and completing within the allotted time, was a source of anxiety for facilitators – given the
need for a smooth conclusion by the time taxis arrived:
It was a booster session I did recently, and erm this client said, halfway through she like put her hands,
er her head on table, and she said ‘I’m going to have to go . . . I’ve lost the will, you know. Because
everything’s been said over and over’ she said, ‘and I’ve just had enough.’ And I thought ‘well that’s
how I were feeling actually’.
Facilitator S01/F02
RESULTS OF THE PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
102
In general, facilitators maintained trust in each other’s work and expertise during the delivery of STEPWISE
(‘relational integration’). In particular, they described being reliant on each other to share the logistical
burden and provide cover when things went wrong in session delivery. They felt that a wide range of
other people would need to be involved in one way or another, aside from the facilitators and the senior
management, to ensure the smooth running of STEPWISE:
GPs . . . community teams . . . nurses, social workers . . . care co-ordinators, medics involved in the
community mental health teams, so they can, you know, have an overview of you know the blood
results . . . and signpost people that might be having any issues with physical health . . . someone to
arrange taxis . . . an admin person . . . people’s carers or support network . . .
Facilitator S01/F04
Two types of comments indicated that some facilitators felt that others might not be qualified to deliver
the intervention; some felt that more specialist nutritional training should be required and one felt that
overweight facilitators should not be delivering the course, although other facilitators had talked about
being overweight themselves:
I’d say it’s the people who haven’t got the nutrition background that I worry about, not necessarily the
. . . or not feeling competent, or not knowing that they’re not competent.
Facilitator S02/F06
[Facilitators] are like a role model, you know what I mean? . . . if I am overweight . . . they will think,
oh my goodness, he or she is overweight and they are talking to me about this programme like to lose
the weight, and he hasn’t or she has not lost any weight at all.
Facilitator S03/F04
Otherwise, facilitators agreed that the work of delivering STEPWISE was appropriately allocated
(‘skill set compatibility’).
Every facilitator mentioned resource scarcity, with even paper and whiteboards at a premium. The venues
provided for sessions were generally adequate, but the storage of materials was often a problem. Programme
or case management and tasks, including preparation/documentation of sessions and writing up telephone
support logs, were very time-consuming and added pressure to the facilitator’s job: facilitators at almost every
trust said that the time required had been radically underestimated in what was allocated to them. More
than one facilitator had to stop delivering STEPWISE because its delivery was affecting their clinical work and
some commented that the intervention was fragile in the face of clinical emergencies and staff sickness,
maternity leave and turnover.
Some facilitators implied that the intervention was not adequately supported by the host NHS trusts
(‘contextual integration’); although the senior management supported the principle of addressing physical
health, the resources were not forthcoming. Backfilling clinical time involved was sometimes a matter of
immediate staff availability rather than financial constraints or management motivation. Facilitators at several
trusts, said that, with inadequate backfill, clinical colleagues had missed their presence. Things were reported
to be working better in trusts, which had clear and meaningful buy-in from the senior management and
when CQUIN incentivised the delivery of something like STEPWISE (see Relational work):
[My time] didn’t get backfilled . . . I did actually get some . . . negativity . . . from some of my colleagues.
Because, well, to quote one person, I was taking the piss because . . . I’d put a lot of this time, blanked
it out in my diary . . . [STEPWISE has been] ignored since we’ve done the training . . . I think the system
has . . . failed the programme a little bit . . . if it’s going to be successful then we’ve got to have
resources for it.
Facilitator S01/F02
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It’s just a case of senior management being completely blind . . . anything above team leader level . . .
They all go, ‘yes it’s lovely’, but then . . . do not then provide us with the resources to be able to do it
. . . there isn’t a system to allow members of staff to do something like this . . . They say there is, but
there isn’t . . . if there is a system it is flawed and broken.
Facilitator S05/F02
It’s a big piece of work when you’re full-time somewhere else, and they would say well we’ve got
money to backfill but there’s no staff to backfill.
S09/F03
Within this particular trust, one of the deputy directors had been involved right from the start and he
was very keen for it to happen so it’s been sort of disseminated downwards from there . . .
Facilitator S03/F05
Appraisal work
The extent to which facilitators accessed information about the effects of the intervention (‘systematisation’)
was limited. None was routinely accessing information on participant weight and this would have been
possible only at a minority of trusts where weighing was routine and performed at regular intervals.
Instead, most facilitators reported participant anecdotes involving the adoption of desirable behaviours by
participants and (in terms of cooking) their carers:
No one seems to be taking weight! [laughs] We’re just getting, I’m not gathering data on individual
clients . . . we do not even have an ongoing way of monitoring weight now. I think the trust would
like it, but we keep telling them there is no way of actually monitoring people’s physical health on the
system that we have got . . . you have to go through a hundred different things and write them all
down separately, and then you can draw a graph . . . I think the trust is willing, and would like it,
but they just do not know, they are just not willing to put the money and the investment into the IT
[information technology] things.
Facilitator S05/F02
I am not sure whether when they leave our session whether they follow the advice . . . [one] service
user has been telling to her mother not to add too much oil to curry and things like that . . . so there
has been some insight there.
Facilitator S03/F04
I had one person that said ‘I was eating takeaways nearly every single night and I’ve stopped doing
that now’.
Facilitator 03/F05
Few facilitators reported having the opportunity to assess the worth of the intervention together
(‘communal appraisal’); however, when this did happen, the conclusion was usually positive:
The facilitators we’d spoke between ourselves, but there wasn’t anywhere where you could go really
and feed back to someone.
Facilitator S01/F02
I did a talk at a . . . bite-sized physical health training game . . . about STEPWISE and it was a very
positive response, and generated a lot of referrals for the group.
Facilitator S06/F04
Well I’ve actually had people come up who’ve heard about it. Who were talking to people that go to
the clubs or clinics. And they’ve spoken to some people who have attended it and they are keen to
know whether there are going to be other groups and things.
Facilitator S08/F03
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Although they stressed that their final appraisal was contingent on the outcome of the RCT, facilitators
individually assessed the intervention as worthwhile (‘individual appraisal’), with only two exceptions.
The benefits for participants were expressed as:
l having the opportunity to think through their lifestyle
l having the opportunity to meet other people and openly discuss antipsychotic-related weight gain
l maintaining self-esteem in the face of weight gain.
Some facilitators thought that these benefits would have positive effects on mental health. The benefits for
professionals included:
l raising the profile of physical health and the poverty of current services
l new communication skills or knowledge they had learned that had applicability beyond STEPWISE,
which, in turn would make them more confident in giving lifestyle advice.
Criticisms of STEPWISE included that elements were repetitive or patronising, that it lacked incentives for
behaviour change, that it was not underpinned by adequate dietary or nutritional knowledge and that
behaviour change momentum would not continue without group support:
One of the patients was saying, it’s all good when we’re doing it together, but I live alone and I find it
difficult to cook just for myself. It would be good if we could you know once in a while meet again
and you know, make a meal for, for each other, altogether sort of thing. So yeah, er, the philosophy is
good, it’s whether people will be consistent and continue it afterwards . . .
Facilitator S07/F05
Many participants said that they would be modifying their work in response to their appraisal of STEPWISE.
In particular, they valued the client-centred, autonomy-enabled communication style, which they had
learned in training, and some planned to use that style and to insert more structure into other clinical
encounters as a result of their experience. Some identified other populations, not targeted by the RCT –
such as people with borderline personality disorder – who could benefit from a STEPWISE programme. On
the other hand, some facilitators thought that, if STEPWISE was sustained, it would have to be modified,
in particular to take account of its current resource intensity, with materials and lunches in particular jeopardy:
It’s actually made me think a little bit more about you know the style that I deliver my groups in for
other service users.
Facilitator S02/F03
I know a number of people that would really benefit from STEPWISE but they can’t take part because
. . . they don’t meet the criteria.
Facilitator S09/F03
If it works, I wouldn’t imagine that we’re going to be running these sessions, it’s going to become
part of like the working practice for everybody. We won’t be giving out free gifts and you know
weight scales and books and everything else. It will just be the programme as it is, as an ongoing
thing. You know part of people’s care plan.
Facilitator S01/F02
Obviously it’s potentially quite expensive to run, that’s the only thing, because the lunches and
support tools, so all those things would need to be considered, uhm . . . whether there were potential
long-term benefits because cost is a huge implication for the trust.
Facilitator S08/F05
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Summary
The findings are summarised in Figure 24. STEPWISE made sense to those who delivered it. They understood
its objectives and believed that it could be worthwhile. At most trusts, change agents in senior management
did not drive the intervention forward and, although facilitators felt that the intervention was the right thing
to do and they became involved, competing clinical caseload demands and other factors resulted in high
staff attrition. Facilitators understood how to deliver the intervention, gaining confidence with practice,
maintaining trust in each other and drawing on their expertise. However, programme management was
under-resourced and facilitators doubted the long-term commitment of senior management to what they
perceived as a resource-intensive intervention. In no trust were facilitators accessing data on weight to
understand the effects of STEPWISE; instead, they relied on ad hoc participant self-reported accounts of the
enactment of cognitive and behavioural skills. Facilitators rarely collectively appraised STEPWISE; individual
appraisals were generally positive. Many reported modifying their own practice based on STEPWISE training
and thought that STEPWISE was applicable to other mental health populations, with some anticipating
modifying STEPWISE, because it would have to be less resource intensive to be sustainable.
Implementation process
Programme theory and logic model
The programme theory, elaborated in the logic model (see Figure 5), is described as follows. For the
STEPWISE programme to work, certain resources need to be in place, including the facilitator training and
quality assurance infrastructure and resource allocated by CMHT management for programme delivery.
This being the case, certain activities can be delivered; LDC would train and quality assure trainers, who
would, in turn, train and quality assure STEPWISE facilitators. Clinical gatekeepers would refer participants.
Facilitators and local co-ordinators would perform case management and wider programme management
functions. The immediate outcomes would be that the quality of every level of training is maintained,
STEPWISE courses are delivered and eligible patients are referred to and attend the group. Through the
participants’ receipt of the course content, the intermediate outcomes measured by the trial were
brought about.
Facilitators:
• Distinguish STEPWISE
   from other services
• Collectively agree on
   its aims and objectives
• Individually understand
   what the programme
   requires of them
• Construct potential
   value for STEPWISE
   conditional on RCT
   results
Facilitators:
• Did not generally find
   that key individuals
   drove implementation
• Bought into STEPWISE
• Enrolled themselves
   and participants
• Dropped out in large
   numbers
Facilitators:
• Translated manuals
   into action
• Occasional concern
   that some facilitators
   had insufficient
   nutritional knowledge
• Believed that they had
   the right skills to
   deliver STEPWISE
• Found that delivery
   was under-resourced
   and sometimes
   doubted management
   commitment
Facilitators:
• Could not access
   information about
   the STEPWISE
   intervention’s effects
• Did not collectively
   assess its worth
• Were mostly positive
   about its effects on
   them and their
   workplace
• Anticipated
   reconfiguring
   STEPWISE, and
   sometimes their
   practice
Sense-making Participation Action Monitoring
FIGURE 24 Summary of the qualitative findings understood through the normalisation process theory.
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Resources
Programme infrastructure/trainers/mentors/managers
During the trial, LDC staff fulfilled these roles (excepting management), as they currently do for active
services such as DESMOND and the Let’s Prevent Type 2 Diabetes programme (see Chapter 1, The Leicester
Diabetes Centre structured education approach). Interviewee D02 highlighted that, should the STEPWISE
intervention be sustained and commissioned more widely, a permanent infrastructure would be required.
At the top end would be a steering group with a national director, educationalists, consultant clinical
psychologists and quality assurance experts (n ≈ 6 in other programmes). Below the steering group would
be a training and assessing team (n ≈ 6 in other programmes). At each site, there would be a STEPWISE lead
linking with the steering group; if the lead does not have easy access to senior management, a separate
champion might be required to ensure adequate resourcing (see Facilitator views, Operational work).
Facilitator training course and venue
During interviews with LDC staff and facilitators, no systemic problems were identified with resources for
training, details of which are in Table 35. Course materials were well regarded by facilitators (see Facilitator
views, Operational work).
TABLE 35 Facilitator training dates and costs
Facilitator training/resources n Cost (£) Details
Original facilitator training 48a 4413.70 3–5 March and 10 June 2015 (Sheffield); 21–23 April and
24 June 2015 (Southampton); 28–30 April and 7 July 2015
(Exeter). Three sites trained six (rather than four) staff
Booster training day (original) 35 3151.51 Not all facilitators in the original training completed the booster
training day (dates above)
Additional (full) training 7 1932.23 Four sites identified seven staff for training: 3–5 November 2015
(Leicester)
Additional booster training 5 554.45 Cost of staff attending alternative training dates (booster session
content only). One out of five did not attend
Additional booster and support
contact
5 1250.00 Five facilitators from three sites were trained: 6 and 7 June 2016
(Sheffield)
Core teaching kit and
supporting kit
– 17,395.34
Training subtotal 28,697.23
Delivery resources n Cost (£)
Patient handbooks – 3908.32
Lunch 4410 Costs based on a price per head of £3, assuming that seven
participants attended all seven group sessions × 3 waves (n= 21
intervention participants) at each site (n= 10). Paid directly to the
University of Leicester by NHS trusts
Resources subtotal 8318.32
NHS staff costs Cost (£) Assumptions/notes
Facilitator/s time to deliver
courses
40 46,980.00 Based on 4 × 0.05 WTE Agenda for Change band 7 (point 30) for
24 months
Administrator time to support
delivery
10 173,412.00 Based on 0.1 WTE Agenda for Change band 3 (point 9) for
24 months. Activity: room bookings, pre-course material, booking
taxis, processing expense claims and collating attendance logs
Staff subtotal 220,392.00
Total 257,407.55
WTE, whole-time equivalent.
a Not all facilitators in the original training completed the booster training day.
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Health professionals motivated to become facilitators
Motivation was generally high in interviewees (see Facilitator views, Relational work) and, although facilitators
had a wide range of exposure to group facilitation (see Table 5), the LDC team felt that appropriate
individuals came forward. However, quantitative data highlighted problems with staff attrition from facilitation
(see Figure 23).
Appropriately resourced co-ordinator
Interviews with facilitators and the LDC team indicated a lack of clarity about the roles of the co-ordinator
and/or under-resourcing at some trusts:
There were sites where you had a very proactive co-ordinator . . . helping the facilitator to make sure
that everything was there and they had everything they needed on the day and the taxis were booked
and you know the logistics of running it went well . . . I got the impression in some other places that
actually that wasn’t quite the case . . . it was very much left to them [facilitators].
Developer D03
Bought-in trust chief executives and gatekeepers
Senior management buy-in was often good, but sometimes did not translate into appropriate resourcing
(see Facilitator views, Operational work). Similarly, gatekeepers referred patients well at some trusts and
less well at others (see Facilitator views, Relational work). The budget for taxis was always available and
deemed to be very necessary (Context, Activities and participation).
STEPWISE course materials
There were difficulties in arranging the storage of course materials (S01/F04). The necessary budget for
consumables [paper, Blu Tack (Bostik, Paris, France), whiteboard] required for the course was sometimes
not forthcoming (S01/F04). The necessity for facilitators to buy materials, in the absence of a properly
funded co-ordinator, was problematic (see Facilitator views, Operational work).
People with schizophrenia motivated to attend
The study screened 1223 people for eligibility, of whom 800 did not participate. A total of 406 out of the
800 people excluded actively expressed a lack of interest or declined consent.
Activities
Mentors assessing the competency of trainers
As the training in the trial was conducted by DESMOND trainers, who are themselves mentors, this activity
was not conducted.
Training of facilitators
Forty-nine facilitators were fully trained in 8 months by seven trainers, with additional booster/support
contact training provided to a further five staff (see Table 35). Training was well regarded by facilitators
(see Facilitator views, Operational work). The STEPWISE programme employed generic strategies24 to
ensure intervention fidelity through training; these included standardised training and accommodating
provider differences (see Table 6). LDC does not assess provider skill acquisition at baseline or attempt to
minimise provider skills ‘drift’;24 rather, the DESMOND programme expect, gradual skill acquisition through
ongoing observation, feedback and self-reflection – a process not simulated in the STEPWISE trial, because of
the short-term study-specific commitment to the intervention, and the burden of additional procedures:
We would never, ever say because we train people for 2 days or 3 days that that means they are
absolutely fantastic . . . it’s only the beginning of the journey . . . the process by which people get
accredited is that, within 6 months after training, people get a mentorship visit from an experienced
trainer/assessor . . . and they’ll sit and they’ll observe and they’ll use tools that are available to the
educators themselves . . . and they will give some mentorship . . . the person does an action plan . . .
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and probably within the next 6 months they’ll have an accreditation visit where they will be observed
delivering 50% of the programme . . . and, as a result of that, they’ll either be accredited or they’ll
have to do a little bit more work. Most people get accredited within 18 months if they follow
that process.
Developer D02
The LDC’s approach to minimising skills drift is to encourage facilitators:
To form a community of interest in their organisation, support each other, make links with
neighbouring organisations . . . the reason that we don’t do any more competency [assessment]
is because organisations won’t pay for it and . . . they’d never get the time released.
Developer D02
Programme management
The work taken to realise the client interactions was described universally as greater than anticipated.
Although facilitators at many trusts rose to the challenge, the experience of programme management had
distressed or overfaced some facilitators. Scheduling of courses was reported to be chaotic in some trusts,
with delays and cancellations observed and facilitators being obliged to travel long distances to deliver
courses in multisite trusts. Facilitators sometimes found it difficult to protect time to plan, to deliver the
intervention uninterrupted by client emergencies associated with their usual clinical role or to debrief (see
Facilitator views, Operational work). Under-resourcing of local co-ordinators or a lack of clarity about their
role meant that facilitators spent undue time preparing refreshments, booking taxis, transporting or storing
materials, and so on (D01):
I think they underestimated the amount of time doing these programmes . . . you have got to spend a
lot of time reading through the material . . . And because the, the groups are run off site from where
I work, I’ve got to get there, set the groups up . . . it is a big investment in time. And it does sort of
create strains a lot of days . . .
Facilitator S02/F02
But for me there was a lot of work behind the scenes . . . obviously my caseload is my paramount
priority so if there’s any kind of downtime, STEPWISE would slip into that . . . I’ve had to do some at
home . . .
Facilitator S02/F03
It’s the calls that . . . take quite a lot of time. Because not everybody picks up the phone the first time,
you need to call back . . . the groups are quite easy to, to manage, with workload, but I think the calls
are definitely more difficult to fit in.
Facilitator S02/F06
It takes planning . . . the 4 weeks [foundation course] . . . it was almost impossible. Because I was
suddenly having to put 5 days of work into 4 days of work. You know, but our caseload did not go
down, I still had the same number of ward rounds to attend, same number of clients to see each
week . . . I was told there would be backfill, I was then . . . told that the backfill would not actually
cover the hours that I was actually working it . . . there was no acknowledgement of the fact that
every e-mail takes 5, 10, 15 minutes to reply to, that there were extra meetings . . . they wanted us
to buy our own tickets for . . . 3 days travel down [to training] . . . We absolutely refused, it was a
nightmare getting those tickets . . . I cannot remember how many hours . . . I’d put into it. But it’s a
lot more than other people thought . . . I think they thought . . . that delivering the session would be
3 hours of our worktime. No! It’s a day of our work time . . . far more than just 4 hours a week.
Because . . . it was 2–3 hours of preparing each session at home.
Facilitator S05/F02
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Gatekeepers actively refer people
Gatekeepers were rarely reported to be a barrier to participant recruitment (Facilitator views, Relational work).
Health professionals encouraged involvement with STEPWISE, as they recognised that weight management
was a huge problem for the client group.
Case management
Many facilitators described having an existing psychiatric caseload ‘over multiple wards in multiple
locations’ (facilitator S02/F03). Inadequate resourcing and lack of protected time (see Facilitator views,
Operational work and Implementation process, Activities) made individual-level, STEPWISE-specific
participant interaction difficult to schedule and complete. Scheduling telephone calls could be difficult
because of staff availability and participant commitment, as could arranging cover for staff leave to avoid
missing calls that were due. Telephone calls were often described as resource intensive, owing to the
number of calls that had to be made before contact was established and, for this reason, the workload
of case management was easier in small groups. Facilitators recalled providing additional support to
cognitively challenged participants who were struggling with content in the sessions. Many also felt that
they needed to be responsive to non-weight management concerns brought up during booster sessions
and one-to-one calls, which made calls longer:
I felt it would have been better to have people . . . specifically doing that role . . . being taken away
for half a day . . . for the period for when you’re doing telephone calls . . . having a block of time not
at your own desk, at another desk ‘cause . . . if I’m on this call . . . for STEPWISE I could easily get
interrupted because . . . we respond quickly to our patients and somebody might come in and say,
‘OK I need you now!’ You know and then you’re having to stop.
Facilitator S01/F04
Patients also can be funny with a strange voice or someone they don’t know. I’ve had that problem
with follow ups. The patients wouldn’t answer, or when they heard somebody’s voice sometimes
they’d just put the phone down. And then I would then phone them . . . and then explain that my
colleague would be doing the follow up, and he is trying to get in touch. There was one participant
. . . she said yeah I haven’t been feeling well so I haven’t been answering my phone.
Facilitator S07/F05
Immediate outcomes
Eligible people invited to attend STEPWISE ‘recruitment’ and ‘reach’
Recruitment to STEPWISE was somewhat artificial, owing to the trial-specific consent and randomisation
procedures. Recruitment to the STEPWISE trial and programme was reliant, primarily, on referral from
direct care teams. A script was circulated for use by clinical team members in conversations with patients
about recruitment, in order to provide a consistent message. Site PIs talked to clinical teams about the
study and intervention around 1 month before recruitment commenced. Posters, including eligibility
criteria, along with short information leaflets co-produced with patients, were displayed by clinical teams
in reception areas. Given the engagement of gatekeepers and adequate co-ordination, it seems unlikely
that recruitment in real-world circumstances would be problematic.
Estimates on the number of potential participants varied significantly between NHS trusts, partly because
of different methods and definitions of ‘first episode psychosis’; for example, these ranged from 1233
(Sheffield; 2 June 2017), 2420 (Bradford; 28 March 2014) to 12,968 (Sussex; 11 April 2014). Target versus
actual recruitment at these sites was 40 out of 36, 50 out of 45 and 42 out of 35, respectively. Work and
family commitments affected the attendance at (or reach61 of) STEPWISE. Qualitative work identified two
participants who were unable to make certain sessions because of child care responsibilities. Care providers
rescheduled the start time of foundation sessions to accommodate participant child care responsibilities
(S04/Q06) and for when booster sessions fell on a school holiday (S04/Q02). Information from screening
logs showed that 11 people gave employment commitments as the reason for them being unable to
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participate. Many participants said that they were unable to attend, but did not provide specific reasons;
however, one interviewed participant (S06/Q01) was able to attend STEPWISE because it fell on a
non-work day.
Foundation, booster and telephone support calls: ‘dose delivered’
Foundation sessions and most booster sessions were delivered as planned. Not all sessions were delivered
by two trained facilitators, and, on one occasion, a (7-month) booster session was not delivered. Further
non-compliance was recorded as a result of only one facilitator delivering the sessions (see Chapter 4,
Course delivery and protocol non-compliance). When this occurred, most centres provided the facilitator
with an (untrained) member of staff to provide support in the sessions.
Sessions delivered in line with the STEPWISE philosophy: ‘fidelity’
When we interviewed LDC staff about their observations and read their notes, they generally indicated
that facilitators had achieved a reasonable initial level of fidelity with the STEPWISE philosophy, although
there was often room for improvement. For instance, most LDC interviewees identified that facilitators
would give their own examples of a phenomenon, rather than allowing participants to remember and
voice their own experiences. Equally, LDC staff felt that participants were sometimes not given sufficient
thinking time to answer a question, which was particularly important given the cognitive challenges some
participants face (see Body functions) and that aspects of the programme, such as action-planning, were
not given adequate time:
I think overall with the ones I observed, they did overall well with the talking time, erm but I did
observe a couple of times in terms of asking questions to the group they weren’t really giving them
time to answer back, in terms of kinda letting them think about the answers.
Developer D01
It was done in a more didactic telling way than what we’d hoped . . . there were people who went
off-piste . . . and added bits . . . there was one place where somebody . . . started doing CBT . . .
because they’d been on the [CBT] course recently . . . it took it huge amount of time and there wasn’t
enough time left for the, for the other elements.
Developer D03
The facilitators were very conscious of – and expressed mixed views on – how structured the intervention
was, with some acknowledging departures from the course:
I think the level of structure has probably been the most structured that I’ve come across [in a
manualised course].
Facilitator S08/F05
I’ll be quite honest and say we haven’t been quite so structured as the book will give it. And we sort
of twisted things slightly in the way we might use some of the supporting tools.
Facilitator S08/F03
CPNs [community psychiatric nurses] tend to work very individually . . . tend to be very autonomous
workers, and it was challenging . . . to follow specific guides and you know . . . leave gaps and things.
Facilitator S05/F02
Table 36 and Figure 25 show that the overall mean (SD) for the percentage of facilitator talk time (DOT
scores) across four sections of sessions (‘Sharing stories’, ‘Topic a’, ‘Topic b’ and ‘Next steps’) was 47.6%
(12.3%). Mean (SD) scores ranged from 36.8% (6.4%) in Devon to 63.2% (9.4%) in Cornwall. Although
the DOT scores provide indicators of the level of competence of the facilitators, precise scores that would
be considered acceptable cannot be determined by the trial, as a large sample would be needed and
linked to outcomes.
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TABLE 36 Fidelity ratings for session sections observed by centre
Centre
Group
sessions
observed (n)
‘DOT’ scored
session
sections (n)
% of facilitator talk time Facilitator
behaviour
scores, session
sections (n)
% positive (‘left’) % negative (‘right’)
Mean (SD) Median (range) Mean (SD) Median (range) Mean (SD) Median (range)
Bradford 2 8 46.6 (6.8) 45.5 (39.0–57.0) 8 46.4 (12.2) 47.1 (25.7–62.9) 26.8 (8.2) 28.6 (14.3–37.1)
Cornwall 2 8 63.2 (9.4) 63.8 (50.0–78.0) 8 31.8 (13.2) 34.3 (14.3–54.3) 38.9 (13.9) 35.7 (20.0–62.9)
Devon 2 7 36.8 (6.4) 37.0 (28.0–44.0) 7 59.6 (6.7) 57.1 (54.3–71.4) 3.7 (2.2) 2.9 (0–5.7)
Leeds and
York
6 22 50.0 (13.1) 52.5 (27.0–78.4) 24 57.5 (10.2) 57.1 (37.1–77.1) 21.0 (11.5) 20.0 (2.9–40.0)
Manchester 2 8 41.6 (8.3) 45.5 (29.0–50.0) 8 64.6 (17.7) 65.7 (42.9–85.7) 7.1 (11.7) 0.0 (0–28.6)
Sheffield 1 4 42.5 (5.2) 42.3 (36.4–48.8) 4 63.6 (16.9) 65.7 (42.9–80.0) 20.7 (15.5) 15.7 (8.6–42.9)
Somerset 1 4 44.0 (8.8) 45.5 (32.0–53.0) 4 64.3 (6.8) 61.4 (60.0–74.3) 15.0 (4.9) 15.7 (8.6–20.0)
Southern
Health
2 8 50.8 (8.2) 49.0 (41.0–66.0) 8 45.4 (11.1) 45.7 (28.6–62.9) 41.4 (14.6) 40.0 (14.3–60.0)
South
London
6 23 49.3 (13.0) 48.1 (25.0–75.0) 23 48.1 (14.2) 45.7 (20.0–71.4) 31.4 (14.5) 28.6 (11.4–65.7)
Sussex 6 24 44.5 (12.9) 44.5 (22.0–65.0) 23 61.5 (12.2) 57.1 (34.3–85.7) 20.7 (12.4) 20.0 (0–40.0)
Overall 30 116 47.6 (12.3) 47.4 (22.0–78.4) 117 54.1 (15.0) 54.3 (14.3–85.7) 23.8 (15.4) 22.9 (0–65.7)
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Facilitator behaviour was also assessed by direct observation and categorised as ‘positive’, reflecting a
facilitative approach, and ‘negative’, reflecting more didactic teaching. Positive behaviour was observed
for a mean (SD) of 54.1% (14.97%) of the time, with a range across centres of between 31.8% (13.18%)
in Cornwall and 64.6% (17.67%) in Manchester (see Table 36 and Figure 25). Conversely, the mean (SD)
time of negative behaviours observed was 23.8% (15.45), with a range between centres of 3.7% (2.16)
in Devon and 41.4% (14.57) in Southern Health.
The STEPWISE intervention contained explicit strategies for assuring the fidelity of delivery in terms of
reducing differences within the treatment and ensuring adherence to the protocol (see Table 6). It did
not contain any explicit strategy for controlling provider differences; findings from the session feedback,
interviews and observations were not fed back to facilitators during the study. Serious contamination seems
unlikely, although facilitators from a number of trusts admitted lifting content or using the communication
style that they had learned in STEPWISE training in interactions with other patients. When asked, they did
not believe that this might have involved control arm participants, with one exception:
I care co-ordinate one of them . . . we’ve always discussed actually longer term what she needs to be
doing to lose weight. To get motivation and things like that. So it just, that’s in use. I tried very hard
not to bring STEPWISE stuff into it because honestly I don’t want to impact on her control group but
in conversations that I’ve with her for a number of years.
Facilitator S08/F03
Attendance and ‘receipt’ of behaviour change content (‘dose received’)
Participants attended a median of four (0–4) group foundation sessions and two (0–3) booster sessions.
Forty-seven out of 172 participants randomised to STEPWISE attended all seven group sessions, 96 attended
all foundation sessions and 61 attended all three booster sessions. One hundred and sixty-nine participants
(81.6%) had at least one support contact. Most (75.6%) were by telephone and 167 (81.0%) had at least
one telephone contact. Participants received, on average, 15 contacts and the average time per contact was
5.2 minutes. Fewer participants, 68 (32.9%), had at least one face-to-face contact with an average of three
contacts and an average time of 59.4 minutes per contact. Furthermore, 105 participants (50.7%) had at least
one mail contact, with the average number being five, whereas 24 (11.6%) had at least one contact by e-mail.
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FIGURE 25 Box plot for percentage of facilitator talk time (DOT scores) across sites.
DOI: 10.3310/hta22650 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 65
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Holt et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113
Strategies to ensure ‘receipt’ of the intervention, in terms of ensuring participant comprehension or using
cognitive and behavioural skills, were less robust than those to ensure delivery (see Table 6), with the
intervention prioritising client autonomy. Some of the LDC team and a minority of facilitators acknowledged
this as a potential problem, owing to the cognitive function of some of the participants (see Context,
Body functions):
Sometimes it wasn’t explored to check understanding . . . for example when people were asked to do
their plans . . . I would want to say with somebody, ‘summarise what key message you’ve taken away
from that session’, and I didn’t see a lot of that . . . I don’t think we cover it in training so again,
it’s something that could be emphasised more.
Developer D07
Their functioning is quite different, you know, there’s . . . [a] lady there who understood the thing
straight away, and another guy who . . . I think he does have an understanding but it’s very difficult to
find out what his understanding actually is. Because he tends to talk in slightly psychotic terms and . . .
very concrete thinking.
Facilitator S05/F02
Triangulation
Convergence assessment
Table 37 shows how the quantitative and qualitative findings converge. There was agreement on three
components, partial agreement on two, silence on six (all expected areas were amenable to only one
form of assessment), and dissonance on seven. Some areas of dissonance indicated that data were being
collected on quite different aspects of the construct, for instance the amount of resource committed versus
how the result was valued. In other areas, qualitative research revealed nuances, for instance, although
resource for co-ordination was allocated, it was insufficient.
Completeness assessment
The quantitative research contributed information to 14 out of 18 logic model components, whereas the
qualitative components contributed to 16. This was expected: some components were not amenable to
investigation in quantitative terms.
Brief summary
The numbers relate to rows in Table 37. The study was not run in naturalistic conditions, meaning that
national (1, 11) and local (6) infrastructure for quality assurance was not in place. Training resources
were adequate (2). Most health professionals were motivated, but neither co-ordination resource nor
senior leadership were adequate at some trusts (3). The STEPWISE course materials were popular with
participants; professionals doubted their sustainability (4). When offered the STEPWISE trial, half of the
people with schizophrenia were motivated to participate (5).
Training and fidelity assessments were conducted (7). Facilitators often felt that programme management
(8) and case management (10) were under-resourced and, as a result, stressful. There was some evidence
of clinical gatekeepers barring entry to eligible people, but we do not think that this was widespread (9).
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TABLE 37 Triangulation table
Logic model construct
Data
Convergence codeQuantitative Qualitative
Resources (see the Resources section, except where stated otherwise)
1 STEPWISE programme
l Infrastructure
l Trainers
l Their mentors/managers
Costs of infrastructure and mentors/
managers not included in this experiment
Seven LDC mentors/managers played
the role of trainers for this experiment.
Infrastructure to be established if the trial
is successful and the market allows
Agreement. This research does not
provide evidence of effective infrastructure
to sustain the STEPWISE programme
2 Training course materials and venue Training costs: £2868 for 10 centres Course materials are universally popular
resources (see Relational work). Limited
availability but good acceptability of
venues
Dissonance. The meaning of items coded
to this construct are different. Costs were
committed; they were adequate and
deployed successfully
3 Health professionals motivated to become
STEPWISE facilitators (ideally experienced in
group facilitation) and an appropriately
resourced co-ordinator and a bought-in
NHS trust chief executive and gatekeepers
Group facilitation experience was variable;
co-ordinator excess treatment costs were
£1734 per centre; facilitator excess treatment
costs were £468 per centre (10 centres) for
three courses of six to eight participants
Motivation generally good, with some
exceptions (see Relational work). Co-
ordinators assumed to be appropriately
resourced – although administration load
on facilitators was a common complaint
(see Operational work). A minority of
those interviewees did not believe that
people of sufficient seniority drove the
intervention forward (see Relational work)
Dissonance. The meaning of items
coded to this construct are different.
Costs were committed. In some cases,
it was claimed that both monetary and
wider organisational commitment was
inadequate
4 STEPWISE course materials: venue, leaflets,
patient handbook, refreshment, travel costs
Excess treatment costs for course materials:
£832 per centre (10 centres); venue costs
hidden in crude costs
Subsidised travel, course materials
and refreshments were popular with
participants (see Course delivery and
protocol non-compliance), but facilitators
sometimes doubted their sustainability
(see Predictors of weight change)
Dissonance. The meaning of items coded
to this construct are different. Resource
was committed, popular with patients,
but sometimes seen as unsustainable by
professionals
5 People with schizophrenia were motivated
to attend the course
The study screened 1223 people, of whom
800 did not participate. A total of 406 out
of 800 exclusions expressed a lack of
interest or declined consent
– Silence. No qualitative data about the
motivation of the wider population
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TABLE 37 Triangulation table (continued )
Logic model construct
Data
Convergence codeQuantitative Qualitative
Activities (see the Activities section, except where stated otherwise)
6 STEPWISE programme mentors frequently
assess the competency of trainers
– The research project did not incorporate a
system of mentorship located within trusts
Silence. Quantitative data did not speak
to mentorship arrangements
7 Trainers train and periodically assess the
fidelity of NHS trust-based group
facilitators
Three facilitator training courses ran from
March to July 2015; 48 facilitators attended
core training, of whom 42 attended booster/
support training. November 2015 to June
2016, seven staff attended full training; five
were trained in booster/support contact only.
Ten per cent of group sessions were
observed using the DOT and facilitator
behaviours checklist
LDC interviews confirmed training and
fidelity assessment observations
Agreement. Both data types confirmed
that action was completed
8 Programme management (including the
identification of staff, booking rooms)
– Programme management felt
under-resourced and stressful for many
facilitators (see Operational work)
Silence. Quantitative data did not speak
to programme management
9 Gatekeepers actively refer people Screening CRFs captured three incidents in
which the care co-ordinator did not give
permission to contact potentially eligible
candidates, and two in which an assistant
practitioner referred a candidate and the
care co-ordinator blocked contact
Facilitators confirmed that gatekeepers
sometimes presented barriers to
participation (see Relational work)
Agreement. Quantitative and qualitative
data confirmed the existence of clinical
‘gatekeeping’
10 ‘Case’ management (booking people on
the course, sending letters, follow-up)
– Facilitators had trouble protecting time for
individual-level case management, which
was labour intensive
Silence. Quantitative data did not speak
to case management
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Logic model construct
Data
Convergence codeQuantitative Qualitative
Immediate outcomes (see the section Immediate outcomes, except where stated otherwise)
11 Quality of STEPWISE training maintained – The research project did not incorporate a
system of continuous quality assurance
Silence. Quantitative data did not speak
to quality assurance arrangements
12 Sessions delivered in line with the
STEPWISE philosophy (‘fidelity’)
Mean (SD) facilitator talk time (DOT score)
was 47.6% (12.26%). Mean percentage
(SD) of facilitator behaviours that were
deemed positive was 54.1%
(17.67/35 items)
LDC staff indicated that facilitators
sometimes gave insufficient time to action-
planning or for the participant to answer
questions – often offering, rather than
eliciting, solutions. Facilitators reported
that the highly-structured character of
the intervention was challenging and
acknowledged deviation
Partial agreement. DOT scores were
difficult to interpret, but data of both
types indicate that fidelity was not
complete, with a highly structured
intervention proving challenging to some
staff, who were used to more professional
autonomy
13 Attendance at all foundation and booster
sessions; one-to-one telephone support
sessions with demonstrable in-session
‘receipt’ of behaviour change content
(‘dose received’)
82.6% of participants (n= 171) attended
at least two sessions. 36 (17.4%) allocated
to the intervention were non-attenders,
whereas 111 (53.6%) attended ≥ 3 core
sessions and ≥ 1 booster session. 3218
support contacts were made, with 169
participants (81%) receiving one or more
contact. 167 (81%) had at least one
telephone contact (average of 15).
105 participants (50.7%) received
at least one mail contact (average of five)
and 68 (32.9%) received a minimum of
one face-to-face support contact
(average of three)
Adequate strategies to understand
participant ‘receipt’ (understanding and
internalisation) of behaviour change
content not in place
Dissonance. Quantitative data show us
that most people attend; qualitative data
show our lack of understanding about
whether or not they understand or can
use the intervention skills
14 4 × weekly foundation and three ‘booster’
sessions; one-to-one telephone support
calls made (‘dose delivered’)
All foundation sessions were delivered;
one booster session did not run. Not
all support contacts were delivered.
Facilitators found it difficult to contact
some participants; however, there was
incidence of non-compliance (such as first
attempt to contact not being personalised
and failure to conduct contacts)
Interviews with facilitators indicate that
sessions were delivered, but a large
number of support contact attempts were
unsuccessful
Partial agreement. Qualitative research
shows that support contact metrics must
be interpreted with caution
continued
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TABLE 37 Triangulation table (continued )
Logic model construct
Data
Convergence codeQuantitative Qualitative
15 Eligible people were invited to attend the
STEPWISE programme (‘reach’)
414 out of 1223 potentially eligible service
users were randomised. Estimates of
potentially eligible service users varied
significantly between trusts for which data
were available (1233–12,968). Target vs.
actual recruitment at these sites was 40
out of 36, 50 out of 45 and 42 out of 35,
respectively
– Silence. Qualitative data did not speak to
reach
Selected intermediate outcomes (see Outcomes and estimation and Perceived effectiveness)
16 Physical activity Accelerometry shows no statistically
significant difference between the
intervention and control groups
Qualitative research participants claimed to
have achieved changes in physical activity
Dissonance. Data types suggest different
outcomes
17 Nutrition DINE shows no statistically significant
difference between the intervention and
control groups
Qualitative research participants claimed to
have achieved dietary changes
Dissonance. Data types suggest different
outcomes
18 Weight No statistically significant difference
between the intervention and control
groups
Qualitative research participants claimed
to have achieved weight loss; for most,
this was not borne out by quantitative
evidence, or the weight loss was not
clinically significant
Dissonance. Data types suggest different
outcomes
R
E
S
U
L
T
S
O
F
T
H
E
P
R
O
C
E
S
S
E
V
A
L
U
A
T
IO
N
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
1
8
Lapses in fidelity included giving insufficient time to answer questions and giving, rather than eliciting,
solutions from participants (12). STEPWISE has no reliable mechanisms by which facilitators can investigate
whether or not participants understand or can use the intervention (13).24 Scheduled sessions went ahead
but, when support contacts were attempted, they were not always successful (14). During the trial period,
we reached a small fraction of those who were potentially eligible in the study areas (15).
Although many participants claimed to have achieved important changes in physical activity levels,
nutrition and weight, quantitative data showed that this was true only for a minority and that any
differences between trial groups could not be explained by receipt of the STEPWISE intervention.
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Chapter 6 Results of the health economic analysis
Health-related quality of life
The EQ-5D-5L utility scores (Table 38) at the 3-month follow-up point were slightly higher in the intervention
group (0.81 in the intervention group vs. 0.79 in the control group); however, at the 12-month point, there
was no difference between the tariff values of the two groups (0.793 in the intervention group vs. 0.794 in
the control group). At baseline, the EQ-5D-5L score was higher in the intervention group than in the control
group, which has a negative effect on the cost-effectiveness calculations that consider the level of QoL
(measured by the tariff) before the intervention. The total QALYs were very similar over the 12-month
period, with a slight advantage for the intervention group.
Short Form questionnaire-36 items questionnaire and Short Form
questionnaire-6 Dimensions measure of quality of life
Short Form questionnaire-6 Dimensions scores, in contrast to the EQ-5D scores, were slightly higher in the
control group (0.01 tariff points) than in the intervention group at baseline. Tariff scores also appear to be
0.02 tariff points higher in the intervention group at the 3- and 12-month follow-up periods. There is still
only a very small advantage in the QALYs of the intervention group when using the SF-36 questionnaire to
calculate a SF-6D QALY (Table 39). It is of interest that the tariffs using the SF-6D are substantially lower
than those obtained from the EQ-5D, but this is in line with earlier findings.128
TABLE 38 The EuroQol-5 Dimensions, five-level version tariffs at all time points and total QALYs
Time point
Trial arm, mean (SD)
All, mean (SD)Treatment Control
Baseline 0.79 (0.20) 0.78 (0.19) 0.79 (0.19)
3 months 0.81 (0.16) 0.79 (0.21) 0.80 (0.19)
12 months 0.79 (0.24) 0.79 (0.24) 0.79 (0.24)
Total QALYs 0.81 (0.012) 0.79 (0.015) 0.80 (0.010)
TABLE 39 Short Form questionnaire-6 Dimensions tariffs at all time points and total QALYs
Time point
Trial arm, mean (SD)
All, mean (SD)Treatment Control
Baseline 0.61 (0.005) 0.62 (0.005) 0.62 (0.004)
3 months 0.63 (0.005) 0.61 (0.006) 0.62 (0.004)
12 months 0.63 (0.006) 0.61 (0.005) 0.62 (0.004)
Total QALYs 0.63 (0.005) 0.61 (0.006) 0.62 (0.004)
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Costs
Intervention costs
For the base case, the unit cost of two facilitators providing the intervention was provided, assuming that a
group of four participants attended the intervention and the cost of facilitators was based on the wages of
a mental health nurse. In this case, the cost of the intervention is around £35.20 per patient per hour and
£88 for a full 2.5-hour session. The mean cost of the intervention is £565 for the base case. The maximum
cost of the intervention, in the base-case scenario, is £616 for seven full sessions and £283.20 for 24 support
contacts at a price of £1.18 per minute for 10 minutes.
Health and social care costs and lost work/education
Table 40 shows the number and percentage of service users accessing each type of care, the mean
number of contacts with the service for those using it, and the mean cost of the service across all
participants. Less frequently visited health-care professionals were combined into one category: other
health-care professionals. This category includes drug advisors, other counsellors, home treatment teams,
outreach workers, intervention therapists, occupational therapists, drug service facilities and community
mental health support workers. The costs of social care were combined into another category, including
day care, drop-in centre, self-help group, leisure groups, adult classes and other types of care. The number
of contacts for the intervention is shown separately for each time point and represents the number of
full sessions attended in the case of the intervention group. However, the cost calculations for other
health-care services take into account patients attending part of a session.
At baseline, the most frequently consulted health professionals were GPs (68% in the intervention arm and
67% in the control arm), psychiatrists (61% in the intervention arm and 60% in the control arm) and mental
health nurses (58% in the intervention arm and 60% in the control arm). At baseline, 20% of participants in
the intervention group and 17% in the control group accessed social care. Fifty per cent of participants in
the intervention group accessed other health-care professionals and 49% in the control group did so.
At the 3-month follow-up, the most frequently consulted health professionals were still GPs (46% in the
intervention arm and 54% in the control arm), psychiatrists (41% in the intervention arm and 43% in
the control arm) and mental health nurses (42% in the intervention arm and 47% in the control arm).
At the 3-month follow-up, 13% of participants in the intervention group and 14% of those in the control
group (a slightly lower proportion than at baseline) accessed social care. Thirty per cent of participants in
the intervention group and 32% in the control group accessed other health-care professionals. Overall, the
level of participants reporting use of all of these categories of services was slightly lower in both groups.
At the 12-month follow-up, the most frequently consulted health professionals remained GPs (reported by 62%
in the intervention group and 64% in the control group), psychiatrists (reported by 60% in the intervention
group and 56% in the control group) and mental health nurses (reported by 47% in the intervention group
and 56% in the control group). At 12 months, 14% of participants in the intervention group and 15% in the
control group accessed social care. According to self-reported data, 33% of participants in the intervention
group and 38% in the control group accessed other health-care professionals. At baseline, 43% of participants
in the intervention and 49% in the control group group reported receiving informal, largely unpaid, care.
The same percentages also reported this at the 3-month follow-up. At the 12-month follow-up, 65% of the
intervention group and 59% of the control group reported receiving informal care.
Table 40 also includes productivity losses, which are the cost of lost work and education time of
participants in the study and informal care received from carers. As informal carers are largely unpaid,
productivity losses relating to informal care indicate that the amount of money that could have been
gained by working during the time that informal care is provided (i.e. the opportunity cost of caring for the
service user). At baseline, 56% of participants in the intervention group and 61% in the control group
were employed. By the end of the study, these figures had fallen slightly to 43% in the intervention group
and 49% in the control group. At baseline, 13% of participants reported that they were working and
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TABLE 40 Health and social care service use and productivity losses
Category of service use
Health and social care service use and productivity losses during the
3 months pre randomisation
Trial arm, n (%) of
participants using
services
Trial arm, mean (SD)
contacts for those
using services
Trial arm, mean (SD)
costs (£) for all
participants (2015–16
pounds sterling)
Treatment Control Treatment Control Treatment Control
GP 142 (68) 138 (67) 2 (0.2) 3 (0.2) 83 (9) 90 (9)
Psychiatrist 127 (61) 122 (60) 2 (0.2) 2 (0.2) 94 (14) 89 (10)
Psychologist 25 (12) 27 (13) 5 (0.8) 4 (0.7) 67 (19) 53 (13)
Other doctor 16 (8) 14 (7) 2 (0.3) 3 (0.8) 8 (3) 10 (4)
Mental health nurse 121 (58) 121 (59) 6 (0.8) 4 (0.3) 172 (38) 137 (22)
Social worker 41 (20) 35 (17) 4 (0.5) 5 (0.9) 52 (14) 91 (30)
Other health-care professionala 104 (50) 99 (48) 5 (0.7) 4 (0.5) 308 (55) 196 (28)
Inpatient (days) 6 (3) 12 (6) 28 (37) 28 (30) 324 (183) 658 (242)
Medication 206 (99) 199 (97) N/A N/A 408 (26) 397 (29)
Other health and social care servicesb 76 (37) 69 (34) 14.8 (2.0) 12.3 (1.4) 308 (55) 195 (28)
Informal care (hours per week) 117 (56) 125 (61) 10.4 (1.1) 10.8 (1.5) 912 (1597) 1019 (2218)
Lost employment (days) 27 (13) 26 (13) 2.6 (1.4) 6.3 (2.8) 29 (223) 66 (453)
Lost education (days) 25 (12) 13 (63) 5.4 (3.3) 1.9 (1.6) 54 (34) 10 (9)
Police 3 (14) 6 (29) 1.7 (0.7) 1.2 (0.2) 2 (1) 1 (1)
Total health and social careb 208 (100) 202 (99) 1623 (236) 1802 (260)
Total societal 208 (100) 205 (100) 2619 (258) 2900 (315)
Category of service use
Health and social care service use and productivity losses during the
3 months post randomisation
Trial arm, n (%) using
services
Trial arm, mean (SE)
contacts for those
using services
Trial arm, mean (SE)
costs (£) for all
participants (2015–16
pounds sterling)
Treatment Control Treatment Control Treatment Control
GP 96 (46) 112 (54) 2 (0.2) 2 (0.1) 83 (9) 90 (10)
Psychiatrist 86 (41) 90 (43) 3 (1.1) 1.2 (0.3) 94 (14) 89 (10)
Psychologist 15 (7) 16 (8) 4 (0.9) 6 (1.1) 67 (19) 53 (13)
Other doctor 15 (7) 14 (7) 2.4 (0.9) 1.6 (0.4) 7 (3) 10 (4)
Mental health nurse 88 (42) 98 (47) 6 (1.1) 5 (0.5) 172 (39) 136 (22)
Social worker 27 (13) 29 (14) 9 (3) 4 (0.9) 52 (14) 91 (30)
Other health-care professionala 62 (30) 67 (32) 2 (0.4) 3 (0.7) 304 (55) 195 (28)
Inpatient (days) 7 (3) 8 (4) 18 (32) 7 (10) 238 (157) 112 (57)
Medication 177 (86) 168 (85) N/A N/A 159 (21) 175 (24)
Other health and social care servicesb 82 (40) 46 (23) 15.0 (1.9) 13.2 (1.4) 304 (55) 195 (28)
Informal care (hours per week) 106 (52) 114 (58) 13.3 (1.8) 12.2 (2.1) 1038 (2264) 1018 (2671)
Lost employment (days) 5 (2) 11 (6) 1.6 (0.9) 6.9 (3.4) 19 (11) 86 (44)
continued
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TABLE 40 Health and social care service use and productivity losses (continued )
Category of service use
Health and social care service use and productivity losses during the
3 months post randomisation
Trial arm, n (%) using
services
Trial arm, mean (SE)
contacts for those
using services
Trial arm, mean (SE)
costs (£) for all
participants (2015–16
pounds sterling)
Treatment Control Treatment Control Treatment Control
Lost education (days) 3 (1) 1 (0.5) 1.25 (0.8) 0.8 (0.8) 6 (4) 3 (3)
Police 7 (3) 5 (2) 1.3 (0.3) 2.0 (0.6) 3 (2) 2 (1)
Intervention 174 (85) – 2.83 (0.1) – 305 (7) –
Total health and social careb 205 (100) 195 (98) 1640 (197) 1133 (100)
Total societal 205 (100) 198 (100) 2599 (248) 2135 (214)
Category of service use
Health and social care service use and productivity losses between
3 and 12 months post randomisation
Trial arm, n (%) using
services
Trial arm, mean (SE)
contacts for those
using services
Trial arm, mean (SE)
costs (£) for all
participants (2015–16
pounds sterling)
Treatment Control Treatment Control Treatment Control
GP 128 (62) 133 (64) 4 (0.4) 5 (0.5) 132 (15) 150 (19)
Psychiatrist 124 (60) 116 (56) 3 (0.3) 2 (0.2) 123 (14) 111 (13)
Psychologist 29 (14) 22 (11) 11 (3) 9 (2) 176 (56) 92 (27)
Other doctor 24 (12) 22 (11) 2 (0.4) 3 (0.5) 15 (4) 19 (6)
Mental health nurse 97 (47) 102 (49) 6 (1.1) 5 (0.5) 107 (30) 270 (73)
Social worker 30 (14) 31 (15) 9 (3) 4 (1) 75 (22) 107 (30)
Other health-care professionala 69 (33) 79 (38) 8 (2) 8 (2) 390 (95) 413 (136)
Inpatient (days) 18 (8) 14 (7) 20 (7) 25 (8) 670 (251) 607 (249)
Medication 204 (98) 195 (97) N/A N/A 1080 (67) 1033 (82)
Other health and social care servicesb 51 (25) 59 (29) 43.7 (8.2) 33.3 (4.8) 390 (95) 413 (135)
Informal care (hours per week) 90 (43) 99 (49) 13.2 (1.9) 10.9 (1.3) 1038 (2264) 1018 (2671)
Lost employment (days) 12 (6) 14 (7) 6.9 (3.6) 20.8
(10.8)
77 (42) 237 (128)
Lost education 3 (1) 4 (2) 1.8 (1.1) 2.0 (1.2) 7 (5) 7 (4)
Police 7 (3) 6 (3) 2.7 (0.8) 1.8 (0.4) 28 (8) 4 (2)
Intervention 174 (85) – 1.43 (0.1) – 273 (13) –
Total health and social careb 208 (100) 200 (99.5) 3616 (353) 3319 (387)
Total societal 208 (100) 201 (100) 8734 (898) 8170 (863)
N/A, not applicable; SE, standard error.
a Drug and alcohol advisor, other counsellor, home treatment team. Assertive outreach, early intervention team,
occupational therapist.
b Drug/alcohol service, community mental health centre, day care centre, drop-in centre, self-help/support group, leisure
centre group, adult education.
Note
Reproduced from Holt et al.23 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table
includes minor additions and formatting changes to the original.
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missing work because of illness in the intervention group and 13% reported this in the control group.
This was reported at similar levels (12% in the intervention group and 14% in the control group) at the
12-month follow-up. At baseline, 12% of participants in the intervention group and 13% in the control
group attended further education, mostly further education colleges. At baseline, the proportion of
participants who reported that they were unable to attend further education college because of illness was
4% in the intervention group and 2% in the control group. At the 12-month follow-up, the percentage
of participants in further education and missing one or more days of education was 2% in both the
intervention group and the control group.
Health and social care costs included the costs of medicines and of visits to NHS professionals in primary
and community care and inpatient settings, as well as social care costs. Over the follow-up period, the
mean total health and social care costs were £5255 in the intervention group and £4453 in the control
group. Societal costs were calculated using police costs, productivity losses from lost education and
employment and informal care costs. The mean total societal costs were £11,332 in the intervention group
and £10,305 in the control group. The cost differences were partly attributable to the intervention, but
were also caused by greater use of other services.
The differences in health and social care and societal costs are not significant. For health and social care
costs, the difference (after controlling for baseline) was £870.39 (p-value = 0.132, bootstrapped CI –£262
to £2003). For societal costs, the difference (after controlling for baseline) was £1295.37 (p-value = 0.33,
bootstrapped CI –£1329 to £3919).
Cost-effectiveness analysis
The net benefit approach was used in order to produce cost-effectiveness planes and CEACs. Multiple
imputation (chained equations) was applied to the cost and QoL data.
Cost-effectiveness results based on the EuroQol-5 Dimensions, five-level version
The incremental costs and QALYs are shown in Table 41. The ICER from the health-care perspective is
£246,921 per QALY and from the societal perspective is £367,543 per QALY.
The bootstrapped replications of the difference in health and social care costs range from £433 to £1392.
The bootstrapped replications of the difference in EQ-5D QALYs range from –0.012 to 0.013 (Figure 26).
It is clear that the intervention is cost-increasing and results in better or worse outcomes to a similar extent.
The line shown on the scatterplot represents the NICE threshold, below which the replicates should fall for
the intervention to be cost-effective. No replications fall below this line. The probability that the STEPWISE
intervention is cost-effective is 0% at the £20,000 threshold set by NICE, as shown by Figure 27. The
probability that the intervention is cost-effective is still only 17% at a threshold of £200,000 when the
analysis is conducted from the health-care perspective.
TABLE 41 Cost-effectiveness results at 1 year (QALYs)
Outcome: QALYs from the EQ-5D-5L Treatment vs. control
Incremental effect 0.0035234
Incremental health-care cost £870
ICER (health care) £246,921
Incremental societal cost £1295
ICER (societal) £367,543
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The ICERs for the societal perspective showed similar results to those for the health-care perspective. The
bootstrapped replications of the difference in societal costs range from £192 to £2382. The bootstrapped
replications of the difference in EQ-5D QALYs range from –0.012 to 0.013 (Figure 28). Again, the intervention
results in higher costs and approximately equal likelihoods of better or worse outcomes. We have not shown
an ICER line, as NICE does not take a societal perspective. However, the probability that the STEPWISE
intervention is cost-effective is 0% at a £20,000 threshold (Figure 29). The probability that the intervention
is cost-effective is still only 7% at a threshold of £200,000 when the analysis is conducted from the societal
perspective.
Cost-effectiveness results based on the Short Form questionnaire-6 Dimensions
Health and social care perspective
The bootstrapped replications of the difference in health and social care costs range from £433 to £1392.
A total of 1000 bootstrapped replications of both the costs and the QALYs were performed. The bootstrapped
replications of the difference in SF-6D QALYs range from 0.003 to 0.012 QALYs (Figure 30). Table 42 shows
the SF-36 QALY outcomes at 1 year. It is clear that the intervention is cost-increasing and results in better or
worse outcomes to a similar extent. The line shown on the scatterplot represents the NICE threshold, below
which the replicates need to fall for the intervention to be cost-effective. No replications fall below this line.
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FIGURE 28 Cost-effectiveness plane for EQ-5D QALY from the societal perspective.
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FIGURE 29 Cost-effectiveness acceptability curve for EQ-5D QALY from the health and social care perspective.
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FIGURE 30 Cost-effectiveness plane for SF-6D QALYs from the health and social care perspective.
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The probability that the STEPWISE intervention is cost-effective is therefore, 0% at the £20,000 per QALY
threshold set by NICE, as shown by Figure 31. The probability that the intervention is cost-effective is 50%
at a threshold of £110,000 per QALY and 99% at a threshold of £200,000 per QALY when the analysis is
conducted from the health-care perspective.
Societal perspective
The bootstrapped replications of the difference in societal costs range from £403 to £1667. The
bootstrapped replications of the difference in SF-6D QALYs range from 0.003 to 0.012 QALYs.
The probability that the STEPWISE intervention is cost-effective is 0% at the £20,000 threshold set by
NICE, as shown by Figure 32. The probability that the intervention is cost-effective is 74% at a threshold
of £200,000 when the analysis is conducted from the societal perspective (Figure 33).
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FIGURE 31 Cost-effectiveness acceptability curve for SF-6D QALYs from the health and social care perspective.
TABLE 42 Cost-effectiveness results at 1 year (QALYs from the SF-6D)
Outcome: QALYs from the SF-6D Treatment vs. control
Incremental effect 0.0148241
Incremental health-care cost £870
ICER (health care) £58,688
Incremental societal cost £1295
ICER (societal) £87,358
RESULTS OF THE HEALTH ECONOMIC ANALYSIS
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Sensitivity analysis
Table 43 shows the different outcomes for the ICER and the optimal strategy if the costs of the intervention
and the group size attending the intervention are varied in the health and social care perspective. The table
also shows how varying the cost of informal care and lost employment days affects the outcomes if the cost
of the intervention is held constant at the price of a group of four patients receiving the course from two
mental health nurses. Attendance of sessions was low, with only 53.6% of patients attending more than
three main sessions and one or more booster sessions. Therefore, the base case assumed an attendance of
four patients rather than the six planned for in the study design.
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FIGURE 33 Cost-effectiveness acceptability curve for SF-6D QALYs from the societal perspective.
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TABLE 43 Sensitivity analysis (STEPWISE vs. TAU)
Health-care perspective (EQ-5D)
Profession Group size
Unit cost, £
(per hour)
Incremental
Cost (£) Benefit ICER (£)
Mental health nurse 4 35 870 0.0035234 246,921
Mental health nurse 6 24 746 0.0035234 211,727
Mental health nurse 8 18 685 0.0035234 194,414
Societal perspective (EQ-5D, assuming a group of four patients)
Informal care wage rate Employment wage rate
Unit cost, £
(per hour)
Incremental
Cost (£) Benefit ICER (£)
Average Average 12 1295 0.0035234 367,543
Minimum Minimum 7 785 0.0035234 222,796
Health-care worker Minimum 20 795 0.0035234 225,634
Health-care perspective (SF-6D)
Profession Group size
Unit cost, £
(per hour)
Incremental
Cost (£) Benefit ICER (£)
Mental health nurse 4 35 870 0.0148241 58,688
Mental health nurse 6 24 746 0.0148241 50,323
Mental health nurse 8 18 685 0.0148241 46,209
Societal perspective (SF-6D, assuming a group of four patients)
Informal care wage rate Employment wage rate
Unit cost, £
(per hour)
Incremental
Cost (£) Benefit ICER (£)
Average Average 12 1295 0.0148241 87,358
Minimum Minimum 7 785 0.0148241 52,954
Health-care worker Minimum 20 795 0.0148241 53,629
RESULTS OF THE HEALTH ECONOMIC ANALYSIS
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Chapter 7 Discussion
Conduct of the trial
The STEPWISE trial was a complex trial, which faced many challenges. Previous studies have suggested
that the recruitment and retention of people with schizophrenia are difficult. In addition to this generic
problem, the STEPWISE trial faced the additional challenge of recruiting in short waves because of the
nature of the group intervention. We recognised that, if recruitment took too long, those who were
recruited first would have to wait for a group to start and may lose interest by the time the intervention
started. We also recognised the importance of delivering the intervention before the 3-month follow-up
visits. Consequently, a concentrated period of recruitment was needed at each site to overcome this.
The STEPWISE trial was undertaken in 10 locations across England, covering both the north and south
of England, rural and urban settings and mixed ethnic populations. Although this had the strength of
representing the diversity of the NHS, it posed logistical challenges for the conduct of the trial, requiring
robust organisation at sites and the Sheffield CTRU.
In STEPWISE, we used the methodology designed to develop interventions for people with, or at risk of,
diabetes mellitus. At the outset, it was unclear whether or not it would be possible to transfer this process
to a different disease area, namely schizophrenia. The intervention development phase showed that this
was achievable, but it took 3 months longer than originally anticipated.
Despite the challenges of recruitment, the trial recruited 414 participants (original target: 396) in just over
1 year, which was almost 3 months quicker than planned. This illustrates the level of interest for such
interventions among people with schizophrenia and mental health care professionals. Previous studies have
indicated that people with psychotic illness have the same level of interest in their physical health, but
struggle to prioritise this over other issues, such as their mental illness.
Following successful recruitment, 341 participants (81.6%) completed the trial. This retention was similar
to our original estimates and other intervention studies for people with schizophrenia.55 A total of
20 participants were lost to follow-up, 48 withdrew consent and three died. The reason for withdrawal
of consent was often the worsening of mental illness precluding attendance at research assessments.
A strength of the STEPWISE trial was the use of an objective primary outcome measure, which could
not be greatly affected by knowledge of the intervention.129 Although participants were not blinded,
the STEPWISE assessors were blinded and largely remained blind during follow-up, further reducing the
risk of observer bias.130
As a result, the STEPWISE trial is the largest trial of weight management in severe mental illness of its kind.
It was adequately powered to answer the hypothesis we posed at its outset. Furthermore, through the use
of sensitivity analyses, even under extreme assumptions about missing data, the results of the trial would
be unchanged.
Summary of the findings
The STEPWISE intervention was neither clinically effective nor cost-effective over the 12-month trial period.
Both groups lost an average of 0.5 kg, suggesting that there may have been a small benefit to participation
in the trial, given the known trajectory of weight gain for people taking antipsychotics,131 but there was
no difference in weight change between groups. To achieve weight reduction, the intervention needed to
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promote changes in dietary intake, physical activity or both. The baseline data confirmed that the trial
participants were eating a diet that was high in refined carbohydrates and low in fibre. In addition, the
accelerometry data indicated that they were physically inactive, with levels of activity similar to older adults
from the general population aged 75–79 years.132 The imprudent diet and physical inactivity provided
substantial opportunity for change, but there was no sustained behaviour change in either of these crucial
behaviours. Furthermore, the intervention did not lead to changes in other biomedical outcomes, psychiatric
well-being, QoL or obesity perception.
The estimated cost of the STEPWISE programme was £565, but the intervention was not cost-effective,
owing to the relatively small effect of the intervention on the (EQ-5D-5L) QoL measure (a QALY difference
of around 0.0035 between the treatment and control groups after controlling for baseline utility scores)
and increased costs of other services. This results in an ICER of > £200,000 in the base-case analysis.
The lack of effect on weight contrasts with previous reports that suggested that lifestyle interventions
could help people with severe mental illness to lose weight. The STEPWISE study drew heavily from the
experience published in the meta-analysis by Caemmerer et al.,12 which reviewed 17 studies and included
810 people receiving antipsychotics. This paper found that lifestyle interventions led to significant weight
reduction, in association with concomitant improvements in cardiovascular risk factors. However, most of
the studies were of short duration, with most lasting for 12–16 weeks, and included a small number of
participants (median 53, range 15–110).
The 2014 NICE guidance for psychosis and schizophrenia in adults14 included 24 studies and came to
similar conclusions. Both reviews included studies that had recruited on the basis of antipsychotic treatment
rather than diagnosis, and so significant numbers of participants had other types of mental illness. This is
important, as the strategies needed to promote weight loss in people with schizophrenia may be different.
NICE comments that few studies examined weight change beyond 6 months, and only six included > 100
participants. With relevance to the NHS, no study was conducted in the UK. There was a moderate risk of
bias for most studies and there was substantial heterogeneity of effect size. The evidence review concluded
that lifestyle interventions were effective in reducing and maintaining body weight in the short term, but,
without longer-term data, effects beyond 6 months were unknown. Despite the limitations in the evidence,
based on expert opinion, NICE recommends that mental health-care services should offer a combined
healthy eating and physical activity programme to people with severe mental illness, particularly if they are
taking antipsychotics.14
The length of follow-up of the STEPWISE trial allowed a longer-term perspective, which addressed some
of the shortfalls of earlier studies. Over the course of the STEPWISE trial, several other long-term studies
examining the effect of lifestyle interventions were published and are included in the most recent systematic
review.15 Six studies reported that interventions lasting for more than 1 year showed a more consistent
weight reduction (SMD = −0.24, 95% CI −0.36 to −0.12), although only two of the six studies recorded a
statistically significant weight loss, both of which included substantial numbers of people with other severe
mental illnesses.
Given the unexpected results of the STEPWISE trial, we examined why the intervention failed, in order to
inform future research and clinical practice. The first question is whether or not the intervention was fit
for purpose.
Development and implementation of the intervention
The STEPWISE programme meets most of the Department of Health and Social Care guidelines,17 on which
its parent programme, DESMOND,19 was based. It is theory driven (see The intervention’s theory of change)
and evidence based (see Intervention development), coproduced with patients and flexible to emerging
individual needs (see Intervention development). Its specific aims and objectives are shared with users and
it supports self-management attitudes, beliefs, knowledge and skills for the user (see Intervention
development).17 The structured, written curriculum incorporates the assessment of individual learning
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needs and can be flexibly applied, meeting diverse needs (see Intervention development). It appears to be
reliable, valid, relevant and comprehensive and uses different teaching media and supporting materials
(see Table 35). However, staff raised questions about its resource efficiency (see Chapter 5, Appraisal work)
and the health economic model (see Chapter 6, Cost-effectiveness analysis).
The STEPWISE facilitators demonstrated an understanding of empowerment philosophy133–135 (see
Chapter 5, Facilitator views of STEPWISE, Sense-making), but perhaps lacked an understanding of the
behaviour change theories that underpinned the intervention. It is possible that a narrow interpretation of
empowerment, as autonomous change driven by intrinsic motivation, deprived some participants of more
external support that they desired (see Chapter 5, Facilitator views of STEPWISE, Sense-making) and of
effective behaviour change techniques such as monitoring by, and feedback from, others (see Chapter 5,
Facilitator views of STEPWISE, Appraisal work). If such case-by-case adaptations are a matter of informed
choice, then they should not be seen as a departure from empowerment philosophy.
Although a participatory approach to intervention design involved service users, a potentially ‘over-controlled’
intervention,136 in which the work as done was different from the work as imagined,137 may have been
prevented by participatory implementation and adaptation during the trial itself.138–141 Although the developers
considered the course to be of low intensity and modest in cost, at a time when NHS mental health trusts
were under considerable pressure,142,143 some struggled to release resources, making programme management
difficult for front-line staff (see Chapter 5, Facilitator views of STEPWISE, Operational work).
The training was well received, and the delivery of programme content in line with empowerment
philosophy principles was evident (see Chapter 5, Activities, Trainers train and periodically assess fidelity of
facilitators). A quality assurance programme was developed with relevant assessment criteria. The user
experience was described positively in general (see Chapter 5, Participant acceptability), but this was audited
as part of this evaluation, not as part of the intervention. Routine auditing of content comprehension,
behaviour change and clinical outcomes formed no part of the intervention programme, meaning that
facilitators could not appraise its effects (see Chapter 5, Appraisal work).24,80
Staff tailored the intervention appropriately for individuals, whose views and experiences were mostly valued,
which is an important marker of quality. Although the pace of delivery could not always be adjusted to
everyone’s needs, many participants found that the duration of support was acceptable, although in some
cases it may not have been adequate to develop and apply behaviour change strategies that would lead to
lasting benefits.144
The two successful long-term trials employed interventions that were considerably more intensive than
STEPWISE, and a more intensive intervention may have achieved better results. The ACHIEVE study by
Daumit et al.145 included 291 participants who were seen in 10 community psychiatric rehabilitation
outpatient programs. The intervention, which involved a combination of group weight management
sessions (weekly in the first 6 months, then monthly), monthly individual visits and thrice-weekly group
activity classes, achieved a mean weight loss of –3.2 kg over 18 months. The more recent STRIDE study146
included 56 men and 144 women who were randomised to routine care or a 6-monthly weekly group
intervention plus six monthly maintenance sessions. STRIDE intervention participants lost 4.4 kg more
than control participants from baseline to 6 months (95% CI –6.96 to –1.78 kg), but this difference
was reduced to 2.6 kg by 12 months (95% CI –5.14 to –0.07 kg). Further evidence in favour of a more
intensive programme comes from a service evaluation of a UK-based weight management programme in
which the only predictor of weight loss was the number of sessions attended.53 Many participants valued
the group sessions and the opportunities to interact with others with the same condition; however, there
was a breadth of understanding and ability to learn. For some participants, one-to-one sessions, with
greater attention to memory support, may have proved more effective. However, intensity may not provide
the whole explanation. The Danish CHANGE trial147 randomised 428 people with schizophrenia spectrum
disorders and abdominal obesity to 12 months of intensive lifestyle coaching plus care co-ordination plus
usual care, or care co-ordination and usual care, or usual care alone. In the lifestyle coaching arm, the
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participants were offered contact with a team member for 1 year. These personal one-to-one contacts
occurred at least once per week and typically lasted for up to 1 hour. Despite the similar intensity to the
ACHIEVE and STRIDE studies, neither lifestyle coaching nor care co-ordination reduced body weight or
waist circumference.
Another alternative explanation may lie in the diagnoses of the participants. Unlike the STEPWISE and
CHANGE studies, which recruited only people with schizophrenia spectrum disorder, ACHIEVE and STRIDE
included significant numbers of people with other psychiatric disorders. Only 58.1% of the participants in
the ACHIEVE study had schizophrenia or schizoaffective disorder, and one-third of participants had a mood
disorder. Only 29% of the STRIDE participants had schizophrenia spectrum disorders.
Given the current funding constraints within the NHS, it is debatable whether or not a more intensive
intervention would have been affordable within a UK NHS setting and it is noteworthy that the total
contact time in the STEPWISE sessions (17.5 hours) is similar to that recommended by the NICE prevention
of diabetes mellitus guidance.18 Even with the current number of STEPWISE sessions, fewer than one-
quarter of participants attended all sessions, with more participants attending core sessions than booster
sessions. This problem is not unique to the STEPWISE trial, and the level of engagement is similar to other
group-based education programmes.16,27,148
Although the duration of illness and antipsychotic treatment was not reported in the ACHIEVE and STRIDE
studies, differences in these factors may further explain the differences in results. We deliberately set out to
include a broad range of people with schizophrenia to represent those in contact with NHS mental health
services. Consequently, our participants had a wide spectrum of BMI, ranging from normal weight to morbid
obesity. It is possible that, had we restricted our entry to the study to those with a BMI of 25–35 kg/m2, the
intervention may have proved more successful. Fifty-eight people had type 2 diabetes mellitus, for whom
lifestyle intervention is key to self-management. Although there is overlap between obesity and diabetes
mellitus management, there are areas in which this diverges and could lead to different results.
Most STEPWISE participants had a long history of an established psychiatric disorder, and it is possible that
different approaches are required depending on disease duration. Weight gain is most rapid during the early
phase of psychosis,149,150 and this may be the time when lifestyle approaches are most effective. Although
we planned to include individuals shortly after the diagnosis of first episode psychosis, very few participants
had been on treatment for < 3 months, because of the need to recruit in waves for the group intervention.
Usual care and the risk of contamination
The trial followed best practice for pragmatic trials by allowing considerable leeway for alternative
management strategies in the control arm.34 The use in combination of the usual care survey,36 the CSRI43
and a weight loss programme CRF ensured that the treatment effect was not diluted by a control arm that
was more active than intended.151,152
We undertook a survey of usual care to ascertain the physical health provision at each site. Although
there was considerable variation between sites, none was compliant with the latest NICE guidance. To
standardise usual care for control participants, the research team provided each participant with written
lifestyle advice. Arguably, this went beyond usual care and it is possible that this brief intervention may
have a small beneficial effect for control participants, thus minimising the observed effect of the trial.
Participation in the trial may have heightened awareness of the obesity problem and led to changes in
behaviour. The reduction in body weight in both arms, as opposed to the expected weight gain, suggests
that this may have occurred.
Only 8.6% of participants attended weight loss programmes outside the trial, with a slightly higher
proportion in the intervention group. There were a few ad hoc reports of referrals by GPs for diet advice or
gym membership for those who were newly identified as having diabetes mellitus or prediabetes mellitus.
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Other strengths of the trial
The trial results came as a surprise to investigators working at sites that had experienced benefits at their trust.
At the results meeting, the investigators described how health-care professionals had become more engaged
in weight management and how trusts had improved physical health monitoring. The STEPWISE programme
had addressed both patient and care co-ordinator demand for weight management programmes and, in
some cases, led to substantial weight reduction. The investigators also reported that participants overcame
their anxiety of group-based sessions and reported the value of sharing experiences with other people with
severe mental illness with similar weight problems. The social interaction of the groups undoubtedly had a
positive effect for participants. The investigators reported how their own practice and personal lives had
changed as a result of participation in the trial. They valued the opportunities for interaction between the
clinical and research teams within the trust.
Strengths and weaknesses of the process evaluation
Following guidance,68 we fully explored how context affected implementation and identified – as have
others153 – poverty, under-resourced public services and stigmatisation of people with diagnoses of mental
illness as key issues. The process evaluation showed that the funding of transport and the patient-focused
educational approach was popular with participants, but the scarcity of resources remains a problem
for implementation.
The study used direct observation of STEPWISE sessions, the gold standard method for investigating
intervention fidelity.24 Although the intervention developers undertook the fidelity assessment, other
aspects of the process evaluation were conducted by evaluators (DH and RG-W) who were sufficiently
independent to observe the work of stakeholders critically, as recommended in the relevant guidance.68
The process evaluation was informed by both programme theory and middle range theory, allowing some
investigation of the causal assumptions that underpinned the intervention. However, the use of the
Behaviour Change Wheel95 in the analysis of participant transcripts was ‘after the fact’; as it did not inform
the topic guide, the associated analysis (see Tables 33 and 34) reflects the participants’ patterns of
attention rather than systematic elicitation of information based on all theoretical constructs.
Strengths and weaknesses of the economic analysis
Strengths
The high follow-up rate has generated reliable results; however, the use of the relatively new EQ-5D-5L
tariffs to calculate the QALY values may mean that the results are not easily comparable with previous
results of other studies using the EQ-5D-3L questionnaire, which gave participants three instead of five
options to each question. With the extra options, the EQ-5D-5L is more sensitive to change than EQ-5D-3L.
Limitations
Information on service use was collected with questionnaires, which may limit the data accuracy. However,
the CSRI method is a well-established method for collecting service use data and this is a data collection
issue, which would affect both groups. We also accept that there may be some recall bias in the 9-month
follow-up period between 3 and 12 months post randomisation, whereby patients found the number of
appointments difficult to remember. There is no reason to suggest that there would be a difference between
the treatment and control groups in this respect.
The EQ-5D is sometimes considered to be insensitive to changes in QoL in people with serious mental illness,
in comparison with the SF-6D.128 That is to say, many patients in the disease area report no problems in each
area in the EQ-5D questionnaire, perhaps because the domains are less relevant than in other disease areas.
The STEPWISE economic evaluation also used the SF-6D, but found a similarly small QALY difference
between the two groups. As the STEPWISE intervention was aimed at improving physical health, we might
expect to see more improvement than usual on the EQ-5D, which is more focused on physical symptoms,
but this was not the case.
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In STEPWISE, all participants received a lifestyle information booklet, which was not costed as part of the
study. A nominal value was used to cost e-mail and postcard support contacts, which may not accurately
represent the cost of the programme. As we did not have data on the wages or education levels of
participants and carers, we used the common approach of taking average, minimum and home carer
wage rates, but this may not present an accurate picture of the economic impact of the productivity losses.
The benefits of lifestyle behaviour change may take longer to emerge than the intervention tested; however,
it is unlikely that longer-term benefits would be observed, given the lack of short-term benefits.147
Implications for policy-makers, health professionals, people with
schizophrenia and their families
The trial has important clinical implication for practice, despite being no closer to finding the best way to
manage obesity and weight gain in people with schizophrenia. The STEPWISE trial has focused on lifestyle
modification, as have previous studies, but this does not recognise the breadth of factors that contribute to
weight gain and obesity. Antipsychotics are associated with significant weight gain, and broader approaches
that combine individualised lifestyle modification with tailoring of antipsychotic treatment or co-prescription
with drugs that reduce antipsychotic-associated weight gain may be needed.
Currently, NICE guidance recommends that mental health trusts should offer lifestyle interventions to
people with psychotic illnesses.14 Although it is clear that behavioural change to address the challenge of
obesity is effective for some people with severe mental illness, STEPWISE has indicated how difficult this
is to achieve. Furthermore, the results of our study and the CHANGE study147 suggest that people with
schizophrenia may respond differently to lifestyle interventions from people with other severe mental illness.
It is also possible that people with schizophrenia require an intervention that is of greater intensity than
other populations to achieve weight loss. In addition to our experience, the INTERvention to Encourage
ACTivity, Improve Diet, and Reduce Weight Gain (InterACT) study, which evaluated a healthy-living
intervention to control weight in people taking antipsychotic medication after a first episode of psychosis,
found no difference in weight change between the intervention and usual care groups.154
The results of this trial suggest that interventions that have been shown to be effective in other populations,
such as people with diabetes mellitus, are not necessarily effective in people with schizophrenia. Lifestyle
programmes for people with schizophrenia should have proven effectiveness and it needs to be recognised
that these may need greater resourcing than for other populations.
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Chapter 8 Further research
Further analyses of the STEPWISE data set will be undertaken to understand further what predicts a positiveresponse to the intervention. Further health economic analyses within the project will include a comparison
of the EQ-5D-5L QALY results with those gained from the SF-36 questionnaire, which generate SF-6D tariffs,
which are then used to calculate a QALY. The final analysis will also include a sensitivity analysis, which varies
the cost of employment to the minimum wage rate and the cost of informal care to the minimum wage rate
and the cost of a home care worker, as mentioned in the methodology.
STEPWISE recruited limited numbers of people with first episode psychosis, and further research is needed
into the timing of the intervention to coincide with the often rapid trajectory of weight gain that
characterises the early treatment phase for those with a first episode psychosis; moreover, the nature of
the intervention may need to reflect the lifestyles and concerns of this typically young population.
Further research into physical health conditions such as diabetes mellitus in mental health should fully explore
the optimal approach to ensure that weight loss or QoL changes are sustained over the follow-up period.
Further research should investigate if:
l a more intensive lifestyle management programme with longer periods of maintenance support,
complemented by objective measures of weight, diet and exercise, delivered by more experienced
facilitators or those from different professional backgrounds, is clinically effective and cost-effective
l a more flexible approach, including both group and one-to-one sessions, is more effective
l a broader approach incorporating the adjustment of antipsychotic treatments and the use of adjunctive
pharmacological interventions may be required
l it is possible to overcome the barriers to attendance at lifestyle management programmes
l other formats including family members or carers would be more effective
l lifestyle management programmes should be tailored on the basis of the duration of psychotic illness;
for example, interventions for people with first episode psychosis may need to be different from
interventions for people with more established disease
l a lifestyle intervention should be combined with specific medication review and/or pharmacological
approaches to weight management.
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Chapter 9 Conclusions
Despite concerns about the feasibility of undertaking this RCT in people with schizophrenia, we recruitedand retained participants successfully in the RCT, indicating the level of interest in this topic among
both people with schizophrenia and their mental health care professionals. The RCT showed that the
STEPWISE intervention was neither clinically effective nor cost-effective.
Current NICE guidance recommends that mental health-care services should offer a combined healthy
eating and physical activity programme to people with severe mental illness, particularly if they are taking
antipsychotics.14 It is clear that many mental health trusts are not implementing this guidance, in part
because of a lack of clear evidence about how to do so. When we conceived the STEPWISE trial, we
hoped to provide this evidence; however, the results of the trial mean that this is not the case.
Although the process evaluation has identified some of the reasons why the intervention was not delivered
as effectively as planned, engagement by staff and participants was good and the sessions were valued
highly. This indicates that alternative strategies are needed to overcome the clinical challenge of obesity
and overweight in this patient population. A broader perspective that takes account of antipsychotic
medication and utilises adjunctive therapies for those who are unable to achieve weight loss through
lifestyle modification may be needed. Further research is needed to address these questions.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it is important that there are safeguards to make sure that they are stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Semistructured interview guide
for participants
TOPIC GUIDE: Participants
Notes: This topic guide is a flexible tool and may be revised as new areas of interest arise during 
the process of data collection. The wording of questions is for guidance only and can be varied to 
suit the natural style of the interviewer and the level of understanding of the participant. 
Welcome and context-setting 
Introduce yourself
Remind the participant (and their carer if present), “I work for the University research team, 
not for the NHS. The content of the interview will not be shared with their health care 
providers. Nothing you say will affect the care you receive”.
Inform them, “I want to find out what you thought about the STEPWISE programme, so 
that we can make it better. And I also want to find out how you felt being in the research
study so that we can improve research studies in the future.”
“The interview will last approximately an hour”
Explain that, “to help us with this study, we would like to make a recording of what we all 
say today, but nobody will be able to identify you from that recording other than me. Is that 
okay?”.
…There are no right or wrong answers
You are free to withdraw at any point and you don’t have to answer any of the questions if
you don’t want to.
Check they are happy to continue and ask if there are any questions.
Questions 
1. How did you find the STEPWISE programme?
Was there anything in particular that you liked about it? 
Was there anything in particular that you didn’t like about it?
How long were the sessions? Was that okay?
How many sessions did you attend? [Probe: if sessions were missed, why?] 
What did you think of the people who led your group
Did you feel you got any benefit from the programme? Were there any downsides? 
Did you feel it got the balance right in terms of talking about both diet and physical activity?
Did you bring somebody with you to the sessions – like a family member? [If no] Do you 
think that would have been helpful?
Did the programme meet your needs?
Did you attend the Booster sessions (if scheduled); 
o Was it useful? 
Did you have any of the one-to-one sessions with your facilitator?
o [If yes] How often they happen? Was it over the phone? Face-to-face? Some other
way?
 Did you find it useful?
[If no] Would you like to have done so?
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2. Was it easy to fit STEPWISE sessions into your usual routine? 
3. How did you get to the STEPWISE sessions? 
Was it easy to get to the sessions? 
How long did it take? 
[If using a car] What kind of distance did you have to drive, there and back again for each
session? 
[If travelling by public transport] Do you mind telling us what you spent getting there and 
back again for each session? 
4. How do you feel now it’s the end of the weekly course?
5. Would you have preferred it if the STEPWISE sessions had been closer together – for
example, every day for four days – rather than spread out over several weeks?
6. How did you hear about this study?
How did you feel about being approached to participate in the study?
How did you feel about a computer deciding whether you were going to go to the 
STEPWISE sessions or not?
7. We asked you to fill in some questionnaires with the STEPWISE logo on the top, at the 
beginning of the study and again recently.
What did you think about the number of questions you were asked?
Did you have any trouble answering any of the questions? 
We use those questions to find out whether how you are feeling. Did you feel any of the
questions were more important than others?
8. What else should I have asked you?
Thank you for your time
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Appendix 2 Semistructured interview guide for
health professionals
TOPIC GUIDE: Health Professionals
Notes: This topic guide is a flexible tool and may be revised as new areas of interest arise 
during the process of data collection. The wording of questions is for guidance only and can
be varied to suit the natural style of the interviewer and the level of understanding of the
participant. 
Section 1. Normalisation Process Theory for implementing interventions (Murray E,
BMC Medicine 2010, 8:63) 
“I’m going to ask you some questions about the STEPWISE intervention and the service 
here”
Coherence (meaning and sense-making by professionals):
Is the intervention easy to describe when you’re talking to patients and professionals?
Is it clearly distinct from other interventions?
Does it have a clear purpose for patients and professionals? 
Do you think patients and professionals have a shared sense of its purpose? 
What benefits do you think the intervention will bring; to whom?
Are these benefits likely to be valued?
Does the intervention fit with the overall goals and activity of your organisation?
Cognitive participation (commitment and engagement by professionals)
Do patients and professionals think the STEPWISE programme is a good idea?
Do they see the point of the STEPWISE programme?
Are patients and professionals prepared to invest time, energy and work in it? 
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Collective action (the work professionals and patients do to make the intervention
function)
How has the STEPWISE programme affected your work; 
What effect has it had on your consultations and communication with patients and carers?
How does it impact on the way that health professionals in the unit relate to each other?
How compatible is the trial with existing work practices? 
Does it seem to be the right thing to be doing? 
It is perceived as valid…. as useful?
Who needs to be involved in STEPWISE?
How do we get them informed them and link up with them? 
Does rolling out the STEPWISE programme mean health professionals learning new skills or
doing things differently?
Do all individuals involved in STEPWISE have the right set of skills? 
What impact does the STEPWISE programme have on:
the division of labour in your unit
resources
responsibility between different professional groups? 
Does a rigorous protocol for STEPWISE challenge professional autonomy over working 
practices? 
Does the STEPWISE programme impact on case load and allocation of work?
Who has the power to make the STEPWISE programme happen?
Do you think the system wants the STEPWISE programme to happen?
Do we need to and, if so, how can we divert resources to the STEPWISE programme?
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Reflexive Monitoring (professionals reflect on or appraise the intervention) 
How are users likely to perceive the intervention once it’s been on-going for a while?
Is it likely to be perceived as advantageous for patients or staff?
Will it be clear what effects the intervention has had?
Can patients and professionals contribute feedback about study procedures? 
Can the intervention procedures be adapted/improved on the basis of experience?
“Thank you, is there anything else you want to say about the STEPWISE programme?”
Section 2. Normalisation Process Theory for optimisation of trial parameters (Murray 
E, BMC Medicine 2010, 8:63)
“I’m going to ask you some questions about the trial and its procedures now”
“First of all, do you have any general comments about the trial?”
Coherence (meaning and sense-making by professionals):
Is the trial easy to describe when you’re talking to patients and professionals?
Is it clearly distinct from other trials?
Does it have a clear purpose for patients and professionals? 
Do you think patients and professionals have a shared sense of its purpose? 
What benefits do you think the trial will bring; to whom? 
Are these benefits likely to be valued by professionals and patients who might take part in the 
main trial?
Does the trial fit with the overall goals and activity of your organisation?
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Cognitive participation (commitment and engagement by professionals)
Do patients and professionals think the trial is a good idea? 
Do they see the point of the trial easily?
Are they prepared to invest time, energy and work in it? 
Collective action (the work professionals and patients do to make the trial function)
How do the trial procedures affect your work; do they promote or impede it? 
What effect has the trial had on your consultations?
Does participation in the trial require extensive training for staff involved?
How compatible is the trial with existing work practices? 
What impact does it have on division of labour, resources, power, and responsibility between
different professional groups? 
Reflexive Monitoring (professionals reflect on or appraise the trial)
How are users likely to perceive the trial once it’s been on-going for a while?
Is it likely to be perceived as advantageous for patients or staff?
Will it be clear what effects the study has had?
Can users/staff contribute feedback about study procedures? 
Can the study procedures be adapted/ improved on the basis of experience?
“Thank you, have you got any other comments you’d like to make?”
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
160
Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
